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Thesis Overview 
 
Insomnia disorder is characterised by difficulties with initiating and/or maintaining sleep.  
Similar to most psychiatric and mental health conditions, insomnia is defined according to 
subjective complaint, and achieves disorder ‘status’ when associated daytime functioning 
impairment is present.  Yet, ironically, it is these two cornerstones of insomnia disorder, 
combined, that have achieved relatively minimal attention in the literature.  That is, perhaps 
surprisingly, the subjective experience, and impact of insomnia, at least from the patient 
(‘expert’) perspective, has been under-researched.  Night-time symptoms and sleep 
parameters have typically been the target of both treatment and non-treatment (clinical, 
epidemiological, mechanistic) research. 
 
In this thesis, a multi-method, multi-level approach is adopted to better understand the 
daytime experience of those with chronically disturbed sleep.  First, a brief overview 
(chapter one) of insomnia is provided to familiarise the reader with the ‘problem of 
insomnia’.  A narrative review (chapter two) then sets the scene in relation to the 
assessment and measurement of health-related quality of life (HRQoL) and daytime 
functioning.  This work reveals several inadequacies and limitations of existing work, and 
outlines a prospective research agenda.   
 
Chapter three describes the first ever phenomenological study carried out in primary 
insomnia patients.  Here, two qualitative methodologies, focus groups and audio-diaries, 
are combined to help better understand the proximal and distal impairments attributed to 
chronic sleep disturbance.  Chapter four builds on this work by describing the creation of 
 iii 
two new clinical scales, developed to quantify, in both valid and novel ways, the impact of 
poor sleep on aspects of daytime functioning and insomnia-related quality of life. 
 
Chapter five combines the aforementioned qualitative and questionnaire approaches to 
explore the experience of an effective behavioural intervention for insomnia, sleep 
restriction therapy (SRT).  The application of these refined methods provided insight into 
the effects of SRT on both sleep and daytime functioning, but also permitted exploration of 
treatment-related issues - such as adherence, side-effects, and mechanisms of action - that 
have otherwise been difficult to probe using traditional quantitative methodologies. 
 
Chapter six tackles the issue of objective daytime impairment, typically assessed using 
computerised reaction time tasks.  Through ‘mining’ an existing brain and behavioural 
database, and applying an algorithm to select poor and normal sleepers, it was possible to 
investigate cognitive functioning at two broad stages of processing – event-related 
potentials generated from the scalp-recorded electroencephalogram (EEG), and 
performance output using neuropsychological testing.  The results provide some interesting 
hypotheses concerning possible cognition-arousal and -effort interactions.  Importantly, as a 
by-product of this work, a methodological template for the future standardized assessment 
of brain and behavioural function in insomnia is considered. 
 
Finally, chapter seven synthesises the results of each preceding experimental chapter, with 
particular emphasis on how this work will advance research, measurement and 
understanding of insomnia-related functioning.  Immediate clinical implications and 
relevance to other areas of insomnia research are also briefly considered. 
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“When you lose sleep, you lose the better part of yourself.  You’re not all there-as 
insomniacs know, as we say with the terms we use for ourselves: zombies, the living dead, 
nobody home.  It seems ironic that sleep is feared as the loss or disappearance of the self, 
when it may actually be the way we become most fully ourselves, maintain the continuity 
of past and present selves, retain our identities through time and change, become our most 
creative, intelligent, and alive.  Sleep is how we manage to be all there.  You might even 
say, I sleep, therefore I am.”   
Greene (2008, p.48) 
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The Problem of Insomnia: A Brief Overview 
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1.1. Insomnia: defining features 
 
The core symptoms of insomnia, specified in major disease and sleep disorder classification 
manuals (ICSD-2, 2005; DSM-IV, 1994; ICD-10, 1992), correspond to difficulties with 
initiating and/or maintaining sleep, or non-restorative sleep (i.e. poor quality sleep).  To 
achieve disorder ‘status’, sleep disturbance must not be simply a function of restricted sleep 
opportunity (i.e. curtailment), or environmental perturbation (such as noise, bed partner 
snoring etc.).  Importantly, the diagnosis of insomnia disorder is made only when 
impairment in daytime functioning is present, which is linked (attributionally) to night-time 
sleep difficulties.  Daytime impairments may be measured with reference to isolated 
symptoms, such as fatigue and concentration (Research Diagnostic Criteria - Edinger et al., 
2004; ICSD-2, 2005), but also to more global dysfunction; for example, in areas of social 
and occupational functioning (DSM-IV, 1994).  One additional marker of insomnia severity 
refers to the frequency and length (persistence) of insomnia symptoms, which, for an 
insomnia diagnosis, is usually set at greater than or equal to three nights per week 
(Lichstein et al., 2003; Ohayon & Reynolds III, 2009), being present for at least a one 
month period (Edinger et al., 2004; DSM-IV, 1994).  It is notable that there is currently no 
ubiquitous cut-off for daytime functioning severity, though a score of at least 2 (range: 0-4) 
on the ‘daytime interference’ question (item 5) from the Insomnia Severity Index (ISI; 
Morin, 1993) has been recommended by some (Morin & Espie, 2003).  
 
It is important to note that there are two main diagnostic manuals for categorizing 
insomnia, which vary with respect to the level of symptomatic detail and sub-type 
classification.  For example, the International Classification of Sleep Disorders manual 
 19 
(ICSD-2, 2005) identifies several different sub-types of insomnia disorder; whereas the 
DSM-IV presents a more narrow focus on just a few (see table 1.1).   
 
Table 1.1 - Insomnia classification according to ICSD-2 and DSM-IV. 
DSM-IV insomnia categories ICSD-2 insomnia categories
Adjustment insomnia (acute insomnia)
Primary insomnia Psychophysiological insomnia
Paradoxical insomnia
Idiopathic insomnia
Inadequate sleep hygiene
Insomnia related to (Axis I or II 
category) Insomnia due to mental disorder
Sleep disorder due to general 
medical condition, insomnia type Insomnia due to medical condition
Sleep disorder due to substance 
abuse, insomnia type Insomnia due to drug or substance
Insomnia not due to substance or 
known  physiological condition, unspecified 
(Nonorganic Insomnia, NOS)
Physiological (organic) insomnia, unspecified
Behavioral insomnia of childhood
 
One prominent difference is that DSM-IV does not distinguish between primary insomnia 
sub-types, unlike the ICSD-2 where there are four specified sub-types.  DSM-IV tends to 
focus on primary insomnia as an exclusionary diagnosis, where insomnia disorder is 
present in the absence of additional psychiatric, medical, sleep or substance abuse 
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pathology.  Conversely, ICSD-2 has specific characteristic inclusion criteria for each sub-
type (see table 1.2 for a description of sub-type features). 
   
Table 1.2 - Essential features of primary insomnia phenotypes in ICSD-2, redrawn from Schutte-Rodin et al. 
(2008). 
Disorder Essential features
Psychophysiological Insomnia
The essential features of this disorder are heightened arousal and learned sleep-preventing associations.
Arousal may be physiological, cognitive, or emotional, and characterized by muscle tension, “racing thoughts,” 
or heightened awareness of the environment. Individuals typically have increased concern about sleep 
difficulties and their consequences, leading to a “vicious cycle” of arousal, poor sleep, and frustration.
Paradoxical Insomnia
The essential feature of this disorder is a complaint of severe or nearly “total” insomnia that greatly exceeds 
objective evidence of sleep disturbance and is not commensurate with the reported degree of daytime deficit. 
Although paradoxical insomnia is best diagnosed with concurrent PSG and self-reports, it can be 
presumptively diagnosed on clinical grounds alone. To some extent, “misperception” of the severity of sleep 
disturbance may characterize all insomnia disorders.
Idiopathic Insomnia
The essential feature of this disorder is a persistent complaint of insomnia with insidious onset during infancy 
or early childhood and no or few extended periods of sustained remission. Idiopathic insomnia is not 
associated with specific precipitating or perpetuating factors.
Inadequate Sleep Hygiene
The essential feature of this disorder is insomnia associated with voluntary sleep practices or activities that 
are inconsistent with good sleep quality and daytime alertness. These practices and activities typically 
produce increased arousal or directly interfere with sleep, and may include irregular sleep scheduling, use of 
alcohol, caffeine, or nicotine, or engaging in nonsleep behaviours in the sleep environment. Some element of 
poor sleep hygiene may characterize individuals with other insomnia disorders.
 
 
 
Numerous epidemiological studies have been conducted to assess insomnia symptom and 
disorder prevalence rates (Ohayon, 2002).  Estimates naturally depend on the definition 
used, but prevalence of insomnia symptoms is estimated to affect one third of the 
population, and insomnia disorder (core sleep symptoms and daytime impairment) affects 
approximately 5-10% (Roth, 2007).  Of note, few epidemiological studies have 
implemented strict diagnostic criteria in relation to both classification manuals (i.e. ICSD-2 
& DSM-IV), or recorded data on whether the individual actually endorses a sleep 
problem/complaint.  A recent important study in the field by Ohayon & Reynolds III (2009) 
employed both DSM-IV and ICSD-2 criteria to assess prevalence rates in a large sample of 
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individuals (25,579), aged 15 and over, residing in seven European countries.  It was found 
that 34.5% of the sample reported at least one difficulty at the ‘symptom’ level (i.e. sleep 
initiation and/or maintaining difficulties or non-restorative sleep).  Just less than ten percent 
(9.8%) were found to meet insomnia at the criterion level; that is, reporting both night-time 
symptoms and daytime consequences.  After excluding those not scoring ‘positive’ for the 
complaint of insomnia, it was found that 6.6% of the general population met criteria for 
DSM-IV insomnia disorder.  When further broken down, based on DSM-IV criteria, 3.3% 
of the sample met classification for primary insomnia.  Most of the specialised ICSD-2 
insomnia sub-types had a prevalence of less than 1% in the general population, and the 
prevalence of Psychophysiological Insomnia, the most common primary insomnia sub-
type, was found to be 1.4%.  These results reasonably approximate previous 
epidemiological studies (e.g. Morin et al., 2006a; NIH state-of-the-science conference 
statement, 2005; Ohayon, 2002), though an important issue that arose was that a large 
number of individuals who, although reporting an insomnia complaint, failed to be 
categorized by the classification systems, suggesting future refinement of criteria and 
measurement may be necessary.   
 
1.2. Risk factors and precipitants 
Several risk factors have been associated with increased insomnia prevalence.  Among the 
most strongly supported are: increasing age, being female, shift work, and co-morbid 
medical and psychiatric disorders (Roth, 2007).  Psychiatric disorders are particularly 
pronounced in those with insomnia; with estimates suggesting 40% of all patients with 
insomnia experience a co-occurring psychiatric condition (Ford & Kamerow, 1989).  
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Specifically, depression and anxiety have been found to be highly prevalent in those with 
an insomnia diagnosis compared to those without (Taylor et al., 2005).  Moreover, those 
with insomnia syndrome, relative to both good sleepers and individuals with insomnia 
symptoms, demonstrate higher scores on questionnaire measures of depression, anxiety, 
neuroticism, extraversion, arousal predisposition, and stress perception, as well as a 
tendency towards emotion-oriented coping (LeBlanc et al., 2007).  Another intriguing 
finding from this latter study by LeBlanc and colleagues was that the group with insomnia 
symptoms also tended to score higher than good sleepers on measures of depression, 
anxiety, and neuroticism; suggesting a possible linear trend with increasing insomnia 
‘severity’.  
 
In a recent study of good sleepers (n=464), measured at three time-points over the course 
of a one-year period, many of these aforementioned factors (recorded at baseline) were also 
found to be involved in the onset of insomnia symptom ‘incident’ cases, the onset of 
insomnia syndrome ‘incident’ cases, and new (first time) onset of an insomnia syndrome 
(Beaulieu-Bonneau et al., 2007a).  Natural evolution studies of this nature have the capacity 
to substantially advance our understanding of the aetiology, development and maintenance 
of chronic insomnia.  For example, similar prospective longitudinal work by the same 
group, over a three year period, also revealed that insomnia disorder tends to persist long-
term, with little deviation in severity (Morin et al., 2009). 
 
Clinically, patients often ‘anchor’ the onset of sleep disturbance to significant life events.  
In support of this, Bastien and colleagues (2004a) systematically examined precipitating 
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factors of insomnia in a sample of 345 patients presenting at a sleep disorders clinic.  They 
discovered that events relating to family, health, and work or school, were most frequently 
associated with the onset of sleep disturbance.  Of note, across all recorded events, the 
majority (65%) were considered to be negative in nature (e.g. loss of job, bereavement). 
 
A few studies have reported increased familial susceptibility to developing insomnia.  For 
example, Dauvilliers et al. (2005) found that 73% of a sample of primary insomnia patients 
(n=77) had a positive family history for familial insomnia, compared with just 24% in a 
normal-sleeping control group.  A recent population-based study similarly found that those 
with a past (or current) history of insomnia had a greater likelihood of a positive family 
history for insomnia, relative to good sleepers that had never experienced insomnia before 
(Beaulieu-Bonneau et al., 2007a).  Moreover, monozygotic twins have also been found to 
have higher rates of insomnia concordance, within pairs, in comparison with dizygotic twin 
pairs (Watson et al., 2006).     
 
Although candidate genes have not yet been reliably identified, there are several possible 
targets relating to sleep homeostasis, circadian timing, and general arousal/de-arousal 
regulation (Riemann et al., 2010); all of which appear to be worthwhile investigating, and 
particular so given the high heritability of sleep EEG power spectra (δ, θ, α, σ bands; 
Ambrosius et al., 2008) as well as conventional PSG sleep parameters (Tafti, 2009).  It is 
worth mentioning that a very recent paper (Deuschle et al., in press) has, for the first time, 
revealed an association between primary insomnia and a serotonin transporter length 
polymorphism (5-HTTLPR short allele).  This association remained robust after controlling 
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for those with a lifetime incidence of affective disorder.  Such a finding needs replicated 
but is intuitively appealing given the greater occurrence of this genotype within other 
stress-related psychiatric conditions (which are frequently related to insomnia) and 
suggestions of enhanced cortisol reactivity to experimental psychosocial stress in healthy 
individuals with this genotype (Way & Taylor, in press).  
 
1.3. Insomnia assessment 
Insomnia is typically diagnosed according to subjective report; that is, through clinical 
interview, prospective sleep diary completion, and retrospective questionnaire assessments.  
Assessments probe sleep and functioning symptoms, but also beliefs and attitudes about 
sleep, pre-sleep arousal, and applied sleep effort – constructs considered important markers 
of insomnia, particularly the psychophysiological phenotype (Espie & Kyle, 2009).  
Polysomnography (PSG), the gold standard for objectively measuring sleep, is only 
indicated in circumstances where insomnia is suspected to be related to other sleep disorder 
pathology, such as periodic leg movements and sleep-related breathing disorders (Reite et 
al., 1995).   
 
There are at least two main reasons for this conservative use of PSG.  Firstly, it has been 
known for several decades that individuals with insomnia tend to (as a group) misperceive 
sleep: significantly underestimating total sleep time and overestimating time taken to fall 
asleep compared with PSG recordings (Carskadon et al., 1976).  This notwithstanding, 
insomnia patients report statistically significant differences in sleep parameters compared 
with normal sleepers, such as reduced total sleep time and sleep efficiency, and greater 
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number of awakenings; these differences, however, are typically disproportionate to the 
subjective complaints of patients (e.g. Feige et al., 2008).  Indeed, the core defining feature 
of the paradoxical insomnia sub-type (see table 1.2) is gross sleep misperception, when a 
substantial mismatch occurs between subjective report and objective recordings (PSG or 
actigraphy). 
 
Finally, PSG is an expensive procedure, and given the high prevalence of insomnia disorder 
in the general population, coupled with limited clinical/treatment insight, overnight 
laboratory-recording of sleep is not cost-effective, at least in insomnia clinical practice.  It 
is worth pointing out though that PSG is recommended in research as a screening tool and 
as an outcome measure in efficacy studies (though not as the primary dependent variable; 
Buysse et al., 2006).  
 
The lack of clinical necessity for objective sleep recordings, however, does not mean that 
PSG has had little impact on furthering our understanding of pathophysiologic mechanisms 
relevant to insomnia disorder.  For example, power spectral (microstructure) analysis of 
EEG amplitude during wake, non-REM sleep, and REM sleep states provides information 
on level of cortical arousal/excitability.  A number of studies report evidence for increased 
power, both relative and absolute, in fast EEG rhythms (sigma, beta, or gamma 
frequencies) during wakefulness, NREM sleep or REM sleep, compared with normal 
sleepers (Merica et al., 1998; Freedman, 1986; Perlis et al., 2001a; Perlis et al., 2001b; 
Krystal et al., 2002; Buysse et al., 2008).  These alterations tend to occur in the absence of 
conventional PSG abnormalities (when compared with controls), and are thought to 
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account, in part, for the subjective experience of being awake during objectively scored 
sleep (e.g. Borkovec et al., 1981).  Indeed, in the Perlis study (2001b), it was found that 
increased beta power during NREM sleep was associated with greater subjective-objective 
sleep discrepancies.  Similarly, slow wave spectral power in the delta range (0.5-4Hz), a 
marker of homeostatic drive for sleep (or sleep intensity), has been found to be both 
reduced (Merica et al., 1998; Krystal et al., 2002) and increased (Buysse et al., 2008*) in PI 
patients relative to controls.  Variability in methods, small sample sizes, and new findings 
concerning sex differences (Buysse et al., 2008), suggests more work in this area is 
required. 
 
Another emerging technique to study the microarchitecture of sleep is the cyclic alternating 
pattern (CAP).  CAP can be thought of as a measure of sleep instability (Terzano et al., 
2002), represented as periodic ‘activation’ features of non-REM sleep, involving delta 
bursts, K-complexes, K-alpha complexes, and other arousal-related events, which occur in 
defined clusters (so-called phase A types: of which there are three) interspersed with 
background EEG activity (phase B type).  Alternatively, a period of non-CAP (> 60 
seconds in duration in the absence of phase A type) is characterised by the absence of 
activation patterns, and therefore is considered a marker of sleep stability (Terzano et al., 
2002).  In one study, untreated (placebo) individuals with primary insomnia were found to 
spend more time in CAP, have a greater CAP rate (% of CAP time spent in NREM sleep), 
and a higher number of phase A1 and A2 types, compared with normal sleepers (Terzano et 
al., 2003).  Interestingly, sleep quality assessed using a 100mm visual analogue scale 
(VAS) correlated, negatively, and more strongly, with CAP rate than conventional PSG 
                                                 
*
 Spectral differences were only found for female insomnia patients 
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parameters.  A recent study also found that total CAP rate, and, in particular, CAP rate for 
sleep stages 1 and 2, was higher in individuals with paradoxical insomnia relative to normal 
sleepers (Parrino et al., 2009).  It is argued that CAP rate may be related to the 
misperception of sleep and reports of poor sleep quality in those with insomnia.  This 
technique appears promising for understanding possible microstructural abnormalities not 
otherwise measureable using conventional PSG parameters.  
 
1.4. Insomnia costs: economic and psychobiological considerations 
A handful of studies have estimated both direct (e.g. health-care utilization, physician 
consultations) and indirect costs (downstream consequences, e.g. work productivity) of 
insomnia (Martin et al., 2004).  Perhaps the most comprehensive study to date on cost 
impact was carried out by Daley and colleagues (2009a) in the province of Quebec, 
Canada.  A random sample (n=948) of residents were classified, according to strict 
diagnostic criteria, into good sleepers, those with insomnia symptoms, and those with 
insomnia syndrome (disorder).  Assessments were made for use of health-care services, 
products to treat sleep disturbance, accidents, insomnia-related work absenteeism and 
productivity (presenteeism).  Objective data were also obtained through a government 
register regarding recorded health-related consultations.  The total estimated cost of 
insomnia for that particular region (when extrapolated) was $6.6 billion (Canadian) dollars.  
In particular, insomnia-related absenteeism, reduced work-related productivity, and use of 
alcohol as a sleep aid were the three biggest contributors.  The average annual cost per-
person with insomnia syndrome was $5,010; $1,431 for those with insomnia symptoms; 
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and just $421 for good sleepers.  This study underscores the economic costs induced by 
both chronic and transient symptoms of sleep disturbance. 
 
Insomnia also appears to have general health costs.  It has been two decades since Ford & 
Kamerow (1989) published their seminal finding that insomnia is a risk factor for the 
development of subsequent psychopathology (depression).  This relationship has been 
repeatedly found in several investigations (for reviews see Riemann & Voderholzer, 2003 
and Pigeon & Perlis, 2007), suggesting that insomnia may be an independent predictor of 
depression.  Indirect mounting evidence also supports a role for insomnia in the 
perpetuation of depression.  For example, Pigeon and colleagues (2008) show, in a large 
sample of elderly individuals undergoing treatment for major depression, that persistent 
insomnia at baseline is significantly associated with poorer (depression) treatment response.  
Moreover, specifically targeting insomnia within the context of standard treatment for 
depression - using both cognitive behavioural therapy (Manber et al., 2008) and 
Eszopiclone (Fava et al., 2006) - subsequently leads to improvements in sleep but also 
potentiates the anti-depressant effect beyond monotherapy. 
 
Associations between insomnia and cardiovascular morbidity have similarly been reported 
for some time, though possible confounders have limited conclusions regarding causality 
(Bonnet & Arand, 2007).  An important study by Vgontzas et al. (2009) has recently 
advanced the field in terms of identifying a robust link between insomnia and hypertension.  
Using PSG recordings (one night) in a large random population sample (n=1,741) it was 
found that those meeting criteria for insomnia disorder, and who also (objectively) slept 
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less than five hours, had a greatly increased risk of experiencing hypertension.  This was 
not the case for individuals without insomnia symptoms and who also slept less than five 
hours (short sleepers).  Importantly, this insomnia-hypertension relationship held after 
controlling for several major confounders, including depression and sleep apnea.  Recent 
experimental data showing attenuated systolic blood pressure (SBP) day-to-night dipping, 
and elevated night-time SBP in normotensive primary insomnia patients compared with 
normal sleepers, provides one possible pathway for this link between sleep disturbance and 
hypertension risk (Lanfranchi et al., 2009).  Another interesting finding from this study was 
that insomnia patients showed a trend towards increased beta activity in NREM sleep, and 
beta activity (across the whole group) was positively associated with night-time SBP.   
 
1.5. Contemporary models of insomnia 
Over the years, several ‘single factor’ as well as multi-factorial models have been put 
forward to account for the aetiology and maintenance of chronic insomnia.  These ‘single 
factor’ accounts have tended to focus on specific, focused abnormalities, which have some 
degree of support in the existing literature, and include: stimulus dyscontrol and 
instrumental conditioning (Bootzin, 1972); altered sleep homeostasis (Pigeon & Perlis, 
2006); alterations in the circadian parameters involved in the timing of sleep (Lack & 
Wright, 2007); physiological hyperarousal preventing the de-aroused state necessary for 
sleep (Bonnet & Arand, 1997; Richardson, 2007); and dysfunctional cognitive processes 
surrounding sleep and sleep-related daytime functioning (e.g. Harvey, 2002).  Whilst these 
‘models’ are well formulated, it is likely that multi-component perspectives are required to 
capture the heterogeneity of insomnia symptoms, associated sub-types, and insomnia 
 30 
development/trajectory.  Although it is outwith the scope of this brief review to describe 
each multi-component model in detail, it is worth outlining some of the main accounts, 
which are inclusive and encompassing with regard to associated characteristics of insomnia 
disorder.  
  
1.5.1. The 3P (predisposing, precipitating, perpetuating) model: a general framework 
The main framework for most working models of insomnia was set out by Spielman et al. 
(1987a) in the form of the 3P model.  This stress-diathesis conceptualization outlines how 
chronic insomnia may develop over time; proposing, as a first step, that acute sleep 
disturbance occurs as a consequence of both predisposing (e.g. altered neurotransmission, 
trait arousal, genetic susceptibility, ruminative personality etc.) and precipitating factors 
(life-stressors such as occupational stress, emotional and health problems).  Perpetuating 
factors refer to maladaptive sleep practices, which interact with experienced insomnia 
symptoms, and are aimed at coping with the consequences of poor sleep during the day 
(e.g. drinking coffee to improve alertness) or directly trying to increase the probability of 
‘achieving’ sleep (e.g. extending time in bed).  After the precipitant resolves, most 
individuals will return to the default mode of sleep automaticity, but in those with a 
predisposition for sleep disturbance, combined with the continued practice of maladaptive 
perpetuating behaviours, sleep disturbance may become chronic.   
 
Thus a main assumption of this model is that sleep disturbance may, over time, become 
dislocated from the precipitating trigger (Ebben & Spielman, 2009).  Such a model is 
intuitively appealing because it suggests that treatment should target, specifically, 
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perpetuating factors involved in the maintenance of insomnia.  Indeed, this is exactly what 
cognitive behavioural therapy for insomnia (CBT-I) attempts to do; with an emphasis on 
correcting maladaptive coping strategies, behaviours and sleep-related dysfunctional beliefs 
and attitudes (Espie & Kyle, 2009).   
 
1.5.2. Neurocognitive Model 
Perlis and colleagues (1997) extend this behavioural perspective, acknowledging that acute 
insomnia is initially precipitated by life stress, is similarly maintained by maladaptive 
coping strategies (for example, extending time in bed), but that, importantly, the associated 
wakefulness becomes classically conditioned in terms of arousal (somatic, cognitive and 
cortical).  It is argued that increased cortical arousal (as measured by fast rhythms in the 
EEG) at sleep-onset, during sleep, and middle of the night awakenings, subsequently 
disrupts sleep initiation and maintenance through enhanced sensory/information processing 
and attenuated mesograde amnesia.  These altered cognitive parameters may subsequently 
help explain sleep-state misperception.  A later addition to this model also includes the 
possibility that sleep-related objects (bed, pillow etc.) become conditioned stimuli for 
cortical arousal (Perlis et al., in press A) and hence contribute to the perpetuation of 
continued sleep disturbance.  
 
1.5.3. Cognitive Model  
Harvey (2002) describes a (maintenance) model of insomnia which focuses primarily on 
dysfunctional cognitive processes, based upon a large body of work from the anxiety 
disorders literature.  Because it is arguably the first model to give equal attention to both 
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daytime and night-time factors, it is worth outlining some of its main features.  Harvey 
argues that individuals with insomnia tend to excessively worry about sleep and 
catastrophize about the consequences of not getting adequate sleep (in relation to impact on 
health and daytime functioning).  Ensuing negatively toned cognitive activity, typically 
about sleep but also other (negatively valenced) life issues, coupled with the application of 
maladaptive safety behaviours, results in elevated autonomic arousal and emotional 
distress.  As a consequence of this heightened stress state, individuals with insomnia tend to 
monitor for sleep-related threat cues (internal and external) to confirm that they have not 
slept and that functioning is adversely affected.  Pre-existing dysfunctional beliefs 
exacerbate the situation.  Otherwise innocuous cues are subsequently misinterpreted as 
evidence for sleep and daytime deficits, ‘tricking’ the individual into overestimating both 
the level of sleep and daytime impairment.  This serves to cause further worry and concern 
about not sleeping, which may, through feedback mechanisms, increase anxiety and 
cognitive load, leading to the enhanced possibility of a ‘real’ deficit occurring in both sleep 
and daytime functioning.  The main assumption of this model is that cognitive processes 
have a causal role in the maintenance of an insomnia state.   
 
1.5.4. Psychobiological Inhibition/Attention-Intention-Effort (PIM/AIE) model 
Espie (2002) and Espie and colleagues (2006) take a starting point of normal sleep for their 
model of insomnia.  They acknowledge that normal sleep is governed by two oscillatory 
processes - a self-sustained oscillating circadian rhythm and an ‘hourglass’ sleep homeostat 
- rendering the (adaptive) sleep process automatic, involuntary and, hence, not under direct 
control.  Acute stressful life events can however create both physiological and 
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psychological ‘over-arousal’, which interacts negatively with normal sleep-wake 
regulation, leading to acute sleep disturbance.  For most individuals, the ‘plasticity’ of the 
sleep system accommodates such transient disruptions, without any lasting chronic 
modifications.  However, it is argued that the development of acute to chronic insomnia, 
where the defining feature is a fundamental difficulty in inhibiting wakefulness, is 
precipitated by three related cognitive processes (Espie et al., 2006).  Attending to sleep-
related stimuli, explicitly intending to sleep, and applying voluntary effort to the sleep onset 
process, all represent an attempt to control sleep, an otherwise automatic process.  These 
attempts have the opposite effect: preventing de-arousal by failure to reach a level of 
inhibitory sufficiency.  Factors relevant to this resultant ‘sleep effort syndrome’ (Espie, 
2007), include enhanced sleep-preoccupation, affect dysregulation, sleep-incompatible 
conditioning, dysfunctional beliefs and expectations about sleep, and enhanced focus on the 
consequences of poor sleep. 
 
 
1.5.5. Beyond dualistic tendencies: towards an integrative psychobiological insomnia 
model   
 
Although not strictly a new ‘model’, it would be fair to say that in the last few years a new 
perspective has been put forward to explain insomnia across a number of different ‘levels’; 
with particular emphasis on underlying neurobiology.  For example, in the most up-to-date 
account, Riemann and colleagues (2010) synthesise work on the hyperarousal concept of 
insomnia, focusing on hyperarousal across autonomic, neuroendocrine, 
neuroimmunological, electrophysiological and neuroimaging parameters.  They also draw 
on extensive theorizing by Perlis and colleagues (2007; 2009; Pigeon & Perlis, 2007) in 
relation to possible neurobiological abnormalities relevant to the features of insomnia; as 
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well as cutting-edge work on rodent models of stress-induced insomnia (Cano et al., 2008).  
The development of testable hypotheses has been aided largely by recent understandings on 
the neurobiology of normal sleep-wake regulation (Saper et al., 2005a; Schwartz & Roth, 
2008).   
 
The perspective outlined is a further update of the Neurocognitive account, originally set 
out by Perlis et al. (1997).  Although at a speculative stage regarding possible mediators of 
insomnia aetiology and development, it is proposed that a genetic arousal predisposition 
may render certain individuals at greater risk of developing insomnia via altered 
neurobiology and neurochemistry.  In particular, modified levels of several neurochemicals, 
including orexin, monoamines (histamine, dopamine, norepinephrine, serotonin), 
adenosine, and the stress hormone cortisol, may, during acute periods of stress, disrupt 
arousal-related (ascending reticular activating system; ARAS) and/or sleep-promoting 
(ventrolateral preoptic nuclei; VLPO) components of the ‘flip-flop’ sleep switch.  Inputs to 
the VLPO from various limbic structures may also directly impact the capacity to de-arouse 
adequately, overcoming homeostatic sleep pressure (Saper et al., 2005b).  This, of course, 
would normally represent a typical adaptive response to stress.  However, the subsequent 
development of chronic ‘arousal’, post-acute phase, possibly more likely in those with a 
genetic predisposition for arousability and/or increased stress responsivity, interacts with 
maladaptive sleep practices, resulting in both circadian and homeostatic dysregulation.  
This dysregulation may, over time, induce chronic changes in the sleep-wake system, 
perhaps reflected in cortical hyperarousal, arousal across other physiological parameters, 
and difficulties in inhibiting wakefulness.  Recent work by Seugnet et al. (2009) in which 
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Drosophila melanogaster were artificially selected and bred over many generations to 
create insomnia-like characteristics (sleep initiation and maintenance difficulties, and 
daytime impairment), helps one conceive of an inherited sleep-system with reduced 
plasticity and/or an altered stress reactivity threshold (Perlis et al., in press A). 
  
Although this perspective focuses predominantly on neurobiology, it clearly acknowledges 
that insomnia is a psychobiological disorder, with psychological and neurobiological 
abnormalities likely to be highly inter-related (Perlis et al., 2009).  This seems to be a more 
convincing integrative account of insomnia and its associated features, rather than just a 
pure physiological hyperarousal perspective (see Bonnet & Arand, 2010).  Indeed, in an 
inclusive depiction, physiological changes are paralleled with cognitive-behavioural 
features, which are likely to interact at multiple levels, capturing maintenance and 
development factors relevant to the original neurocognitive model, Spielman’s 3P 
framework, Espie’s PIM/AIE formulations, and Harvey’s cognitive model.  It will be 
important to investigate insomnia at each ‘level’, and ultimately to understand how genetic, 
biological, and psychological factors interact to determine the course of sleep disturbance 
over time.     
 
1.6. Evidence-based treatment of Insomnia 
It is important to note, firstly, that the majority of patients with insomnia do not actually 
seek treatment for their sleep difficulties (Morin et al., 2006a; Bartlett et al., 2008).  
Although only a small amount of work has been carried out to understand why this is the 
case, it appears likely that a perception of sleep as not being viewed important by the 
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medical profession (Stinson et al., 2006); a poor understanding and/or recognition of sleep 
disturbances by health-care providers; and limited public knowledge of available treatments 
(Ancoli-Israel & Roth, 1999), may mediate, to some extent, this phenomenon. 
 
1.6.1. Pharmacotherapy    
A number of pharmacological agents exists for the treatment of insomnia symptoms, most 
of which primarily work via their agonistic effects on gamma-aminobutyric acid (GABA), 
the major inhibitory neurotransmitter in the central nervous system (CNS).  Specifically, 
the most common class of hypnotics, benzodiazepines (e.g. temazepam), and the newer 
non-benzodiazepine receptor agonists (zolpidem, eszopiclone; BZRAs or ‘z drugs’) 
modulate GABAA receptors, facilitating the inhibitory effects of GABA on overall CNS 
arousal, while similarly inhibiting norepinephrine activity (Mitchell & Wienshenker, in 
press).  BZRAs are considered more effective due to their greater selectivity for the alpha 1 
sub-unit, thus enhancing activity in terms of sedation and limiting more generic effects 
involved in the interaction with other subunits (Nutt & Stahl, in press).  These compounds 
also tend to have shorter half-lives than the original benzodiazepines, reducing the 
likelihood of carry-over effects the next day; though available data on side-effects and 
comparable efficacy do not allow for clear conclusions to be made (e.g. Dundar et al., 
2004; Krystal, 2009).     
 
Although demonstrating effectiveness (moderate to large effects) in terms of improving 
major indicators of sleep continuity and quality in those with insomnia, positive effects of 
BZRAs/benzodiazepines have yet to be reliably demonstrated beyond active administration 
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(Riemann & Perlis, 2009).  Indeed, as it stands, there is not enough evidence to suggest or 
recommend that BZRAs/benzodiazepines are useful for the long-term management of 
chronic insomnia beyond four weeks of treatment (NIH state-of-the-science conference 
statement, 2005).  Some recent studies report improvements during extended/intermittent 
use of hypnotics over 6 (Walsh et al., 2007) and 12 month periods (Ancoli-Israel et al., 
2005), but again no adequate data exist indicating maintained benefits long after treatment 
cessation.  Concerns about long-term hazardous side-effects and tolerance issues strongly 
argue against long-term prescription: safety and efficacy must be documented (Kripke, 
2000). 
 
The only other class of sleep-promoting agents, licensed and approved for the treatment of 
insomnia, are melatonin receptor agonists, acting on M1/M2 receptor sites in the 
Suprachiasmatic Nucleus (SCN) of the hypothalamus.  Endogenous melatonin is secreted 
by the pineal gland under the control of the SCN; absence of light input to the SCN leads to 
a rise in melatonin from early evening onwards, which is paralleled by an increase in 
sleepiness and a decrease in core body temperature – suggesting melatonin is involved in 
the regulation of the sleep/wake rhythm, and hence, has somnogenic properties (Sateia et 
al., 2008; Arnedt & Skene, 2005).   
 
Ramelteon® is the only approved melatonin agonist on the (US) market and has been 
investigated in a few trials.  Although demonstrating low potential for abuse, and limited 
side effects (i.e. similar to placebo) in comparison with GABA-mediated hypnotics, 
Ramelteon appears to have only moderate effects on sleep latency, and little/no impact on 
WASO and TST (Sateia et al., 2008).  Circadin®, an extended-release melatonin agonist 
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was also recently approved for use in the UK (and other parts of Europe).  Circadin® is only 
indicated for short-term use (< 1 month) in over 55s – owing to documentation of 
melatonin deficiency in elderly individuals with insomnia (e.g. Haimov et al., 1994).  Data 
are limited, but there are some beneficial reports in terms of sleep continuity parameters, 
sleep quality, and daytime functioning, and the safety profile appears encouraging (e.g. 
Luthringer et al., 2009; Wade et al., 2007).  More multi-centred trials with long-term 
follow-ups are required to determine the role of exogenous melatonin in the management of 
chronic insomnia.   
 
A number of other drugs are also used ‘off-label’ to treat insomnia, including sedative anti-
depressants, anti-neuroleptics and atypical (second generation) anti-psychotics; though it is 
important to note, this is not evidence-based practice.  Indeed, the most frequently 
prescribed hypnotic in the US is the sedative anti-depressant, trazadone, yet only one 
randomized trial of this therapy has been conducted with insomnia patients, with 
unconvincing results (Krystal, 2009).  The uncovering of mechanisms involved in basic 
sleep-wake regulation has led to the development of a number of novel compounds, several 
of which are currently under investigation within clinical trials.  These include orexin 
antagonists, novel melatonin compounds, histamine receptor antagonists, and specific 
serotonin (5HT) antagonists - which may help lead to the development of safer and more 
effective pharmacotherapies for insomnia (Sullivan & Guilleminault, 2009).  
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1.6.2. Cognitive Behavioural Therapy for insomnia (CBT-I) 
Given that maladaptive behaviours and cognitive processes are thought to underlie the 
maintenance of insomnia, it is intuitive that therapy targets these factors directly (Edinger 
& Means, 2005).  Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based 
treatment modality, containing a number of supported techniques to improve sleep.  
Practice parameters set out by the American Academy of Sleep Medicine (AASM) 
recommend and endorse the following single components: paradoxical intention therapy, 
stimulus control therapy, sleep restriction therapy, progressive muscular relaxation, and 
biofeedback (Chesson et al. 1999; Morgenthaler et al., 2006).  In addition, two multi-
component CBT approaches are also supported.  Indeed, most outcome research has 
focused on multi-component, multisession CBT interventions.  See table 1.3 for a 
description of the main components that make up a typical CBT-I programme. 
 
Table 1.3 - Main CBT-I components, taken from Morin et al. (2006b). 
Therapy Description
Stimulus Control Therapy
A set of instructions designed to re-associate the bed/bedroom with sleep and to re-establish a 
consistent sleep-wake schedule: (1) go to bed only when sleepy; (2) get out of bed when unable to 
sleep; (3) use the bed/bedroom for sleep only (no reading, watching TV, etc.); (4) arise at the same time 
every morning; (5) no napping.
Sleep Restriction Therapy
A method designed to curtail time in bed to the actual amount of sleep time. For example, if a patient 
reports sleeping an average of 6 hours per night, out of 8 hours spend in bed, the initial recommended 
sleep window (from lights out to final arising time) would be restricted to 6 hours.  Periodic adjustments 
to this sleep window are made contingent upon sleep efficiency, until an optimal sleep duration is 
reached.
Relaxation Training Clinical procedures aimed at reducing somatic tension (e.g. progressive muscle relaxation, autogenic training) or intrusive thoughts at bedtime (e.g. e.g. imagery training, mediation) interfering with sleep. 
Cognitive Therapy
Psychological methods aimed at challenging and changing misconceptions about sleep and faulty 
beliefs about insomnia and its perceived consequences.  Other cognitive procedures may include 
paradoxical intention or methods aimed at reducing or preventing excessive monitoring of and worrying 
about insomnia and its correlates/consequences.
Sleep Hygiene Education
General guidelines about health practices (e.g. diet, exercise, substance abuse) and environmental 
factors (e.g. light, noise, temperature) that may promote or interfere with sleep.  This may also include 
some basic information about normal sleep and changes in sleep patterns with aging. 
Cognitive-Behavioural Therapy (CBT) A combination of any of the above behavioural (e.g. stimulus control, sleep restriction, relaxation) and 
cognitive procedures.
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CBT-I has a large and extensive evidence-base (spanning over 20 years) in treating 
insomnia as a primary disorder, and mounting evidence for the successful improvement of 
insomnia symptoms in the context of co-occurring conditions (Riemann & Perlis, 2009; 
Morin et al., 2006b; Edinger et al., 2009).  Two reviews carried out by the American 
Academy of Sleep Medicine (AASM) taskforce revealed that CBT improves sleep 
parameters in approximately 70% of insomnia patients (Morin et al., 1999b; Morin et al., 
2006b).  Effectiveness studies in primary care settings similarly report strong CBT-I 
effects, including those where patients are already on prescription hypnotics (Espie et al., 
2007; Morgan et al., 2003).  Studies have also demonstrated maintenance of sleep 
improvements long after active treatment – indeed, up to two years follow-up (Morin et al., 
1999a; Espie et al., 1989).  Maintenance of gains is important given the persistent and 
chronic nature of insomnia (cf. Morin et al., 2009), explaining why CBT is the treatment of 
choice for the management of chronic insomnia.  This was appropriately summarized by 
the recent National Institutes of Health (NIH) state-of-the-science conference statement 
(2005): 
 
“… [CBT] has been found to be as effective as prescription medications are for brief 
treatment of chronic insomnia. Moreover, there are indications that the beneficial effects of 
CBT, in contrast to those produced by medications, may last well beyond the termination of 
active treatment” (p.1052) 
 
Direct comparisons between CBT and pharmacotherapy reinforce this conclusion: 
treatment gains are similar during the acute treatment phase, but medicated individuals tend 
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to regress after treatment cessation, compared with CBT-treated individuals who maintain, 
or improve on, established gains (e.g. Morin et al., 1999b; Jacobs et al., 2004; Sivertsen et 
al., 2006a).  Despite strong evidential support and demonstrations of cost-effectiveness (e.g. 
Morgan et al., 2004), access to CBT-I remains limited.  Thus, as Espie (2009) notes: 
 
“The challenge for CBT is no longer to prove its credentials, but to punch its weight.  For 
at least a decade, CBT should have been a contender as the treatment of first choice for 
insomnia.  In reality, however, it has had very little impact on the high volume of insomnia 
patient care.  Indeed, it has amounted to little more than a patchy cottage industry.”                
(p.1549) 
Solutions to making CBT-I more available are currently being formulated and tested.  
These include: innovative health care models (Espie, 2009); telephone consultations 
(Bastien et al., 2004b); condensed brief CBT-I interventions (e.g. Edinger & Sampson, 
2003; Germain et al., 2007); bibliotherapy (Mimeault & Morin, 1999); DVD and television 
broadcasts (Van Straten et al., 2009); and internet programmes (Ritterband et al., 2009; 
Vincent & Lewycky, 2009).  This work has important implications for how CBT research 
and evidence can be translated into everyday clinical practice.           
 
1.6.3. What constitutes effective treatment? 
 
It is abundantly clear that CBT-I is an effective treatment for improving night-time 
symptoms of insomnia – several systematic and meta-analytic reviews support this 
perspective (for a synthesis see Riemann & Perlis, 2009).  However, none of these reviews 
report on (perhaps) the major concern of insomnia patients – functional impact/impairment, 
the main determinant of treatment-seeking.  Surely, ‘effective’ interventions should also be 
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defined in terms of how they affect how a person feels and functions?  The same is also true 
for pharmacotherapy research.  Indeed, often in these trials the focus is on documenting a 
lack of daytime impairment/side-effects as a consequence of treatment initiation (compared 
with placebo), rather than actually attempting to demonstrate positive effects on daytime 
functioning and related aspects of quality of life.        
 
There are signs, however, that this exclusive focus on night-time symptoms is changing to a 
more thorough investigation of disorder, and treatment impact, on the ‘whole patient’.  This 
thesis represents a step towards better understanding and measuring insomnia-related 
daytime functioning and quality of life.  Central to this work is the notion that insomnia 
patients, and their narratives, are powerful sources of data, which have the potential to help 
better understand and clarify several related aspects of insomnia, particularly those 
concerning disorder impact and treatment effectiveness.     
 
The next chapter will now outline, firstly, what is currently known about the daytime 
consequences and associated morbidity of insomnia.  The review will then turn to the more 
global constructs of Health-Related Quality of Life (HRQoL) and Quality of Life; with 
particular emphasis on definition, measurement and treatment effects, in insomnia 
populations.  On the basis of this thorough review, a prospective research agenda is set out 
for the insomnia field as a whole, in relation to insomnia and HRQoL.  Some of these 
important research objectives are subsequently addressed and explored in the following 
chapters of this thesis.     
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Chapter 2: 
 
 
 
Insomnia and Health-Related Quality of Life 
 
 
 
The contents of this chapter have been published as follows: 
 
 
Kyle, S.D., Morgan, K. & Espie, C.A. (2010). Insomnia and health-related quality of life.  
Sleep Medicine Reviews, 14, 69-82. 
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2.1. Abstract 
Health-related Quality of Life (HRQoL) has become an important construct in contemporary 
medicine and health care, permitting assessment of disorder burden and evaluation of 
interventions on various aspects of functioning, in a standardized manner.  Here we review 
literature on the measurement of HRQoL in insomnia populations, and the extent to which 
insomnia treatment improves domains of HRQoL.  It is concluded from the relatively small 
literature that insomnia impacts on diverse areas of HRQoL, and that both pharmacological 
and non-pharmacological interventions can produce, to varying degrees, improvements in 
domains spanning physical, social and emotional functioning.  Limitations of the current 
literature are identified; with particular emphasis on measurement and conceptual short-
comings.  Suggestions are made in relation to improving the quality of future research, and 
how to further shed light on the impact of insomnia - and treatment thereof - on both HRQoL 
and global quality of life.      
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“They call this a “sleep disorder”, but it’s actually an all-day disorder. Insomnia is not just 
something that happens to the night, it happens to the day, the whole day, and if it’s chronic 
insomnia, it happens to many days.  A half-life of ruined days.”  
Greene (2008, p28) 
 
2.2. Introduction 
Despite Insomnia being recognised as a ‘24-hour disorder’ in both the major sleep 
nosologies (ICSD, 2005; DSM-IV), historically, there has been less interest in the daytime 
aspects of insomnia compared with night-time symptoms and sleep parameters.  Recent 
recommendations from leading researchers in the field (Buysse et al., 2006; Morin, 2003; 
NIH state-of-the-science conference statement, 2005) encourage further investigations into 
the waking consequences and correlates of insomnia.  Indeed, clinical research in general, 
across a wide spectrum of illnesses, has moved towards a more holistic approach; looking 
beyond proximal symptoms, and viewing the patient within their wider psychosocial 
context (Armstrong et al., 2007). 
 
The purpose of this review is to: a) give a brief overview of the known daytime 
consequences and morbidity associated with insomnia; b) review work on the definition 
and measurement of quality of Life (QoL), or more specifically, health-related quality of 
Life (HRQoL), as it relates to insomnia; and finally, c) outline a prospective research 
agenda, focusing on further understanding and measuring the extent to which insomnia, and 
its treatment, impacts HRQoL and individual QoL. 
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2.3. Insomnia: daytime consequences and associated morbidity 
Impairment in daytime functioning attributed to disturbed and/or poor quality sleep, 
features as one of the core diagnostic criteria for insomnia disorder (ICSD-2, 2005; DSM-
IV; Edinger et al., 2004).  Clinician reports of patient consultations (Moul et al., 2002), and 
cross-sectional (Roth & Ancoli-Israel, 1999) and prospective questionnaire studies (Buysse 
et al., 2007; Levitt et al., 2004), reveal that individuals with insomnia report consistent 
decrements in mood and cognitive abilities (concentration, memory, attention), coupled 
with elevated levels of anxiety, fatigue and physical pain/discomfort, relative to normal 
sleepers.  Such impairments persist in those diagnosed with primary insomnia (PI), after 
screening and excluding co-morbid pathology (Buysse et al., 2007; Kyle et al., in press; 
Lichstein et al., 1997; Orff et al., 2007; Varkevisser et al., 2005).  Evidence for subjective 
(and objective) sleepiness, on the other hand, remains equivocal (Riedel & Lichstein, 2000; 
Sanford et al., 2006), with surveys revealing approximately 25% of PIs report excessive 
daytime sleepiness (Day et al., 2001).  
 
Although reviews of earlier studies failed to find reliable unequivocal differences in 
objective, neuropsychological functioning (Riedel & Lichstein, 2000; Fulda & Schulz, 
2001), more recent controlled work, using sensitive measures that vary in task complexity 
and cognitive load, appear to be isolating and capturing specific impairments in attention 
and vigilance (Varkevisser & Kerkhof, 2005; Edinger et al., 2008a; Altena et al., 2008a).  
The heterogeneity in findings may be explained by both methodological (e.g. sample size 
and composition, assessment tools, time of testing), and theoretical factors (e.g. ‘negative 
cognitive set’, compensatory effort, and cortical arousal; Altena et al., 2008a; Harvey, 
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2002; Bastien et al., 2003; Winkelman et al., 2008).  Further work is needed to tease out the 
contributing roles of each.  Interestingly though, a recently presented meta-analysis 
(Fortier-Brochu et al., 2008) of all studies assessing neuropsychological performance in 
well-defined PIs, revealed significant impairments (small to moderate effect sizes) in 
aspects of attention, episodic and working memory, and executive functioning domains.  
Other groups have focused on the known relationship between sleep and consolidation of 
newly encoded memory traces.  Specifically, PIs show an attenuation of the normal 
overnight sleep enhancement effect on tasks probing declarative (Backhaus et al., 2006) 
and procedural memory performance (Nissen et al., 2006), relative to normal sleeping 
controls.    
 
Recent structural and functional imaging work may also shed light on the neural 
underpinnings of the cognitive dysfunction experienced by insomnia patients.  For 
example, Riemann and colleagues (2007) reported decreased bilateral hippocampal volume 
in a small sample of PIs (n=8) relative to controls, and, more recently, Altena et al. (2010) 
found decreased gray matter volume in the left orbitofrontal cortex† and parietal cortices 
(specifically the precuneus), in a larger sample (n=24) of elderly individuals with primary 
insomnia.  Furthermore, the first published functional MRI study in PIs revealed 
hypoactivation of medial and inferior prefrontal regions during a verbal fluency task – a 
pattern which reversed/normalised post-behavioural therapy (Altena et al., 2008b).  
Although this imaging work is still in its infancy (and issues of causal ordering remain to 
be resolved), such atrophy, and functional alterations, may map onto reported daytime 
impairments in mood, memory, and reduced cognitive flexibility.  Daytime event-related 
                                                 
†
 gray matter density significantly and strongly (negatively) correlated with subjective insomnia severity  
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potential (ERP) data, though relatively sparse, also point to potential impairments in 
aspects of attention and processing speed (e.g. Bruder et al, 1991; Szelenberger & 
Niemcewicz, 2001); though again, more work in this area using sophisticated paradigms, 
and large, well-defined samples is required.  Recent ERP studies assessing sensory and 
cognitive processing pre-sleep, during sleep, and on awakening (Bastien et al., 2008; 
Devoto et al., 2005), over multiple nights, are beginning to tease out the relationship 
between sleep quality and cortical arousal, which may have implications for better 
understanding daytime insomnia phenomenology (Turcotte & Bastien, 2009).        
 
Large survey and population-based studies further reveal a number of increased morbidity 
markers in those suffering from insomnia, including: increased rates of health care 
utilization (physician visits, medication prescriptions) and chronic health problems (Leger 
et al., 2002; Simon & Vonkorff, 1997; Hatoum et al., 1998), elevated work absenteeism 
rates, reduced work productivity, and greater frequency of motor and non-motor accidents 
(Roth & Ancoli-Israel, 1999; Leger et al., 2006; Daley et al., 2009b).  Such impairments 
may be moderated, in part, by co-occurring illness; however, workplace studies controlling 
for both mental and physical co-morbidities still reveal significant negative effects of 
insomnia on objective absenteeism, self-report work efficiency (Leger et al., 2006), and 
work disability pension claims (Sivertsen et al., 2006b).  Longitudinal epidemiological 
studies also indicate that isolated sleep disturbance, measured at time point one, can 
independently predict the development of a new depressive episode 1-3 years later (for a 
review see Riemann & Voderholzer, 2003).  Recent work also confirms insomnia as a 
predictor of future clinical anxiety (Neckelmann et al., 2007).          
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Crucially, perceived impact on daytime functioning serves as an important factor in driving 
help-seeking behaviour among individuals with insomnia, rather than simply perceived 
sleep loss (Stepanski et al., 1989).  For example, Morin and colleagues (2006a)  found, in a 
large epidemiological study, that four out of five of the most commonly cited reasons for 
seeking a sleep-related consultation with a health professional, were daytime consequences 
of fatigue, psychological distress, physical discomfort, and reduced work productivity.  
Thus, once a threshold of noticeable daytime dysfunction is reached, individuals feel 
motivated to seek medical advice – ultimately with the hope that successful treatment will 
restore the particular functional impairment back to ‘normal’ status (Henry et al., 2008). 
 
2.4. Quality of Life (QoL) and Health-related Quality of Life (HRQoL) 
In recent years there has been a shift towards assessing the overall impact of illness on 
aspects of QoL, through the measurement of HRQoL (Testa & Simmons, 1996).  QoL and 
HRQoL have become well established terms in the medical and health literature – indeed, a 
PubMed search reveals that published work with the term ‘Quality of Life’ in the title or 
abstract has risen more than fourfold in the last ten years (1998-2008: 62,641), relative to 
the previous decade (1988-1998: 14,428).  This has occurred mainly because of the 
recognition that objective changes in pathology rarely correlate with, or predict 
improvements in, functional capacity or patient experience, and that what the individual 
desires when seeking treatment is, put simply, a return to pre-illness well-being.  Similarly, 
with increasing life expectancy and medical technology advancement, the emphasis has 
shifted to chronic illness management (the quality of life) rather than simply the extension 
(quantity) of life.  HRQoL has thus become a variable that can help policy makers decide 
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on which treatments should get resources and service provision, relative to competing 
others (through cost-effective analyses and health technology assessment).   
 
One effect of this increased attention to quality of life measurement has been the tendency, 
criticised in recent reviews and commentaries (Gill & Feinstein, 1994; Moons et al., 2006 
Dijkers, 2007), for researchers to include QoL and HRQoL scales in intervention and 
epidemiological studies without paying much attention to the concept they are purporting to 
measure.  That is, QoL has become an ‘umbrella term’ (Feinstein, 1987) for a number of 
different concepts and definitions.  The distinction between QoL and HRQoL is an 
important one, yet much of the health/medical literature seems to use these two terms 
interchangeably.  QoL is widely regarded as a complex phenomenon: some argue it 
encompasses both objective and subjective indices of well-being (Cummins, 2000); 
whereas others suggest it is a purely subjective impression of ‘life satisfaction’ (Moons, 
2006).  Factors relevant to quality of life may thus range from emotional functioning and 
happiness, through to material well-being and education; it is therefore difficult to measure, 
not least with a single generic instrument.  The World Health Organization (Herrman et al., 
1993) defines QoL as: 
“An individual’s perception of their position in life, in the context of the culture and 
values in which they live and in relation to their goals, expectations, standards, and 
concerns” (WHOQoL study group) 
A more contemporary definition proposed by Ruta et al. (2007), based on seminal work by 
the economist-philosopher, Amartya Sen, views QoL in terms of a ‘gap hypothesis’: 
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“Quality of Life is the gap between what a person is capable of doing and being, and 
what they would like to do and be; in essence it is the gap between capability and 
expectations” (p. 402) 
 
Inherent in both these approaches is the importance of the individual in the assessment of 
QoL.  The role of relativism and subjectivity in QoL assessment is perhaps best illustrated 
by the ‘disability paradox’ (Albrecht & Devlieger, 1999): individuals who may have 
society-defined functional/health impairment (e.g. cancer sufferers, amputees, the 
physically disabled), can report satisfactory, or in some cases, enhanced, quality of life 
(Moons et al., 2006).  Thus, health is just one of the many components implicitly factored 
into the quality of life equation.  Simply put, having poorer health status does not 
necessarily mean that one has a lower quality of life, than say someone in impeccable 
health (Car & Higginson, 2001). 
 
HRQoL assessment, on the other hand, is concerned with isolating the impact of disease or 
illness on prominent aspects of functioning – ‘…the radiating impact of pathology on the 
patient’s wider world’ (Armstrong et al., 2007, p578).  In clinical medicine the ‘pathology’ 
has both immediate, proximal symptoms (for example, in the case of insomnia, an 
increased sleep latency, or reduced total sleep time), and more ‘downstream’, distal 
consequences (such as reduced work performance, and social impairment).  It is these 
latter, more psychosocial, variables that are the target of HRQoL assessment, capturing 
impairment relevant to patients’ everyday functioning.  Because health impact is easier to 
quantify than global QoL, most generic HRQoL instruments typically focus on similar 
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aspects of functioning: covering physical, psychological (emotional) and social well-being 
(Wood-Dauphinee, 1999).  Subsumed under these functioning domains are isolated 
symptoms, such as mood, memory, and fatigue.  The various ‘levels’ of measurement have 
been likened to a pyramid (Spilker, 1990): the top of which can be thought of as overall 
subjective well-being/quality of life; the second level representing a collection of functional 
domains; and the third, foundation level, consisting of a number of isolated symptoms.  
Disease-specific HRQoL scales will tend to be tailored to aspects of impaired functioning 
that are most salient within a particular population, covering a mix of global functioning 
domains and relevant symptoms (e.g. fatigue, pain, and physical functioning in cancer 
patients).  Table 2.1 provides descriptions of the scales used to assess HRQoL and QoL in 
insomnia populations.   
 
2.5. Does insomnia negatively affect HRQoL? 
Given the reported daytime symptoms attributed to poor sleep (ICSD-2, 2005; DSM-IV, 
1994;  Edinger et al., 2004) it is reasonable to assume that individuals suffering from a 
chronic sleep problem may have a somewhat reduced ‘downstream’ HRQoL.  Indeed, 
about two decades ago, the first studies began to appear focusing on the relationship 
between insomnia and HRQoL.  Rombaut and colleagues (1990) created what they call the 
Quality of Life of Insomniacs (QOLI) questionnaire, a 52-item scale designed from the 
amalgamation of three other questionnaires (Leeds sleep evaluation questionnaire, the 
Jenkins sleep evaluation scale, and the Psychological well-being index) and 22 additional 
items, to assess functioning across five broad domains: quality of sleep, physical well-
being, mood and mental state, and social and professional/work relationships.  
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Concept measured Instrument Brief description Comments
Generic Health status/HRQoL SF-36 
36 items covering 8 dimensions of functioning: physical functioning, physical role 
limitation, bodily pain, vitality, mental health, emotional role limitation, social 
functioning, health perception.  Can calculate dimension scores, and two component 
summary scores for mental and physical well-being. 12 and 8-item versions are also 
available.
Appears sensitive to insomnia impairment and treatment  
Extensive normative data and disease norms available
NHP 
38 items assessing impact of illness across 6 dimensions (sleep, energy, pain, 
physical mobility, social isolations, emotional reactions). Combined weighted values of 
individual items make up total dimension scores (0-100).   
Simplistic dichotomous response format. Focus on extreme ill-
health
SIP 
136 yes/no items grouped into 12 categories (body care and movement, ambulation, 
mobility, social interaction, alertness behaviour, emotional behaviour, household 
management, recreation and pastimes, communication, eating, work, sleep and rest).  
Items are completed with reference to 'today and because of health'.  Global profile 
score, category scores, and summary physical and psychosocial scores, can be 
calculated.
Exhaustive number of items
Quality of Life QoLI 
Based on a model of 'life satisfaction', covering 17 domains (health and non-health) 
identified from the literature as being important for overall 'life satisfaction': health, self-
regard, philosophy of life, standard of living, recreation, learning, creativity, social 
service, civic action, love relationship, friendships, relationships with children, 
relationships with relatives, home, neighbourhood, community. 
Total score is based on domains only regarded as important 
and relevant by respondents.                                           
Q-LES-Q (short 
form) 
Contains 16 item-domains (health & non-health).  14 of these single item-domains 
make up the total score (physical health, mood, work, social relations, ability to 
function in daily life, ability to get around physically, household activities, family 
relationships, leisure, sexual drive, economic status, living or housing situation, vision, 
overall sense of well-being).     
Sensitive to treatment outcome in depression and anxiety.
Disease-specific HRQoL QOLI 
52-item scale encompassing three questionnaires (Leeds Sleep evaluation 
questionnaire, Jenkins Sleep Evaluation Scale, Psychological well-being index) plus 
additional item questions, grouped into five domains: quality of sleep, quality of 
waking, physical well-being, mood and mental state, and relationships.
Varying response formats
HD-16 16-item scale, covering five core domains (physical role, energy, cognitive, social, and psychological well-being). Global and domain scores can be calculated.  Items generated by insomnia patients and experts
Table 2.1 - Instruments used to assess HRQoL and QoL in insomnia populations
 
        HD-16 = Hotel Dieu-16; Q-LES-Q = Quality of life enjoyment and satisfaction questionnaires; QOLI = Quality of life of insomniacs questionnaire;  
        QoLI = Quality of life inventory; NHP = Nottingham health profile; SF-36 = Short-Form health survey; SIP = Sickness impact profile.                                           
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The scale therefore measures both sleep and non-sleep variables.  The initial pilot study 
revealed good discriminant properties between untreated insomnia patients and normal 
sleeping controls, with the patient group showing statistical impairments on each 
domain.  However, the scale has not been widely used since; only a few early studies 
have employed it (Kelly et al., 1993; Goldenberg et al., 1994), or variants of it 
(DeSouza, 1996).  This is likely to be because of poor face validity (i.e. items are not 
grounded in the words of individuals with insomnia), the simultaneous evaluation of 
both sleep and daytime variables, varied response formats, and the exhaustive number 
of items.  Nevertheless, the limited data on the QOLI do indicate sensitivity to 
impairment in a number of HRQoL domains, relative to normal sleepers. 
 
The bulk of published studies focusing on HRQoL and insomnia have used a generic 
health status measure, the Medical Outcomes Study short-form health survey 36 (SF-36; 
Ware & Sherbourne, 1992).  The SF-36 is a generic instrument, initially designed for 
assessment of health status across different disease states.  Eight dimensions (36 items) 
assess aspects of functioning (emotional role limitations, energy and vitality, social 
functioning, physical functioning, physical role limitations, bodily pain, mental health) 
and perceived general health, yielding two component summary scores for mental and 
physical well-being.  Scores range from 0 to 100 - with lower scores indicating greater 
impairment in health status, or HRQoL.  Short forms of the SF-36, the SF-12 and SF-8 
have also been published and validated. 
 
The first studies to use this instrument with insomnia populations consistently 
demonstrated lower scores on all domains, relative to normal sleepers (Hatoum et al., 
1998; Zammit et al., 1999; Hajak & Sine, 2001).  Several large survey studies have also 
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now reported a graded trend with insomnia severity; that is, those with more ‘mild’ or 
occasional insomnia symptoms show greater impairment on all eight domains relative to 
normal sleeping controls, whereas individuals (typically) satisfying criteria for insomnia 
disorder score significantly lower than both groups (Hatoum et al., 1998; Leger et al., 
2001; Schubert et al., 2002; Katz & McHorney, 2002; LeBlanc et al., 2007*).  Such 
associations continue to hold after controlling for both physical (Schubert et al., 2002; 
Katz & McHorney, 2002) and mental health co-morbidities (Leger et al., 2001; Katz & 
McHorney, 2002).  Although these studies differ in terms of what they classify as ‘mild’ 
or ‘severe’ insomnia, the linear pattern between HRQoL and insomnia severity 
consistently emerges.   
 
More recently, Dixon and colleagues (2006) analyzed baseline SF-36 data (n=209) 
collected during a randomized trial of Cognitive Behavioural Therapy (CBT) to reduce 
hypnotic intake (cf. Morgan et al., 2003), and compared them with UK normative 
values.  In this study, the authors stratified domain scores by age, creating three groups 
(30-49, 50-69, 70-100 yrs), and compared them with their corresponding age-matched 
reference values.  Similarly, it was found that those meeting minimum criteria for 
insomnia disorder (DSM-IV), in the ‘young’ category (ages 30-49), had significantly 
lower scores on all domains of the SF-36; the middle category (50-69 yrs) were 
impaired on all but two domains (emotional role limitation, physical role limitation); 
and the elderly category were significantly impaired in four out of the eight domains 
(pain, vitality, mental health, physical functioning), relative to reference values.  The 
high degree of co-morbidities, particularly chronic illness and pain interference (anxiety 
and depression scores were in the normal to mild ranges), may mediate, to some extent, 
the magnitude of impaired dimensions.     
                                                 
*
 LeBlanc et al. used the SF-12 in their Quebec population-based study 
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In contrast to the more clinical- and effectiveness-based approach of Dixon et al., Walsh 
and colleagues (2007) collected SF-36 data in the context of a multi-centred RCT of 
nightly Eszopiclone for a six-month period, on a large sample (n=830, 21-64 yrs) of 
well-defined PIs (sleep parameter inclusion and DSM-IV criteria).  Comparison of pre-
treatment SF-36 scores with US normative reference values, revealed significant 
impairments in vitality, social functioning and the overall mental health summary 
component.  The more selective decrements are likely to be explained by the stringent 
level of screening/exclusion and the nature of recruited versus referred populations (e.g. 
Stepanski et al., 1989; Davidson et al., 2009).              
 
In a similar vein, Omvik and colleagues (2008) recently published baseline data on 
daytime functioning and QoL variables from a randomized trial of CBT versus 
zopiclone (cf. Sivertsen et al., 2006a).  SF-36 scores from 46 elderly individuals (>55 
yrs: mean age 60.9 yrs) with DSM-IV criteria insomnia, who had undergone rigorous 
screening (including PSG), failed to reveal any significant evidence of impairment 
relative to normative values.  The authors do not, however, report data for each of the 
eight dimensions; instead using the mental health and physical health component 
summary scores for comparison.  This may obscure differences at the dimension level.  
Nonetheless, data collected on another generic instrument, the Quality of Life Inventory 
(QoLI; Frisch et al., 1992), in the same sample, also revealed scores within the normal 
range.  The QoLI is based on a conceptual model of general ‘life satisfaction’, asking 
patients to rate the importance of 17 pre-determined domains deemed important for an 
enjoyable life, and thus covers a wide-range of items not necessarily specific to health.  
It is perhaps not surprising that the composite score of this measure failed to detect 
insomnia-relevant impairment.  It is worth pointing out, however, that the key strength 
 57 
of this scale is that composite scores are calculated only on items that are rated as 
important/relevant by the individual. 
 
Another study (Lichstein et al., 2001a), again focusing on older adults (58+ years), 
compared well-defined PIs (n=82), normal sleepers (n=61), and those with ‘secondary’ 
insomnia (n=46) on dimensions of the SF-36.  Only one difference was found for the 
comparison between PIs and normal sleepers; with PIs scoring lower on the vitality 
dimension.  Those with ‘secondary’ insomnia were significantly impaired on seven of 
the eight dimensions (except role-emotional) relative to both the PI group and normal 
sleepers.  The reduced sensitivity of the SF-36 to HRQoL impairment in elderly 
individuals with insomnia, especially those with primary insomnia, seems to be a 
recurrent finding.  It is unclear what may be mediating this trend.  Perhaps elderly 
individuals, who have had their sleep problem for a long period of time, adapt and 
‘recalibrate’ in a way that limits the impact of insomnia on aspects of functioning.  
Conversely, normative reference values for this age group may be low anyway, given 
the high level of co-morbidity and reduced functional abilities associated with normal 
ageing - subsequently obscuring potential differences. 
 
Researchers have also used a variety of other tools to assess HRQoL.  For example, 
Philip et al. (2006) compared those with insomnia (n=986), and normal sleepers 
(n=586), on the Nottingham Health Profile (NHP; Hunt et al., 1980).  The NHP, similar 
to the SF-36, measures salient areas of health functioning, comprising 38 yes/no 
statements under six main domains: energy level, pain, sleep, social isolation, emotional 
reactions, and physical abilities.  Individuals with insomnia were characterized 
according to DSM-IV symptom criteria, and had to report difficulties at least three 
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times per week for the last three months; daytime functioning was not assessed.  
Significant differences were observed on all domains, with the insomnia group 
evidencing significant impairment.  This pattern of impairment was similarly found in a 
selected sub-group (n=442) of the insomnia sample, screened for both organic sleep 
complaints (using the Epworth Sleepiness Scale; ESS) and depressive symptoms.          
 
Leger and colleagues (2005) recently published the Hotel Dieu 16 (HD-16), a disease-
specific measure designed to detect quality of life disturbance relevant to insomnia.  
Items for the HD-16 were initially generated from interviews with 20 patients and 
through expert consensus opinion.  Factor analysis on an initial list of 43 items resulted 
in the final selection of 16 items, subsumed under five categories: physical role; energy, 
will to do things; cognitive (concentration, attention, memory); social (relationships 
with others); and psychological well-being.  Good sleepers (n=391), individuals with 
‘mild’ insomnia (n=422), and individuals with ‘severe’ (n=240) insomnia, were 
selected from SOFRES, a French polling institute.  The ‘mild’ insomnia group were 
defined as those with ‘occasional’ sleep difficulties; whereas those in the severe group 
had at least two insomnia complaints for the last month, and suffered impaired daytime 
functioning as a consequence.  Initial screening excluded those with depressive or 
anxiety profiles; those with other medical co-morbidities were not identified or 
excluded.  A linear trend was again found, similar to studies using the SF-36: the mild 
insomnia group scored significantly lower on all dimensions, and global score, relative 
to good sleepers; individuals with severe insomnia scored significantly poorer than both 
groups, again on each dimension and total score.  Thus, prima facie, the HD-16 does 
look sensitive to the functional impairments experienced by those with insomnia, and 
has good face validity given that items are grounded in words of sufferers.  A further 
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strength is the ability to configure a total score, which may be useful in outcome studies, 
as well as clinical settings.  Despite being a relatively brief measure, however, 
dimension calculation looks to be a rather complex and arduous process (based on 
weighted coefficients from the factor analysis), and so this may preclude it from being 
used on a regular basis in clinical settings.  Further studies are required to assess 
psychometric properties and sensitivity to change.                         
 
The HD-16 was principally devised because of the absence of a widely used insomnia-
specific HRQoL instrument, as compared with, for example, the sleep apnea field, 
where there are three - the Functional Outcomes of Sleep Questionnaire (FOSQ; 
Weaver et al., 1997), the Sleep Apnea Quality of Life Index (SAQLI; Flemons & 
Reimer, 1998), and the Québec Sleep Questionnaire (QSQ; Lacasse et al., 2004).  The 
implication being: generic measures like the SF-36 may not pick up impairments 
relevant to those with insomnia (Moul et al., 2004).  Nevertheless, the main strength of 
the SF-36 is that it permits comparisons with other illnesses; which of course is vital in 
order to document the relative burden of insomnia.  In this context, Katz & McHorney 
(2002) found, in a cross-sectional analysis of data from the medical outcomes study 
(MOS), that those with mild and severe insomnia (defined in terms of frequency of 
symptoms over a 4-week period) scored significantly lower on all domains of the SF-36 
relative to a mild hypertension reference group.  More importantly, however, the 
magnitude and distribution of HRQoL decrements of the severe insomnia group were 
comparable to individuals with clinical depression and congestive heart failure (see 
figure 2.1), even after controlling for 16 co-morbid conditions, and various other 
demographics.  This pervasive nature of insomnia fits well with what patients report: 
sleep disturbance has a knock-on effect on nearly every aspect of daily functioning 
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(Kyle et al., in press), whereas many other conditions are more selective in their 
consequences.   
 
Figure 2.1- Deviations in SF-36 scores for Insomnia, Depression, and Congestive Heart Failure, 
relative to hypertension reference group.  Scores plotted from Katz & McHorney (2002).   
 
PF = physical functioning; RP = role-physical; BP = bodily pain; GHP = general health perception; VT = 
vitality/energy; SF= social functioning; RE = role-emotional; MH = mental health. 
 
One final line of evidence to support the view that disturbed sleep can have a bearing on 
aspects of HRQoL comes from studies looking at the additive effect of poor sleep on 
existing conditions.  In a recent study, ‘poor sleep’ (measured using the PSQI) was 
found to be a significant independent predictor of mental and physical health 
component scores (from the SF-36) in patients with multiple sclerosis (Merlino et al., 
2009).  Fortner et al. (2002), again using the PSQI, categorized breast cancer patients 
into ‘good’ and ‘bad’ sleepers; finding that ‘bad’ sleepers scored lower on six (role-
physical, bodily pain, vitality, social functioning, role-emotional, and mental health) of 
the eight SF-36 dimensions.  Other studies using more concrete definitions of insomnia 
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reveal a similar pattern.  For example, Caap-Ahlgren & Dehlin (2001) reported that 
Parkinson’s disease patients with insomnia had impaired HRQoL on every dimension of 
the SF-36, relative to those without insomnia symptoms.  Rumble et al. (2005) also 
demonstrated lower scores in lung cancer patients meeting criteria for insomnia on the 
‘global health/quality of life’ 2-item sub-scale scale from the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C30; 
Aaronson et al., 1993), a cancer-specific HRQoL questionnaire, relative to a control 
group of cancer patients without insomnia. 
 
Overall, cross-sectional studies highlight the pervasive impact of insomnia on aspects of 
functioning and HRQoL, and this relationship holds, to varying degrees, after 
controlling for co-morbidities.  Well-screened PIs appear to have more selective 
impairments relative to those individuals in the population-based and clinical studies, 
which might be expected given the reported (and unreported) co-morbidities in the latter 
groups.  There is some evidence to suggest that individuals with co-morbid insomnia 
experience greater/entrenched daytime functioning impairments relative to PI patients 
(Lichstein et al., 2001a). Crucially, both disease-specific and generic instruments appear 
to be sensitive to HRQoL impairments.           
 
2.6. Does improving insomnia also improve aspects of HRQoL?  
Because health-related functional impairments are prevalent within insomnia 
populations, and enshrined in the diagnostic criteria, treatment should ultimately target 
and alleviate such impairments.  That is, improving sleep should improve functioning 
(this of course is based on the notion that impaired sleep is causally related to reduced 
HRQoL).  Surprisingly, very few controlled studies (see table 2.2) have included 
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assessments of HRQoL (see Krystal, 2007, for a review of more general daytime 
parameters), and only two have specified HRQoL as the primary outcome measure.   
 
Table 2.2 specifies the following: all controlled studies of insomnia treatment that 
include a HRQoL or QoL measure; two additional uncontrolled trials of insomnia 
treatment, specifying HRQoL as one of the primary outcome variables of interest; and 
finally two large RCTs of CBT-I in those with insomnia and cancer (selected only as 
examples of how treating insomnia can modify HRQoL variables pertinent to the co-
occurring illness).  All papers were sourced by searching major search engines 
(PubMed, ISI Web of Knowledge, ScienceDirect), and through hand-picking citations 
from existing published articles.         
 
2.6.1. Cross-sectional & uncontrolled studies 
Leger and colleagues (1995) conducted a cross-sectional study, selecting patients with 
insomnia who had been on zopiclone for at least twelve months, and compared them 
with a matched group of good sleepers, on a study-specific QoL instrument.  ‘Quality of 
life’ was assessed using questions probing five core domains: work, relationships, 
safety, domestic activities, and leisure activities.  The groups did not differ in terms of 
sleep disturbance, except that the Zopiclone patients had ‘occasional’ difficulties falling 
asleep.  It was also found that both groups had comparable scores for each QoL domain.  
Similarly, using a cross-sectional design, Zammit and colleagues (1999) compared 
recruited treated insomnia patients with a matched group of untreated patients, on the 
SF-36.  They, however, found no differences across dimensions between groups.  The 
use of a non-validated questionnaire in the Leger et al. study, and the poor 
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Study Methods/intervention
Sample size/ 
characteristics Instrument used Sleep outcome HRQoL outcome
Uncontrolled Hajak et al. 2002 
Multi-national randomized trial of 
zolpidem 10mg 5 nights/week 
(remaining 2 nights were given 
placebo) versus nightly use, for 14 
days.
789 PIs (DSM-IV) free from 
medication at intake SF-36
Both discontinuous and continuous 
groups had similar numbers (59 v. 
65%) rating 'much improved' or 
'very much improved' on the CGI-II 
Improvements on all SF-36 
dimensions were similar between 
groups.  No within-subject statistical 
testing reported.
Verbeek et al. 2006 Compared individual CBT with group CBT
32 PIs (Individual CBT) 
versus 74 with mix of PI and 
co-morbid insomnia (group 
CBT)
Three sub-scales from the SIP 
(social interactions, alertness/ 
intellectual functioning, and 
recreation) and four 'sub-scales' 
from the RAND-36 (‘general 
health’, ‘problems at work’, 
‘social occupation’, and ‘feeling’)
Both groups had significantly 
improved SOL, WASO, TST, and 
SE, relative to baseline
Composite ratings on both scales 
significantly improved at 9-month 
follow-up, for both group and 
individual CBT.
Prospective randomized 
controlled trials
Goldenberg et al. 
1994 
Multi-national RCT of zopiclone 7.5mg 
versus placebo taken nightly for 2 
weeks, and on demand for 6 weeks 
thereafter
231 received zopiclone; 227 
received placebo.  
Participants had to report 
two insomnia symptoms for 
inclusion, and were excluded 
for co-occurring illness or 
CNS affecting medication.  
QOLI
Zopiclone  group had significantly 
greater improvements in the sleep 
domain 
2 month follow-up: both groups 
improved on the psychological well-
being domain and overall score, but 
treatment group had significantly 
greater improvements on activity, 
social, and work/profession domains.
Walsh et al. 2000 RCT of zolpidem 10mg versus placebo (3-5 nights per week for 8 weeks)
163 PIs meeting DSM-IV 
criteria SF-36
Treatment group significantly 
improved on patient global ratings 
and diary measures of SOL, TST, 
NAW, and sleep quality
No significant group differences at 
any time point (4,8 weeks)
Morin et al. 2005 Randomized placebo controlled trial of 
valerian-hops and diphenhydramine
184 'mild' insomniacs, 
experiencing initiation and/or 
maintenance problems for 
between 2-4 times per week 
for at least a month.
SF-36
Both treatments had a mild 
hypnotic effect at two-week 
assessment relative to placebo
Small but significant improvement on 
the Physical component summary 
score for Valerian compared with 
placebo group at 4-week assessment 
point.
Savard et al. 2005 RCT of CBT versus wait-list control
57 females who had 
undergone treatment for 
breast cancer, and reported 
significant insomnia for 6 
months (DSM-IV/ICSD-2 and 
standard quantitative criteria)
Sub-scale assessing 
'health/global quality of life' 
taken from the EORTC QLQ-
C30 
Significant CBT improvements on 
measures of SOL, WASO and SE 
post-treatment relative to wait-list 
controls
Significantly greater improvements 
on global 'health/quality of life' scores 
for the CBT treated patients at  post-
treatment.   Pooled data for both 
groups revealed maintenance of 
improvements at 12 months, 
compared to baseline.
Scharf et al. 2005 RCT of Eszopiclone 1mg, 2mg or placebo nightly for 2 weeks.
231 Elderly PIs (age range 
65-85) meeting DSM-IV 
criteria   
Q-LES-Q
Significant treatment effects for 
2mg on SOL, WASO and TST 
relative to placebo
2mg treatment group demonstrated 
improvements in five domains 
(physical health, mood, household 
activities, leisure time activities, and 
medication)
Table 2.2 -  Insomnia treatment studies assessing Health-Related Quality of Life as an outcome variable
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Dixon et al. 2006 
RCT of group CBT versus 'no 
additional' treatment in a general 
practice clinical setting  (Morgan et al., 
2003)
209 hypnotic users meeting 
diagnostic criteria (DSM-IV) 
for insomnia
SF-36
CBT group had significantly 
decreased PSQI global score and 
lower percentage of group on 
hypnotics, compared with controls.
CBT group significantly improved on 
physical functioning, emotional role 
limitation, and mental health, relative 
to control group (6 month time 
adjusted means)
Espie et al. 2007 RCT of group CBT versus TAU  in a 
clinical setting
201 individuals meeting DSM-
IV/ICSD-2 and quantitative 
criteria for insomnia
SF-36
CBT group significantly improved 
on measures of SOL and WASO at 
6 months relative  to TAU group
At 6 months: significant 
improvements in energy/vitality and 
mental health dimensions (small ES) 
for CBT versus TAU
Walsh et al. 2007 Multi-centred RCT of Eszopiclone 3mg 
versus placebo, nightly for six months 830 PIs SF-36
SOL, WASO, TST signficantly 
improved relative to placebo at six-
months (medium to large ES).
Vitality (small to moderate ES), social 
functioning, physical functioning, and 
bodily pain (small ES) were all 
significantly improved relative to 
placebo group at 6 months.
Espie et al. 2008 Pramgatic RCT of CBT versus TAU 
150 cancer patients 
undergoing active cancer 
treatment,  and reporting 
significant insomnia (meeting 
standard quanitative criteria 
for at least three nights in 
last three months, and 
daytime functioning 
impairment). 
FACT-G (functional assessment 
of cancer therapy). Sub-scales  
phsyical, emotional, social and 
functional well-being  
CBT group significantly improved 
on measures of SOL, WASO and 
SE (large ES), realtive to TAU.
At 6 months, CBT group signficantly 
improved on the physical and 
functional domains (large ES)
Soeffing et al. 2008 
Randomized trial of three-component 
CBT (stimulus control, sleep hygeine, 
relaxation) versus sham biofeedback
47 hypnotic-dependent older 
adults SF-36
CBT significantly improved on SOL, 
WASO and SE (medium to large 
ES) relative to sham control group.
Neither group improved on any 
dimension of the SF-36, at 4 weeks.
Omvik et al. 2008 
RCT of Zopiclone 7.5mg versus group 
CBT versus pill placebo for 6 weeks 
(Sivertsen et al., 2006)
46 elderly (mean age = 55) 
adults meeting criteria for PI SF-36 & QoLI
Post-treatment: CBT significantly 
improved relative to placebo and 
zopiclone groups on (objective) 
WASO and SWS; both treatment 
groups had improved objective SE 
compared with placebo (PSG).  
CBT group more improved on 
objective (WASO, SE, SWS) and 
subjective (WASO) parameters 
relative to zopiclone group at 6 
months.
No evidence of improvements 
between or within groups, post-
treatment. or at 6 months follow-up 
(placebo group not included in 
analyses)
CBT, Cognitive Behavioural Therapy; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; EORTC QLQ-C30, European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire; ES, Effect Size; FACT-G, Functional Assessment of Cancer Therapy – General; CGI-II, Clinical Global Impressions Scale; ICSD-2, 
International Classification of Sleep Disorders, 2nd Edition; ISI, Insomnia Severity Index; NAW, Number of Awakenings; NHP, Nottingham Health Profile; PI, Primary Insomnia; PSG, 
Polysomnography; PSQI, Pittsburgh Sleep Quality Index; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; QOLI, Quality of Life of Insomniacs Questionnaire; QoLI, 
Quality of Life Inventory; RCT, Randomised Controlled Trial; SE, Sleep Efficiency; SF-36, Short-Form Health Survey; SIP, Sickness Impact Profile; SOL, Sleep Onset Latency; SWS, 
Slow-Wave Sleep; TAU, Treatment As Usual; TST, Total Sleep Time; WASO, Wake-time After Sleep Onset.      
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characterization of patients in the Zammit et al. investigation, coupled with the cross-
sectional nature of both papers, means these data do not provide strong enough evidence 
to help elucidate the relationship between HRQoL and treatment of insomnia. 
 
As part of a multi-national study, Hajak et al. (2002) compared continuous versus non-
nightly zolpidem in a large sample of individuals with insomnia.  Both groups had a 
similar number of ‘responders’, as determined by the clinical global impression 
improvement score, and SF-36 improvements were also similar for both groups across 
all dimensions (non-significant group x time effect). However, there was no appropriate 
placebo/control group, and within-group analyses were not reported on the dimensions; 
it is therefore hard to tell if and how treatment affected specific domains of HRQoL.  
 
Verbeek et al. (2006) reported data from both individual (n=32) and group CBT (n=74) 
on primary outcomes of both sleep and HRQoL parameters.  Across treatment 
modalities, sleep-onset latency (SOL), wake time after sleep-onset (WASO), sleep 
efficiency (SE), and total sleep time (TST), significantly improved and remained robust 
at the 9 month post-treatment assessment. To sample HRQoL domains relevant to those 
with insomnia, the authors selected items probing four domains (‘general health’, 
‘problems at work’, ‘social occupation’, and ‘feeling’) from the RAND-36*, a 
practically identical scale to the SF-36, and three sub-scales (social interactions, 
alertness/intellectual functioning, and recreation) from the 136-item sickness impact 
profile (SIP; Bergner et al., 1981).  Both treatment groups showed comparable 
improvements in ‘global’ scores of the RAND-36 and SIP, with the SIP demonstrating 
the most robust effects, at 9-month follow-up.  The authors, however, did not detail 
                                                 
*
 The Rand-36 is an exact replica of the SF-36 in terms of content, but has different scoring algorithms for 
the Bodily pain and General Health sub-scales. 
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scores for each subscale, in either the RAND-36 or SIP, making it impossible to identify 
what specific HRQoL components were most sensitive to the CBT intervention.  The 
lack of a control group also prevents ruling out nonspecific effects; it is notable that the 
intermediate phase before receiving therapy (i.e. between baseline and post-waitlist) had 
significant positive effects on both sleep and HRQoL measures.  The authors believe 
sleep hygiene advice, provided at the first screening interview, may account for this, 
although the current literature on sleep hygiene recommendations for insomnia would 
perhaps argue against this interpretation (cf. Stepanski & Wyatt, 2003).  A relevant 
control group seems essential for an accurate interpretation of HRQoL outcomes; the 
placebo impact of sham CPAP, for example, has been documented in OSA patients,  
where ‘active’ and control groups can show comparable improvements across a number 
of functioning and HRQoL domains (Atkeson & Basner, 2008).  
 
2.6.2. Prospective controlled trials 
A number of prospective controlled trials have included a validated instrument to assess 
QoL or HRQoL domains.  Goldenberg et al. (1994) conducted a multi-national RCT of 
zopiclone versus placebo.  Two hundred and thirty one patients were randomized to 
receive 14 days of zopiclone (and on demand for six weeks thereafter) and 227 received 
placebo.  All patients completed Rombaut et al.’ QOLI.  At two weeks, both groups 
showed improvements in the psychological well-being component and overall global 
‘quality of life’ score, but the zopiclone group demonstrated significantly greater 
improvements in the sleep, activity, social, and work/profession domains.  Relative 
improvements remained for activity, sleep and social domains at the two-month follow-
up. 
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Walsh et al. (2000) conducted an 8 week RCT of zolpidem 10mg versus placebo (3-5 
nights per week) in 163 PIs.  Although sleep parameters improved significantly post-
treatment in the experimental group, there was no corresponding change on any 
dimension of the SF-36.  Dixon and colleagues, in their analysis of SF-36 outcome data 
from 209 individuals on hypnotics (with continuing insomnia) randomized to either 
CBT or control, found simultaneous improvements in sleep and HRQoL, relative to a 
control group.  PSQI global scores significantly decreased, as too did the percentage of 
hypnotic users in the experimental group.  Time-weighted mean adjustments across the 
6 month follow-up period revealed significant improvements in physical functioning, 
emotional role limitation, and mental health, relative to the control group.  On closer 
inspection however, these ‘improvements’ do appear to be largely mediated by 
declining functioning in the control group (e.g. up to a 16 point decrease for the 
emotional role dimension).  Regardless, the data show an overall tendency for the CBT 
group to improve, albeit marginally, and the control group to experience further 
impairment.  CBT improvements, in this particular population, might then be argued to 
act as an important buffer, preventing further (likely) decrements in HRQoL.   
 
More recently, Soeffing et al. (2008) reported data from a randomized trial of a three-
component cognitive behavioural intervention (stimulus control, relaxation, and sleep 
hygiene) or sham biofeedback (psychological placebo), in a small sample of hypnotic-
dependent older adults (n=47).  At post-treatment, significant effects were found for the 
CBT treated group in terms of subjective sleep parameters (SOL, WASO and SE; 
medium to large effects) but there was no corresponding improvement in SF-36 scores 
(mean dimension/component scores were not reported).  Indeed, there was no 
improvement in any of the other daytime assessments probing sleepiness, fatigue, 
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anxiety or mood.  The rather early post-treatment assessment could perhaps undermine 
improvements, particularly using the SF-36 instrument which has a 4-week recall 
period.            
 
Espie and colleagues (2007) conducted an RCT of CBT versus treatment as usual 
(TAU) in general practice, using trained nurses as CBT therapists.  At the 6 month 
follow-up, small to moderate effect sizes were found for SOL and WASO relative to 
controls; and a medium effect size (ES) for improvement in sleep efficiency.  Sleep 
improvements were also accompanied by small, but significant improvements in the 
energy/vitality and mental health subscales of the SF-36, relative to the TAU group.  
Importantly, though, these follow-up improvements are still substantially lower than 
normative reference values, which again is likely to be mediated by the ‘real world’ 
clinical context.                  
 
Walsh and colleagues (2007), in their large RCT of Eszopiclone versus placebo, 
assessed HRQoL and daytime functioning as primary outcome measures.  Changes in 
sleep parameters were significantly larger in the treatment group for SOL, WASO and 
TST (medium to large ES) relative to the placebo group at the 6 month follow-up, and 
50% scored ≤ 7 on the Insomnia Severity Index (ISI; compared with 19% in the placebo 
group).  In terms of HRQoL, SF-36 domains of vitality, social functioning, physical 
functioning, and bodily pain were all significantly improved relative to the placebo 
group at six months (small to moderate ES for the vitality domain, and small ES for the 
rest of the domains).  Although the authors report ‘no change’ in terms of sleep 
variables during the discontinuation period (i.e. sleep gains were maintained), they do 
not report data on HRQoL parameters.  This is likely to be because of the short 2-week 
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interval, coupled with the SF-36 recall period; nevertheless, it would be interesting to 
see if these improvements are maintained beyond ‘active’ treatment. 
 
In the original study by Sivertsen et al. (2006a), the authors showed that PI patients 
treated with CBT improved in both objective and subjective sleep parameters, relative 
to a zopiclone treatment group, and that these relative improvements remained robust at 
6-month follow-up.  In a recent follow-up report on daytime functioning measures from 
this trial, Omvik and colleagues (2008) failed to find any evidence of impairment (at 
baseline) relative to normative values, using the SF-36 and the QoLI.  Not surprisingly, 
then, they also failed to find a significant group interaction effect, with neither treatment 
improving mental or physical health component scores (a possible ceiling effect), at 
post-treatment or follow-up.  Again, however, they did not report dimension values, and 
so subtle component effects may be masked.  One interesting finding, when groups 
were collapsed, was a significant association between pre-post increases in QoLI scores 
and increases in slow-wave sleep.  This does point to a potential relationship between 
objective sleep and relevant quality of life variables.   
 
Another study (Scharf et al., 2005) used a generic QoL measure, the Quality of Life 
enjoyment and satisfaction questionnaire (Q-LES-Q; Endicott et al., 1993), comprising 
16 separate dimensions (both health and non-health). Scharf and co-workers reported 
significant improvements in five domains (physical health, mood, household activities, 
leisure time activities, and medication) in a group of elderly PIs treated with 
Eszopiclone 2mg, relative to a placebo group.  These were accompanied by 
improvements in SOL, WASO and TST compared with placebo.  Final assessment was, 
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however, short at two-weeks, and the authors do not present baseline or post-treatment 
means, preventing comparison with norms or other clinical groups. 
 
Morin et al. (2005) conducted a randomized-placebo controlled trial of valerian-hops 
and diphenhydramine, on a group of ‘mild’ insomniacs (n=184; experiencing 
difficulties in initiating and/or maintaining sleep for between 2 and 4 times per week, in 
the last month).  Relatively mild hypnotic effects were found with both treatments, 
particularly at the two week assessment.  In the comparison between valerian and 
placebo at four weeks, the valerian group showed a small but significant relative 
improvement on the physical component summary of the SF-36.  Dimensions scores 
were not presented and the mental health component summary failed to reveal any 
improvements.  The limited and short-lived improvements in sleep may account for the 
marginal improvements in HRQoL, coupled with the fact that patients were not required 
to self-report daytime dysfunction on study entry, perhaps creating a ceiling effect, and 
subsequently making it harder to detect noticeable changes in functioning post-
intervention. 
  
In line with contemporary conceptualizations of insomnia as a potentially ‘co-occurring’ 
phenomenon, and not merely a secondary ‘nuisance’ symptom (Stepanski & Rybarczyk, 
2006; Lichstein, 2006), recent studies have examined the impact of treating insomnia 
within the context of other disorders on aspects of HRQoL.  For example, Espie and 
colleagues (2008) recently conducted a pragmatic RCT of CBT versus treatment as 
usual (TAU) in cancer patients (n=150), who had completed active cancer treatment but 
also reported significant insomnia.  At 6 months follow-up, the CBT group evidenced 
significant improvements in measures of SOL, WASO, and SE, with corresponding 
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large effects, relative to the TAU group.  The authors also included a measure of cancer-
related Quality of Life, the Functional Assessment of Cancer Therapy-General (FACT-
G; Cella et al., 1993), assessing physical, emotional, social and functional domains of 
the cancer experience.  At 6 months the CBT group demonstrated significant 
improvements in both the physical and functional domains (large effect sizes).  The 
potential limitation of this scale, in the context of insomnia and HRQoL, is the inclusion 
of sleep items, which interestingly feature only in the subscales that showed statistical 
improvements.  The authors also note that changes in SE and changes in statistically 
significant HRQoL domains were low.  Results from a similar study (Savard et al., 
2005), adopting an efficacy approach, comparing CBT with a wait-list control, also 
demonstrated strong improvements in sleep parameters.  The authors included the 
‘global health/quality of life’ sub-scale from the EORTC QLQ-C30, which revealed 
significant and enduring improvements in treated patients from baseline to 12 month 
follow-up.  Other sub-scales of this measure were not reported (including social, 
emotional, physical and cognitive functioning). 
 
2.7. Reflections on existing insomnia-HRQoL treatment literature 
From the limited treatment studies it is clear that improving sleep, in some cases, can 
lead to statistical improvements in aspects of HRQoL.  However, what is far from clear 
is whether these improvements are clinically meaningful: do they really matter to the 
patient?  For the most part, improvements are small and/or fall short of normative 
values, though this may be dependent on the particular population under investigation.  
Follow-up assessments have typically been short, with most occurring about 6 months 
post-treatment - it is possible that improvements in functioning become apparent well 
after sleep parameters have stabilized, particularly with CBT.  The converse may also 
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occur in those treated with hypnotics: initial improvements may not be sustained after 
discontinuation.  Relationships between sleep parameter changes and HRQoL 
improvements are rarely assessed (or reported), and no study has yet documented 
adequate improvement in HRQoL in primary insomnia patients, using Cognitive 
Behavioural techniques. 
 
Moreover, to our knowledge, no comparative controlled study of CBT versus hypnotics 
exists that demonstrates superior HRQoL outcomes in favour of a particular treatment 
modality (only one relevant RCT [Sivertsen et al., 2006a; Omvik et al., 2008] has 
included a HRQoL measure).  Comparative treatment studies (and intervention studies 
more generally), probing changes in HRQoL, are important because of their 
implications for cost-effectiveness and utility models.  HRQoL scores are typically used 
in the calculation of Quality Adjusted Life Years (QALYs) – a weighted product of life 
expectancy and quality of remaining life years – which can then be combined with 
intervention costs to produce a cost-utility ratio.  This cost/QALY ratio (i.e. the 
difference between the costs of two interventions divided by the difference in QALYs 
gained) then helps establish costs per QALY for a particular insomnia intervention, 
relative to, say, non-treatment, competing insomnia treatments, and other interventions 
for other common medical problems (Martin et al., 2004).  Inexpensive interventions 
(i.e. low cost per QALY) are subsequently prioritized in terms of resource allocation, 
over more expensive ones.  With the contemporary focus on the burden of insomnia it is 
clear that future intervention research must include, and pay attention to, the HRQoL 
concept, in order to document associated morbidity as well as utility of treatment 
(Morgan et al., 2004; Morin, 2004).            
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However, as a field we also need to strive for a more sophisticated understanding and 
conceptualization of QoL and HRQoL, as it relates to insomnia.  From the studies 
reviewed, only a select few actually defined what they were attempting to measure (and 
these were typically cross-sectional or scale development/validation studies).  
Moreover, many refer to assessing or improving ‘quality of life’ when they were 
actually measuring aspects of HRQoL, using a generic health status measure.  It may 
well be true that treating insomnia does improve ‘quality of life’, but where specialised 
measures such as the SF-36, NHP, SIP, or even the HD-16 are used, it may be more 
appropriate to emphasise the measurement of health-related QoL. 
 
The key strength of generic measures, like the SF-36, is the ability to compare scores 
across disease states and with normative community reference values, in a standardized 
manner.  Such data, of course, are vital for cost-effectiveness analyses when, for 
example, comparing treatments, and assessing whether patients return to ‘normal’ 
status.  The sacrifice, however, is the poor specificity to a particular disorder.  The 
inclusion of non-specific domains may dampen the sensitivity of a measure to detect 
change (Hill et al., 1996); this is especially true when only summary scores are reported.  
Future studies should report both overall summary scores and dimension scores, 
particularly in light of literature questioning the independence of the mental and 
physical health components and their representation of individual profile scores (e.g. 
Taft et al., 2001).  Indeed, for these reasons it is recommended that intervention studies 
include both disease and generic HRQoL measurement – with the former typically 
being more sensitive to change than the latter (Guyatt, 1997).  This approach has 
achieved some success in the sleep apnea field (Reimer & Flemons, 2003); and is the 
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recommended perspective by recent insomnia expert consensus workgroups (Buysse et 
al., 2006).   
 
Currently, there is no widely used insomnia-specific measure; attempts to pilot and 
develop new instruments, and investigate the validity/sensitivity of the recently 
published HD-16, should be considered an important research goal.  In the absence of 
specific measures, researchers need to consider using validated scales that tap 
dimensions relevant to the insomnia experience.  Qualitative work from the Pittsburgh 
group (Carey et al., 2005) and more recently our own group (Kyle et al., in press; also 
chapter three of this thesis), reveal the nature of insomnia-related functional 
impairments - specifically in aspects of cognition, occupational functioning, 
social/interpersonal relationships, and limitations in goal attainment.  It is interesting 
that the SF-36 does not adequately assess any of these dimensions; even the social 
functioning scale of the SF-36 simply probes the extent and frequency of interference 
without detailing what that interference may be.  In the case of insomnia this 
interference is likely to be multi-factorial – from rescheduling activities, failing to 
schedule or commit in the first place, cancelling at the last minute, or not enjoying 
social interaction when present.    
 
Another related issue, again concerning the SF-36, is the construct validity of the 
energy/vitality domain.  This dimension resonates best among sleep-disordered patients, 
particularly individuals with insomnia, capturing fatigue-related symptoms common to 
sleep loss/fragmentation.  This however is the problem; the dimension may simply be 
measuring fatigue.  Scale development and evaluation studies typically use the vitality 
sub-scale as a check for concurrent validity, revealing high correlations with 
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instruments such as the fatigue severity scale (e.g. Kleinman et al., 2000).  The danger 
of course being, that studies (cross-sectional and treatment) may confuse assessing or 
improving HRQoL impairment, with modifications in levels of fatigue.  This may prove 
problematic when, for example, collapsing scores into a physical component summary, 
subsequently leading the author to conclude that ‘x treatment improves HRQoL’.  A 
solution to this issue is to always document all measured dimensions, and include, and 
correlate, validated measures of fatigue with the vitality dimension, to see if there is a 
substantial overlap in variance.            
 
A final note on generic measurement concerns the explicit focus on ‘health’ and 
‘illness’ state terminology.  The SF-36 probes the limiting impact of ‘health’ on aspects 
of functioning; it is, after all, a health status measure.  It is not clear if those with 
insomnia, particularly primary insomnia, actually consider poor/disturbed sleep to 
represent a change or variation in health state (it is not uncommon for an individual with 
PI to proclaim, when searching for an underlying causal factor for why they cannot 
sleep, that they are ‘healthy’ and otherwise have a good life).  In comparison with other 
disorders, that perhaps have a more direct health-link, insomnia impairment may be 
more difficult to document reliably, and thus show improvements post-intervention, 
using generic health status tools.  This may explain HRQoL discrepancies between 
clinical, pragmatic studies, and those where PIs are recruited through media adverts.              
 
2.8. Beyond generic measurement: future directions 
Many questions remain unanswered about the nature of HRQoL in insomnia.  The more 
basic ones, such as what are the predictors/mechanisms of HRQoL impairment and 
subsequent improvement will become apparent as researchers increasingly investigate 
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insomnia as a 24-hour disorder.  Some possible targets include: sleep parameters; 
daytime symptoms like fatigue, mood, and neurocognitive impairment; dysfunctional 
beliefs; cognitive biases; and objective markers of the stress system.  Longitudinal 
studies on the natural evolution of insomnia, and the transition between states (i.e. good 
sleepers >>> acute insomnia >>> chronic insomnia), will also prove helpful in better 
defining causal relations between insomnia and HRQoL.   
 
In relation to assessment and measurement, the scope of this review, a prospective 
research agenda should be initiated on adapting and creating new instruments that 
adequately probe the insomnia experience.  One potential avenue, in addition to generic 
measurement, is to adopt a supplemental modular approach (Aaronson, 1989) to 
functional HRQoL assessment.  That is, to consider important domains that are 
commonly reported to be affected by individuals with insomnia, but are not necessarily 
dealt with comprehensively by generic instruments.  For example, occupational 
functioning is cited as a potential daytime consequence in the diagnostic criteria, yet 
little work has actually focused specifically on this domain.  Encouragingly, David & 
Morgan (2006)  recently created and validated the Occupational Impact of Sleep 
Questionnaire (OISQ), a scale that probes the impact of sleep quality on a number of 
work-related areas.  Initial data collected on the OISQ shows it has good discriminant 
ability to distinguish between PIs and good sleepers, and, more recently, significant 
correlations were found with global sleep quality (as measured by the PSQI) and 
sleepiness (ESS) in a Dutch sample of office workers (Verster et al., 2008).   
 
In this context, two recent pharmacotherapy studies are also worth mentioning (Walsh 
et al., 2007; Erman et al., 2008).  Walsh and colleagues assessed work limitations, using 
 77 
the work limitations questionnaire (WLQ; Lerner et al., 2001), in an RCT of 
Eszopiclone versus placebo.  Baseline data showed lower scores on all domains of the 
instrument (time demands, physical demands, mental-interpersonal demands, output 
demands, and work productivity loss) relative to normative values, and somewhat 
comparable scores to those suffering from clinical depression.  Importantly, all domains 
showed a relative improvement in the treatment group versus placebo, across the six-
month treatment phase.  Erman et al. similarly assessed workplace functioning in PI 
patients (n=752) taking part in a randomized controlled trial of Zolpidem versus 
placebo.  The authors analyzed data from two components of the WLQ, the ‘time’ and 
‘output’ sub-scales.  Again, baseline values were more impaired (approximately three 
times greater) than normative healthy controls.  Significant effects of treatment emerged 
after just 12 weeks, which were sustained at the 6-month follow-up, and improvements 
were related to global sleep changes.  These data are important because they not only 
highlight the burden of insomnia on the workplace beyond traditional measures of 
absenteeism - confirming qualitative reports (Kyle et al., 2008) and population-based 
studies (e.g. Daley et al., 2009b) - but also demonstrate the ability to achieve 
simultaneous improvements in sleep and occupational functioning.  Cognitive 
behavioural interventions should include a similar assessment of occupational 
functioning in future treatment trials.   
 
As well as the development and use of relevant instruments, researchers should also 
consider the merit of applying new methods and approaches to assessing insomnia-
related impairment.  For example, the use of ecological momentary assessment (Buysse 
et al., 2007; Levitt et al., 2004) to collect daily diary ratings of common insomnia 
symptoms might provide a new way to track daytime outcomes during treatment, and 
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post-treatment, as well as establishing relationships with nightly sleep parameters.  
There is no reason why this method cannot be adapted to assess, for example, social 
functioning, or subjective workplace performance.  A ‘significant other’ perspective 
(qualitative and/or quantitative) would also be a useful source of information to gauge 
how sleep, and appropriate treatment, affects domains of HRQoL.  To our knowledge 
no study has used this resource to probe daytime functioning and insomnia specifically.  
This also raises the issue of relationship functioning and insomnia.  It has been reported 
that individuals with insomnia have less satisfying interpersonal relationships (Roth & 
Ancoli-Israel, 1999), and although it is unlikely to follow a simple cause-and-effect 
model (for a review, see Troxel et al., 2007), sleep quality may exert a mediating effect.  
It would be interesting to see if treating insomnia can also improve marital/relationship 
quality; certainly, improvements in marital satisfaction have been reported in sleep 
apnea patients after initiation of CPAP therapy (McFadyen et al., 2001). 
 
Global quality of life has been viewed pragmatically in the literature as a multi-
dimensional construct, assessed using commonly reported domains deemed important.  
The likelihood, however, is that QoL means different things for different people - a 
uniquely personal perception (Gill & Feinstein, 1994) - making it difficult to accurately 
measure at the group level, and especially through modular assessment.  One rather 
simple, but valid method might be to ask individuals to rate their quality of life on a 
Likert item or visual analogue scale.  It could be argued that on making this judgment, 
individuals are factoring in all the domains/life areas that are important to them.  This 
single-item format has proved sensitive when documenting, for example, how many 
people within a sample of individuals with insomnia report a ‘very good’, ‘good’, or 
‘poor’ quality of life, compared to those without sleep-complaints (Roth & Ancoli-
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Israel, 1999; Hajak & Sine, 2001).  A similar approach could be tested alongside 
generic and modular assessment in treatment studies; single item visual-analogue scales 
have been shown to be valid, reliable and responsive to change in patient groups (e.g. 
DeBoer et al., 2004).   
 
A related methodological approach would be to tailor items asking patients to report 
whether they think their QoL has improved as a result of treatment; instead of simply 
trying to demonstrate reductions in functional impairments, as generic measures 
typically do.  The Patient Global Impression improvement scale, developed from the 
Clinical Global Impressions scale (Guy et al., 1976), is used for a similar purpose, 
allowing patients to report the extent to which their overall illness symptoms have 
improved post-treatment.  Such an instrument could be modified to assess perceived 
improvements in focused areas of functioning as well as subjective perceptions of 
global quality of life.                
 
It may also be worthwhile directing efforts towards gathering basic qualitative data on 
the individual experience of treatment.  We (Kyle et al., in press) and others (Carey et 
al., 2005; Fox et al., 2007) have successfully applied qualitative methods to 
understanding the daytime insomnia experience, revealing novel insights on the nature 
of functional impairments.  Similar methodologies (semi-structured interviews, audio-
diaries) could be applied to assessing treatment outcomes, as well as the treatment 
process itself.  The SAQLI (Flemons & Reimer, 1998) includes a section looking at 
negative side-effects of CPAP treatment in OSA patients; it is not yet clear what, if any, 
impairments in HRQoL are incurred during CBT for insomnia (stimulus control and 
sleep restriction would be likely candidates for study).  While clinicians may be familiar 
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with how sleep improvements influence patient well-being, systematic study of the 
patient narrative may prove helpful in understanding the treatment process (side effects, 
locus of improvement, mechanisms of change, adherence), and the net impact of 
treatment on daytime functioning and subjective quality of life (at different time-
points).   
 
The importance of measuring items that are relevant, not just to the disorder, but to the 
individual has been noted in the QoL and HRQoL literature (Gill & Feinstein, 1994; 
Carr & Higginson, 2001; Bilsbury & Richman, 2002), and, more recently, by sleep 
researchers (Reimer & Flemons, 2003; Omvik et al., 2008).  We are currently piloting a 
mixed method, patient-centred approach (Ruta et al., 1994; Kyle et al., 2009) to the 
assessment of insomnia-related quality of life (IRQoL) at the Glasgow Sleep Centre.  
By IRQoL we mean ‘the impact of insomnia on aspects of life that are most salient to 
the individual, as reported by the individual’.  Specifically, patients are asked to 
generate, using their own words, the most important areas of their life that are affected 
by sleep disturbance.  These areas are then ranked in terms of importance, and rated in 
relation to extent of interference over a defined time interval.  Items can be assessed pre 
and post-treatment, within- and between-subjects.  This idiographic approach permits 
assessment of areas that are important to the individual, which is likely to be a lot more 
sensitive to change given that we are enhancing the signal (relevance) and reducing the 
noise (non-relevance) associated with generic instruments.  Moreover, it has been 
commented previously (Buysse et al., 2006; Moul et al., 2004; Reimer & Flemons, 
2003) that the major obstacle to creating an insomnia-specific QoL questionnaire is the 
high degree of co-morbidity.  This is certainly the case when conducting pragmatic 
effectiveness trials, or in clinical settings, where other illnesses may mediate scores on 
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HRQoL instruments.  The strength of our individualized approach is that it emphasizes 
the attribution to sleep, and, therefore, it should be theoretically possible to isolate the 
subjective impact of an intervention on sleep only, even in the context of other illnesses.        
 
2.9. Conclusion 
It is clear that insomnia does have a measurable negative impact on domains of HRQoL, 
and that these impairments are not simply limited to obvious domains, like vitality and 
energy, but also extend to other aspects of mental, social, and physical functioning.  
Comparisons with other illnesses, linear trends with insomnia severity, and additive 
effects of insomnia beyond a primary/co-occurring illness, all support and strengthen 
this perspective.  Although research into HRQoL is in its infancy within the insomnia 
literature, there are already emerging data that successful treatment can improve 
functioning across a number of domains.  Of course, to what extent group mean 
improvements are important to individual patients, and their daily lives, remains an 
unanswered question.  Future research in this area should attempt to approach the issue 
of how insomnia treatment improves functioning and individual quality of life, by using 
new innovative methods and instruments.  Such a task is not a trivial undertaking; the 
impact of insomnia on the individual (Kyle et al., in press) and society (Daley et al., 
2009a) is very real, and authors have suggested that the pathway between insomnia and 
depression, for example, may be mediated, in part, through reduced HRQoL (e.g. 
Taylor, 2008). 
 
In order to improve the quality of future research, outcome studies should include a 
generic measure of HRQoL as well as other measures that are relevant to the insomnia 
experience, and have proven sensitivity.  When reporting results, authors should specify 
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baseline scores and their relationship with normative values, detail each profile score as 
well as component/global summary scores, and make some attempt at investigating the 
relationship between sleep improvements and HRQoL changes (i.e. correlation analysis 
and/or responders versus non-responders, based on ISI category change, or quantitative 
sleep variables).          
 
2.9.1. Practice points 
 HRQoL and QoL are not synonymous constructs.  
 Insomnia negatively affects diverse aspects of HRQoL 
 The limited treatment data tentatively suggest that successfully improving 
sleep, using both pharmacological and non-pharmacological interventions, 
can lead to significant improvements in domains of HRQoL. 
 There is a great need to standardize measurement use and reporting of scores 
to facilitate future comparisons and meta-analyses across studies and 
treatment modalities.    
 HRQoL measurement contributes to cost-effectiveness models and therefore 
plays a pivotal role in service provision and development. 
2.9.2. Research Agenda 
 Include measures of HRQoL in future cross-sectional, natural evolutional 
and interventional studies. 
 Compare different symptom (initiating, maintenance, mixed) and diagnostic 
(idiopathic, psychophysiological) sub-types of insomnia on measures of 
HRQoL.  
 Compare different treatment modalities on HRQoL primary outcomes within 
the same study. 
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 Consider assessing domains that are under-researched, yet part of the 
insomnia experience, such as social, occupational and relationship 
functioning. 
 Follow-up HRQoL outcomes for longer durations and consider using new 
informative methods that capture the patient perspective e.g. qualitative 
research methodologies.  
 Investigate relationships between sleep parameters (objective and subjective) 
and HRQoL dimensions. 
 Identify non-sleep predictor variables of HRQoL impairment and change.  
 Consider the effect of the insomnia treatment process on HRQoL. 
 Measure the impact of treating insomnia in the context of co-morbid illness 
(e.g. cancer, depression, pain), on HRQoL. 
 Develop and validate measures of insomnia-related quality of life that are 
grounded in the words of patients. 
 
2.9.3. Going forward 
This review clearly indicates that many fundamental research questions are yet to be 
addressed surrounding the nature, measurement, and modification of HRQoL and 
functional parameters.  The experimental chapters of this thesis will now explore 
several important related themes from the aforementioned research agenda, specifically 
those with a focus on understanding the daytime experience and associated impairments 
of chronically disturbed sleep; development of novel measures to capture functional and 
quality-of-life impairment; and the integration of mixed methodologies to assess the 
patient experience of behavioural treatment for insomnia.      
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Chapter 3: 
 
 
 
Daytime Phenomenology in Primary Insomnia 
 
 
 
The work presented in this chapter has been accepted for publication as follows: 
 
 
Kyle, S.D., Espie, C.A. & Morgan, K. ‘...Not just a minor thing, it is something major, 
which stops you from functioning daily’: Quality of Life and Daytime Functioning in 
Insomnia.  Behavioral Sleep Medicine, in press.  
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3.1. Abstract 
According to diagnostic manuals, insomnia is a 24-hour disorder, impairing important 
aspects of daytime functioning.  There is, however, little published work describing the 
impact of insomnia on important areas of functioning, or indeed the experience of living 
with chronically disturbed sleep on a daily basis.  We recruited 11 volunteers with 
persistent insomnia to take part in one of three focus group discussions, exploring the 
typical daytime consequences of poor sleep and impact on quality of life (QoL).  A sub-
sample (n=8) were also asked to keep an audio-diary for seven days – appraising sleep 
quality and subsequent daytime functioning.  Interpretative Phenomenological Analysis 
(IPA) of transcripts produced three superordinate themes: ‘just struggle through’, 
‘isolated, feeling like an outsider’, and ‘insomnia as an obstruction to the desired self’.  
Participants described daily difficulties with cognitive, emotional and physical 
functioning; this had the cumulative effect of reducing work performance and social 
participation, as well as limiting life aspirations.  Participants also described feeling 
isolated because of their disorder; this was precipitated by a lack of understanding from 
others, and experiences with health care providers.  Important novel data were generated 
on the proximal and distal impact of insomnia, indicating that chronically disturbed 
sleep can seriously limit overall QoL.     
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3.2. Introduction 
Insomnia disorder is estimated to affect 10% of the adult population (Morin et al., 
2006a) and is characterized by difficulties with initiating AND/OR maintaining sleep, 
or non-restorative sleep (DSM-IV-TR, 2000).  Importantly, the major diagnostic 
nosologies (ICSD-2, 2005; DSM-IV-TR, 2000) acknowledge that insomnia is a 24-hour 
disorder, specifying, to warrant ‘disorder’ status, that sleep disturbance must result in 
some form of daytime dysfunction or distress e.g. in social, occupational, or other 
important areas of functioning.  This is especially important considering that daytime 
distress is often the catalyst leading sufferers to seek treatment; not merely disturbed 
sleep during the night (e.g. Morin et al., 2006a).   
 
Several large survey studies demonstrate that individuals with insomnia report deficits 
in numerous domains.  For example, Roth and Ancoli-Israel (1999), in their analysis of 
the 1991 National Sleep Foundation telephone survey (n=1000), found that individuals 
with insomnia report greater fatigue and mood disturbance, as well as impairments in 
cognitive abilities, physical well-being, and the ability to accomplish certain daily tasks, 
relative to normal sleepers.  Moreover, level of impairment was related to insomnia 
severity: with the ‘chronic insomnia group’ exhibiting greater impairment than the 
‘occasional insomnia group’ (and both showing greater decrements than their normal 
sleeping counterparts).  Reports in clinical samples (e.g. Moul et al., 2002) and well-
screened individuals with primary insomnia (PI), with no other co-morbid pathology, 
corroborate this pattern of daytime dysfunction (e.g. Buysse et al., 2007). 
 
In recent years, there has been a shift towards assessing the overall impact of insomnia 
on QoL, through the measurement of health-related quality of life (HRQoL).  HRQoL 
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can be conceptualized as the distal, downstream effects of illness – “…the radiating 
impact of pathology on the patient’s wider world” (Armstrong et al., 2007, p578); in 
essence, the limitations imposed on a person through disease or illness.  HRQoL 
instruments have thus tended to cover a broad range of quality of life domains e.g. 
physical, mental (emotional) and social functioning (Bowling, 2005).   
 
Early studies assessing HRQoL in insomnia populations, using the generic Short-Form 
Health Survey (SF-36; Ware & Sherbourne, 1992) revealed impairments across all 
domains relative to normal sleepers (e.g. Zammit et al., 1999; Hatoum et al., 1998).  
More recent studies controlling for anxiety and depression (Leger et al., 2001), and 
various medical co-morbidities (Katz & McHorney, 2002; Philip, et al. 2006), confirm 
that poor sleep can independently impair HRQoL, and that severity of sleep disturbance 
is linked to magnitude of impairment (e.g. Leger et al., 2001).  Final evidence that poor 
sleep impairs HRQoL comes from treatment studies (pharmacological and non-
pharmacological) demonstrating improvements in a number of HRQoL domains post-
intervention, in parallel with improvements in sleep (e.g. Walsh et al., 2007; Espie et al., 
2007).     
 
Generic HRQoL measures [such as the SF-36 and Nottingham Health Profile (NHP; 
Hunt et al., 1981)] are useful for several reasons: they permit cross-disease 
comparisons, comparisons with normative community values, assessment of treatment 
outcome, and a measure of cost-effectiveness for a particular intervention.  However, in 
the context of insomnia, such measures are not without limitations: they are not 
developed specifically for use with insomnia populations, and so may not fully reflect 
impairment typical of insomnia; and largely fail to capture the uniqueness of the 
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individual, being “…applied deductively, from the construct to the individual, rather 
than inductively - from individual to construct” (Bilsbury & Richman, 2002, p.8).  As a 
direct result, standardized generic HRQoL measures may miss salient, important issues 
for an individual, while at the same time include redundant irrelevant items.  Therefore, 
reliance on existing questionnaires as a gauge of how insomnia impacts on an 
individual’s daytime functioning and overall quality of life, may underestimate (1) the 
breadth of areas that are impaired by poor sleep; and (2) the extent to which these areas 
limit one’s enjoyment of life i.e. the relative importance of a domain for a particular 
individual.   
 
Two recent insomnia expert panels (NIH state-of-the-science conference statement, 
2005; and the Pittsburgh consensus work groups, Buysse et al., 2006) called for greater 
attention and research into the consequences and correlates of insomnia, with special 
emphasis on waking function.  Given the limited nature of existing measurement (using 
non-specific pre-selected domains) it is possible that insomnia has implications for 
factors that are not so obviously “health-related”, like family relationships, career 
aspirations, performance/productivity at work, or even just general life expectations 
(Reimer & Flemons, 2003).  As a result such factors may have escaped thorough 
investigation.  Similarly, although diagnostic criteria for insomnia specify ‘impairments 
in social, occupational, or other important areas of functioning’ (DSM-IV-TR), little is 
known about the constituent components which underlie these super-ordinate 
impairments, with the majority of published work merely asking an individual to rate 
the extent to which a global area of functioning is affected.  Therefore, the existing 
literature has largely neglected nature of impairment.  Understanding the daytime 
experience of insomnia and how it impacts individual QoL is crucial to fully 
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characterizing insomnia disorder, and its societal impact, as well as forming targets for 
treatment outcome. 
 
The present study sought to characterize, using qualitative methodologies, the daytime 
experience of insomnia.  Qualitative methods were chosen because they allow 
individuals to describe, in their own words, the experience of illness, “reaching the 
parts other methods cannot reach” (Pope & Mays, 1995).  To date there has been little 
published work on illness experience, from the patient perspective – “we’re more like 
objects than subjects, really: we have no speaking part in this literature, no voice” 
(Greene, 2008, p17).  Indeed, to our knowledge there are only two qualitative studies, 
using focus groups, which explored experiences of insomnia (Carey et al., 2005; Green 
et al., 2008).  The study by Carey and colleagues revealed some interesting data on the 
daytime aspects of insomnia disorder; however, half the sample also had a diagnosis of 
insomnia and depression, and the purpose was primarily to create items for a new self-
report metric (content analysis), rather than explore the full impact of insomnia on 
domains of functioning and QoL.  Similarly, Green et al. (2008) conducted focus group 
discussions in a very small sample of individuals with insomnia (n=6).  Again, the 
primary aim was to generate items to help develop a questionnaire, with emphasis on 
insomnia management; little information was provided concerning sample 
characteristics in terms of diagnostic criteria and co-morbidities, and there were 
inconsistencies in focus group methodology between the two conducted groups.  In 
sum, there is a dearth of ‘bottom-up’ research aimed specifically at investigating 
daytime experiences in those with primary insomnia.   
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In the present study, within an Interpretative Phenomenological Analysis (IPA) 
framework, we utilized focus groups to explore, in detail, the daytime experience of 
insomnia, and how sufferers believe poor sleep impacts upon QoL.  To further gain an 
“insider’s perspective” (Conrad, 1987) on the relationship between sleep quality and 
daytime functioning, we asked a subset of our focus group participants to complete a 
prospective one-week audio-diary. 
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3.3. Method 
3.3.1 Participants 
We recruited 11 volunteers (9 female, 2 male: mean age = 38; range 20-64), meeting 
DSM-IV-TR (American Psychiatric Association, 2000), and Research Diagnostic 
Criteria (RDC; Edinger, et al., 2004) for primary insomnia.  Recruitment was achieved 
through newspaper adverts, posters in Dental/GP surgeries and public libraries, and by 
contacting GP-referred patients on the Glasgow Sleep Centre waiting list.   
 
Inclusion criteria included the following: 
- Either difficulties initiating AND/OR maintaining sleep, or non-restorative 
sleep, on at least three nights per week for the last month. 
- Sleep disturbance results in some form of daytime impairment, indicated by the 
presence of at least one associated daytime symptom, according to research 
diagnostic criteria (Edinger et al., 2004). 
- A score of ≥15 (clinical insomnia, moderate severity) on the Insomnia Severity 
Index (ISI; Morin, 1993) and a score > 5 (maximum sensitivity and specificity 
for insomnia; Backhaus et al., 2002) on the Pittsburgh Sleep Quality Index 
(PSQI; Buysse et al., 1989).   
- Sleep disturbance is not due to substance abuse, another mental or sleep 
disorder, or a general medical condition (assessed by structured interview, based 
on Morin & Espie, 2003; see Appendix A). 
Subjects were excluded if they did not satisfy any of the above criteria, if they were 
currently receiving psychological treatment for their sleep problem, or taking sleep 
medication more than 3 nights per week.        
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3.3.2. Procedure 
Approval to conduct the study was obtained from the local NHS ethics committee.  
Interested respondents to advertisements/posters, scoring within the desired ranges on 
the screening questionnaires, were invited to meet with the researcher at the Sleep 
research laboratory to complete a short screening interview. After screening, those 
meeting inclusion/exclusion criteria were invited to attend the focus group discussion 
and subsequent audio-diary component.   
 
3.3.3. Focus Groups 
Three focus group discussions (n=11; two groups contained 4 participants, and one 
group, 3) were facilitated by the researcher, according to recommended guidelines 
(Kitzinger, 1995).  Groups took place in a meeting room at the University of Glasgow 
Sleep Centre, during the evening.  On arrival, participants were instructed on the ground 
rules: aim is to encourage discussion; answers are neither right nor wrong; one person to 
speak at a time, if possible; that the group is being recorded; and everything that is said 
within the group is confidential.  Discussions were recorded using an Olympus© digital 
dictaphone (Model: DS-30), and the facilitator made informal notes on emergent 
themes.  The group was facilitated with minimal direction, allowing the group to 
explore issues they deemed important.  Central topics were addressed using open-ended, 
fixed questions (see Appendix B) across the three groups, tapping into how insomnia 
affects QoL variables, as well as the daily relationship between sleep and next day 
functioning.  Supplementary questions were used to probe areas of interest, and were 
modified in light of each transcription to inform subsequent groups.  Group discussions 
lasted between 1 – 1 ½ hours. 
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3.3.4. Audio-diary reports 
Eight participants from the eleven focus group attendees were selected, based on 
random allotment, to take part in the audio-diary component of the study.  Prospective 
audio-diaries have recently been successfully piloted as a tool to investigate the ‘social 
context’ of normal sleep in both middle-aged women and couples (e.g. Hislop et al., 
2005).  They have the strength of capturing rich qualitative data in the context of 
participants’ own environment, are less prone to recall biases than traditional 
retrospective measures, and provide insights into respondents’ thoughts and 
experiences, proximal to the event.  This is the first application within a sleep-
disordered population.         
 
Participants were briefed (see Appendix C) on how to operate the hand held digital 
dictaphone (Olympus© WS-200s) and semi-structured guidelines for diary entries. On 
awakening (within approx 15-20 mins.) participants were asked to describe their 
experience of the sleep period.  In the evening, approximately two hours before going to 
bed (to avoid creating unnecessary pre-sleep anxiety), they were requested to describe 
relevant feelings and experiences during the course of the day and their relationship (if 
any) with sleep quality.  Guidelines were purposely left open (see Appendix D), 
allowing participants to report information they deemed interesting and relevant. 
 
3.3.5. Framework for qualitative analysis 
Interpretative phenomenological analysis (IPA: Smith, 1996) formed the framework for 
both design and analytical approach.  IPA is concerned with understanding lived 
experiences, and, in particular, the value and meaning participants assign to such 
experiences (Reid et al., 2005).  IPAs exploratory nature, coupled with recruitment of 
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small, homogenous samples (‘experts’ in the phenomenon) renders it a useful method 
for investigating the impact of illness/disease on patient groups.  It is also interpretative 
in the sense that it acknowledges the role of the researcher’s own ideas, conceptions and 
understandings in making sense of participants’ subjective accounts.  That is, the 
researcher attempts to make sense of the participant’s interpretation of their own world, 
rather than trying to make objective statements about experiences or a specific 
population (Smith & Osborn, 2003).   
 
Analysis was conducted according to methods described by Smith & Osborn (2003).  
Focus groups and audio-diaries were transcribed verbatim, including pauses, laughter 
and false starts.  Transcription generated ~38,600 words for focus group discussions, 
and ~17,600 words for audio-diary entries.  Transcripts were analyzed individually by 
first noting significant words or phrases in the margins.  On a second review of the 
transcripts, initial notes were transformed into emergent themes.  Themes were then 
compared across focus groups and individual audio-diaries, looking for common 
recurrent themes as well as deviant/contradicting cases.  This resulted in the generation 
of superordinate themes and corresponding sub-themes.  A sleep psychologist, with 
special expertise in daytime aspects of insomnia and IPA methodology, checked themes 
and supporting quotes for transparency (a credible account as opposed to a true 
account); any discrepancies were reviewed and discussed.             
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3.4. Results 
3.4.1. Participant characteristics 
Mean scores (SD) for the 11 participants on the ISI and PSQI were 19.4 (2.8) and 13.4 
(2.9), respectively (see table 3.1).  Nine of the participants had difficulties with both 
initiating and maintaining sleep, and the remaining two had difficulties with 
maintaining sleep only.  The audio-diary sub-group (n=8) was composed of 6 females 
and 2 males (mean age = 36; range 20-54), scoring 19.8 (3.2) on the ISI and 12.8 (3.4) 
on the PSQI.        
 
Table 3.1 - Participant demographics for those participating in focus groups and sub-set completing 
audio-diaries. 
Focus Groups (n=11) Audio-Diaries (n=8)
Age 38 (20-64) 36 (20-54)
Gender 9 Female/ 2 Male 6 Female / 2 Male
ISI 19.4 (2.8) 19.8 (3.2)
PSQI 13.4 (2.9) 12.8 (3.4)
 
3.4.2. Interpretative analysis 
Interpretative analysis revealed three superordinate, but inter-related, themes: ‘just 
struggle through’, ‘isolated, feeling like an outsider’, and ‘insomnia as an obstruction to 
the desired self’.  Within each main theme, several more specific sub-themes were 
identified (see table 3.2). 
 
Direct participant quotes are presented to support themes along with focus group (FG) 
and audio-diary (AD) identifiers.  Pseudonyms are used to protect the identity of 
participants. 
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Table 3.2 - Superordinate and sub-themes from IPA.  
Superordinate themes                                                 
                   Sub-themes
‘Just struggle through’
                  Cognitive
                  Emotional/Psychological
                  Physical
                  
‘Isolated, feeling like an outsider’                   Lack of understanding
                  Labelling & Scepticism
                  Coping strategies
‘Insomnia as an obstruction to the desired self’                   Vocational functioning
                  Social impact/exclusion
                  Good sleep/remove insomnia
          
 
 
3.4.2.1. ‘Just struggle through’ 
The focus groups captured the most salient daytime consequences of disturbed sleep, 
and these were reinforced, prospectively, by the audio-diaries.  At a general level, 
participants reported impairments in several areas of functioning; this created the 
feeling of “only running at half level or below” (Susan, FG 2), and as a consequence 
participants commonly viewed the day “as a struggle” or an “effort”.        
 
Cognitive 
Participants described how poor sleep has a detrimental impact on their cognitive 
abilities during the day, “you can’t think straight, you can’t think the same” (Alison, 
FG 1).  This inability to ‘think the same’ reflected impairments in concentration, 
attention and memory: 
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“ I need to read quite a lot at work, you find you’ve read a page and you have no clue 
what it said, you have to go back and re-read it” (Rachel, FG 1) 
 
Lapses in attention and concentration were often related to being ‘clumsy’ or nearly 
being involved in car accidents (prompting one participant to seek treatment).  The 
audio-diaries were able to capture instances of these concentration ‘lapses’:  
 
“ I’ve just decided to fill in that form that you gave me, and I’ve just realized that I put 
down my daughters date of birth instead of my own…that is because I’m so tired.. I’m 
obviously not thinking straight” (Alison, AD) 
 
Emotional/psychological  
Participants talked about how poor sleep, especially several days of poor sleep, can 
impact upon mood and emotional well-being. 
 
“I find my mood only kinda starts to be affected after a couple of nights of not having a 
great sleep…like I try [and] just be laid back as possible, but I do find, eventually, it 
starts to wear you down, and then it’s always my boyfriend that gets it…I start to get 
really snappy, and that’s not like my temperament or anything like that, that’s not me at 
all” (Susan, FG 2) 
 
Susan’s assertion - ‘that’s not me at all’ - conveys, rather nicely, a conflict that 
participants battle with on a regular basis: the ‘me’ versus the ‘me after sleeping 
poorly’.  Group members discussed how ’irritable’, ‘moody’, and ‘agitated’ they 
became after a ‘bad’ night, yet maintained this is not what they are normally ‘like’.  
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This dissonance also extended to the social sphere, with participants expressing 
concerns about how others may perceive them during daily interactions.  Not 
performing to others, as well as own personal expectations, cognitively and socially, 
seemed to be a source of worry and anxiety for group members:      
 
“There’s the anxiety of how people are looking at me today...am I behaving alright? 
How am I relating to people today? it puts an extra load of worry, apart from the 
sleeplessness itself there’s another pattern of worry, you know, how you are carrying 
yourself” (Helen, FG 3)  
 
“I’m feeling guilty because I’m not performing to the standard that I would like to think 
I would normally and it makes me feel lazy” (Kate, FG 2) 
 
Audio-diaries also proved extremely useful for tracking modifications in mood and 
getting a real-time snapshot: 
 
“I feel quite low tonight, quite weepy, and I’m sure it’s just because I’m absolutely 
knackered” (Rachel, AD) 
 
Physical 
The physical consequences of poor sleep were present from the moment of waking.  
This was reported as a “sick”, “drained” feeling, or overall “fuzziness”.  There was a 
real sense that participants had been involved in a struggle or “some epic battle” 
(James, AD), throughout the course of the night, often feeling more “exhausted, or 
“knackered” than when retiring to bed: 
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“I’ve had about four hours sleep, I feel really really sick, like really nauseous, and my 
legs feel like jelly, I feel like I’ve got the flu actually, like I just, my legs just feel like I 
wouldn’t be able to walk on them” (Emma, AD) 
 
Persistent fatigue throughout the day was conceptualized as feeling “sluggish” or 
“absolutely shattered”, described by one participant as being like “stuck in a bubble 
that you can’t quite get out off” (Kate, FG 2).   
 
Some individuals also voiced concerns about the long-term impact of chronic insomnia 
on their physical health and well-being.  This was often reported as problems with 
vision and bodily pain, but there was a general consensus of a ‘slump’ in health, 
reflected in a susceptibility to cold/viruses:   
 
“You always feel as though you’re just on the edge of getting a cold” (James, FG 3) 
 
Although separated for clarity here, emotional, physical and cognitive impairments 
typically interacted with each other, creating, as one lady described, a “weight on your 
shoulders” (Mary, FG 1).  This ‘weight’ translated into deficits in several areas of 
functioning and overall quality of life: 
 
“because it’s [insomnia] built up over a week or so many years or whatever, it kind of 
grinds you down, it does affect every single part of your day…and it’s not just a minor 
thing, it is something major which just, you know, it stops you from functioning daily” 
(Mary, FG 1) 
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3.4.2.2. ‘Isolated, feeling like an outsider’ 
There was a general feeling among group members that their sleeping problem made 
them feel different from others, this was captured in the theme ‘isolated, feeling like an 
outsider’.   
 
Lack of understanding 
This perceived isolation was, in part, driven by a lack of understanding and sympathy 
from others, including friends and family: 
 
“I feel very isolated about, basically, that nobody can conceive what it’s like, no one 
understands what it’s like, because they once had a bad night’s sleep and so they ‘know 
what it’s like’ and they ‘just got over it’…so it’s something obviously lacking in me ” 
(James, FG 3) 
 
The perception by others that those with insomnia should just ‘get over it’ not only 
infuriated participants but also made them feel somehow responsible for their own sleep 
difficulties; this appeared to further perpetuate their isolated position and engender 
feelings of self-blame and embarrassment:  
 
“I feel embarrassed even to discuss about my sleeplessness, why I’m so tired, why I’m 
dull, why I’m not performing maybe to my friends expectations, you know, cos to the 
world it is a problem you can sort out” (Helen, FG 3) 
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Labelling & Scepticism 
One group discussed their reluctance to speak to people, even friends, about their sleep 
pattern, because of anticipated labelling: 
 
“SEAN: you don’t really tell people that you haven’t slept for more than one night 
ELAINE: cos they think you’re a freak 
KATE: or they think you’re a liar 
SEAN: or if you say ‘oh I’ve got insomnia’, everyone thinks ‘och you’re just being a 
hypochondriac, stop being silly’... ” (FG 2)   
 
This ‘labelling’ theme also came through strongly when participants discussed 
encounters with the medical profession.  It seemed that sleep not being taken seriously 
as a separate entity, a single problem in isolation, was a common experience.  Many felt 
that a diagnostic label of depression was being thrust upon them, despite their protests 
to the contrary, “I’m not depressed, it [insomnia] just makes me depressed after a 
couple of nights” (Alison, FG 1): 
 
“I don’t think I’ve really seen a doctor who’s believed that it’s a separate kind of entity, 
and it’s not linked to depression”(Laura, FG 3) 
 
One man even felt that doctors were sceptical of him and his sleep problem, as if he was 
acting as a malingerer, failing to reveal other symptoms that might truly account for the 
disturbance:    
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“ I thought that doctors thought that I wasn’t telling them the truth, as in like: ‘ well if 
you’re not depressed, there must be something else, but if you’re not prepared to tell us 
that then just go away and you’ll come back eventually’” (James, FG 3) 
 
The failure of the medical profession to identify the ‘real’ underlying cause of sleep 
disruption created a sense of hopelessness/helplessness among participants; continually 
striving to understand what may have precipitated their sleep disturbance. 
 
 “You see everyone else, how do they manage? They’ve got lives, no worries, I’ve no 
worries I’ve got nothing to worry about, I’ve got a good life.” (Alison, FG 1) 
 
Despite desperate attempts to establish an underlying aetiology or precipitant, 
participants were unable to imagine how their sleep pattern could ever be improved, 
becoming almost resigned to the fact that it may never be successfully treated: 
   
 “… if you’re ill, you take a pill or something, if you’re depressed you can do things… 
or if you have all these other mental health issues, you know, you can get counselling or 
you can work with the issue, I can’t envisage what would happen…you know, for it to 
change…” (James, FG 3) 
 
An exchange between three participants highlighted the ingrained nature of this ‘felt 
isolation’; while others may suffer from sleep problems, they’re in the ‘fortunate’ 
position of having a reason, something tangible that can explain the disturbance, and 
‘legitimize’ their suffering: 
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RACHEL: “Women with small children, with babies, they’re good to talk to, cos they 
don’t sleep either...” 
ALISON: “you feel they get sympathy because they’ve got a baby.” 
MARY:  “in a way that’s funny... they’ve got a reason that another person is causing the 
problem, whereas we don’t really have a problem... so it’s harder” 
RACHEL: “and you know in another year they’ll be fine...they’ll be back to their two 
minutes and snoring on the pillow” (FG 1) 
 
Importantly, the focus group forum was viewed favourably by the participants, nearly 
all of whom had never met someone with a similar problem: 
 
“it’s just so hard sometimes, for not to have other people to talk to about it, cos you 
know, unless they are experiencing it themselves, they don’t really understand it…so 
just something like this is good, cos there’s other people you can reflect, you know, 
what you’re feeling” (Mary, FG 1) 
 
Coping strategies 
To avoid becoming overwhelmed by the consequences of their insomnia and isolated 
‘status’, participants adopt a number of strategies to help them manage and cope during 
the day.  The fear of labelling and stigma meant many would not use sleep as an excuse 
(e.g. for missing work or avoiding social contact); instead, they were forced into playing 
the role of an ‘actress’ - ‘put an act on, put a face on it’ (Alison, FG 1) 
 
“this week I was at a meeting, and I was exceptionally tired, em, and I tend to over 
compensate so that people won’t know that I haven’t slept and that I’m tired, so I tend 
to talk too much, it’s probably a load of nonsense” (Laura, FG 3) 
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Others had to structure their day differently/change activities to try and mask, or at least 
attenuate, the impact of poor sleep: 
 
“Everybody comes into the office about nine or just after nine, I find I’m in from 8 
because if I come in at nine and then everybody else is really cheery and things like 
that, I’m just, it makes me really annoyed .. so if I’m in at eight, then at least by the time 
they all come in at nine, I’m maybe wakened up a bit, and then I’m a bit more social” 
(Rachel, FG 1) 
 
Such well developed “coping mechanisms” (James, FG 3) extended also to dealing with 
cognitive impairment (e.g. using memory aids, having set schedules) and staving off 
sleepiness (e.g. splashing water on face to increase alertness).  There was a real sense 
that participants had to ‘regroup’ at several points during the course of a day; this 
reinforced the idea that life was often a “struggle”, and that a continuous battle was 
being fought – an approach described by one lady as “retreat, come back in and attack 
it again, different front” (Elaine, FG 2) 
 
3.4.2.3. ‘Insomnia as an obstruction to the desired self’ 
The last major theme, ‘insomnia as an obstruction to the desired self’, captured how the 
specific consequences of disturbed sleep – that we all experience from time to time – 
can culminate in deficits in important areas of functioning, and restrict life goals,  when 
experienced frequently. 
 
Vocational functioning 
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In particular, participants felt that their ability to perform and fulfil work/university 
roles is adversely affected by their insomnia.  In extreme cases this meant a reduction in 
hours, but more generally, participants reported impairments in work performance:  
 
“my [work] performance has dropped big time, I’ve always been good at multi-tasking, 
and I feel the more I go without sleep, I just cope with less at the one time” (Elaine, FG 
2) 
 
Impairments in learning/retaining information were particularly noticeable for those in 
full-time education, and could be captured through audio-diary entries: 
 
 “…my last class was just really, I don’t know…I just can’t concentrate on anything, 
I’m just so tired, and just want to fall asleep, so I never learnt much in educational 
studies today…just because I had such a crap sleep last night” (Susan, AD) 
 
Social impact/exclusion 
Not surprisingly, given the reported impairments in mood and fatigue, participants 
frequently described a negative impact on social activities and meeting with friends.  
This tended to be expressed as having to cancel or avoid committing to social fixtures, 
because of the unpredictability of poor sleep and subsequent effects on functioning: 
  
“I had planned to go to Edinburgh today but that I had to cancel, my friend came over 
later on, and I decided against going out because I just felt too tired, I find this all very 
frustrating, I’m a pretty sociable person...so it doesn’t suit me at all” (Laura, AD) 
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Others would make the effort to attend social gatherings, but risk being tired and/or 
leaving early: 
 
 “because I’m so used to not sleeping, I just get by anyway, but by the end of the night I 
might be the first one home” (Kate, FG 2) 
 
 “…today my sleep really did impact my day, I was really really slow, and couldn’t keep 
up with anyone’s jokes at university, eh I was just kinda like unresponsive” (Sean, AD) 
 
Participants also voiced concerns that sleep, indirectly through fatigue and reductions in 
energy, affected keeping in touch with friends.  This was a largely ‘self-imposed’ 
exclusion from social activities, with participants making the ‘choice’ not to call/answer 
phone calls: 
  
 “I’m terrible for em, I don’t get away with it if I’m not in the house myself, but if I’m in 
the house myself I let the answer machine pick up because I just canny be bothered with 
the conversation” (Rachel, FG 1) 
 
Good sleep/remove insomnia 
The greatest insight into the limiting and obstructive nature of insomnia was best 
achieved when participants discussed how their life would change if their insomnia 
were to cease.  The majority of participants described predicted improvements in 
lifestyle (including retraining for a preferred occupation, taking up hobbies, enhanced 
social life), and importantly, enjoyment of life. 
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“I certainly have lots of regrets about my life and things that I haven’t done and haven’t 
achieved... and I put it down to the chronic insomnia... so if I could establish a sleep 
pattern again, I would take on a lot of challenges in my life, I would go overseas to 
work for example, and socially I would change my social situation as well.. I would 
definitely change a lot” (Laura, FG 3) 
 
Thus, in a way, it appeared that insomnia was acting as an obstruction, preventing 
participants from attaining goals, otherwise achievable if they were good sleepers: 
 
 “I don’t really like the job I’m in at the moment, and I just…to apply for a job and go 
for interview it’s just too much of a task...I feel just plod along and do what I’m 
doing…I just feel I could make a life changing difference, a new job…” (Alison, FG 1)  
 
Participants realized that because poor sleep has a knock-on effect on many aspects of 
functioning, then several diverse areas would improve simultaneously: 
 
“I feel as if my life would be fuller...if I was getting a proper sleep every night, then my 
concentration would be better, so my uni work would be better, so I’d probably get a 
better degree, I’d probably phone my friends a bit more because I’d have time to spend 
on the phone..I feel as though I’d go out and do things more” (Susan, FG 2) 
 
Interestingly, such changes could actually be tracked with the audio-diaries.  Even from 
waking ‘a good sleep’ could be conveyed not only in content of words but also tone: 
 
 108 
“It’s Wednesday morning and I had a fantastic night’s sleep… I literally jumped out of 
bed to get ready to go out” (Sean, AD)  
Sleeping well often then translated into a reversal, an almost ceasing of symptoms 
(‘condition on-condition off’ nature): 
 
“I’m pleased to say I did have a much better day today, I managed to do everything that 
I had planned to do, I was able to concentrate a lot more, felt in a much happier mood, 
physically I had the energy to go out for a walk and enjoy chatting with friends etc., and 
all this is basically down to having a less disturbed night’s sleep” (Laura, AD)   
 
It is important to note, however, that a small minority of participants didn’t feel that 
improvements in sleep would necessarily lead to dramatic alterations/improvements in 
functioning.  Having lived with sleep disturbance for a number of years, and as a result, 
adapting and adjusting to its consequences through compensatory strategies, it appeared 
that life, after the removal of insomnia, would simply be much less of an effort.  This 
‘recalibration’ meant that although major transformations were not predicted, 
participants would definitely notice alleviation of forced effort: 
 
“Well I don’t think, personally, it probably wouldn’t have any big life changes because 
I just do try and not let it stop me doing as much as possible... so I would just do things 
more willingly” (Rachel, FG 1) 
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3.5. Discussion 
The goal of this study was to explore the daily experience of insomnia, with particular 
emphasis on functioning and individual QoL.  Interpretative phenomenological analysis 
of focus group and audio-diary transcripts produced three superordinate themes: ‘just 
struggle through’, ‘isolated, feeling like an outsider’, and ‘insomnia as an obstruction 
to the desired self’. 
 
Participants reported, in their own words, daily decrements in cognitive, emotional and 
physical functioning because of disturbed sleep.  This supports existing work in those 
with PI, using both self-report retrospective and prospective rating scales (e.g. Moul et 
al., 2002; Buysse et al., 2007; Orff et al., 2007).  The failure of people with insomnia to 
show unequivocal objective cognitive deficits, yet report enduring subjective 
impairment, continues to perplex the field (Orff et al., 2007).  One potential explanation 
is that individuals with insomnia can exert enough ‘compensatory effort’ to overcome 
performance deficits during testing.  Interestingly, our participants consistently reported 
“struggling through the day” or putting in extra “effort” to complete tasks; thus, it may 
be that such “compensatory mechanisms” are sufficient to minimize any ‘obvious’ 
performance decrements (Orff et al., 2009; Espie & Kyle, 2008).  It is intuitive also that 
putting in extra ‘effort’ in an attempt to maintain functioning during the day may 
exacerbate feelings of fatigue, poor concentration and memory, perhaps contributing to 
inflated subjective-objective discrepancies (Varkevisser et al., 2007). 
    
Alterations in mood and increased irritability were frequently reported by participants 
after several days of poor sleep.  Compared to normal sleepers, individuals with PI 
typically show elevated scores - but below clinical thresholds - on measures of 
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depression, worry and anxiety (e.g. Buysse et al., 2007).  Moreover, it has been 
documented that insomnia assessed at time point one can independently predict the 
development of depression at time point two (e.g. for a review see Riemann & 
Voderholzer, 2003).  Interestingly, participants frequently reported feeling ‘depressed’, 
‘weepy’ or ‘low’ after a couple of nights of poor sleep, and made strong causal 
attributions to their disturbed sleep.  It is intuitive that the limiting daytime 
consequences of insomnia, such as impairment in social functioning, may also 
precipitate the onset of a depressive episode – participants were certainly frustrated at 
having to cancel/avoid social contact.  Although such a hypothesis may be hard to test, 
practically and ethically, audio-diaries do appear to be a particularly sensitive tool for 
capturing how an individual feels, and thinks, after sleeping poorly.  Future studies 
using this methodology, over a longer duration, may provide better insights into the link 
between insomnia and mood disturbance.  
 
Participants further described how insomnia impacted upon physical functioning and 
health.  Cross-sectional data suggest associations between insomnia and increased 
medical consultations, as well as more frequent health problems, relative to normal 
sleepers (e.g. Simon & VonKorff, 1997).  Causality is, however, difficult to establish.  
Immune functioning would appear to be an obvious link, and although alterations in 
immune markers (i.e. elevated IL-6, lower counts of lymphocyte subpopulations) have 
been documented in those with PI, the clinical significance of these alterations remain 
unknown (Burgos et al., 2006; Savard et al., 2003).  Further studies using larger samples 
and repeated measurement points are needed to determine if insomnia is associated with 
significant immune alterations at baseline, and if so, whether these (and subjective 
reports of well-being) ‘normalize’ after successful treatment.     
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During focus group interactions, participants expressed feelings of ‘isolation’ because 
of their insomnia.  This was attributed to a lack of understanding and sympathy from 
others, as well as sleep disturbance not being taken seriously as a single, important 
issue.  Previous qualitative work supports the notion that those with insomnia feel that 
others, including medical staff, do not realize how serious sleep disturbance and its 
consequences can be: insomnia as a ‘hidden disorder’ (Carey et al., 2005) and ‘an 
invisible weight’ (Greene, 2008).  Participants frequently felt that others believed they 
should ‘get over it’, ‘stop being silly’, or that there must be some other deep-rooted 
issue, like depression.  This led some to look inward, questioning whether they were 
doing something ‘wrong’, or that poor sleep was somehow self-inflicted (‘something 
lacking in me’).  This not only amplified perceptions of isolation but also created a sort 
of ‘felt stigma’ (Scambler, 1988) among participants, choosing to conceal their sleeping 
problem from others.  Intriguingly, similar experiences of ‘felt scepticism’ and 
‘rejection’ have been reported by patients with other conditions, such as chronic fatigue 
syndrome and chronic pain, where there are no obvious exposed or ‘objective’ 
symptoms (Dickson et al., 2008; Glenton, 2003).   
 
Not being taken seriously forced participants to adopt a hopelessness/helplessness 
approach to their insomnia; possibly accounting for the recent finding that individuals 
with PI fail to seek treatment primarily because of the perception of insomnia as a 
“benign, trivial problem or that one should be able to cope with alone” (Stinson et al., 
2006).  Importantly, participants found the group format helpful for discussing and 
sharing experiences.  Given that most of the sample had never met anyone with similar 
sleep difficulties, the chance to reflect and exchange experiences was viewed positively, 
and some argued that this facility may have helped had it been available at the onset of 
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their sleep difficulties.  This does raise the issue whether targeted social support groups 
could prove useful in ameliorating insomnia-associated concerns and ‘felt stigma’, 
potentially removing barriers to treatment.  Patients taking part in a group cognitive 
behavioural intervention (CBT) for insomnia have certainly reported great value from 
meeting others with similar difficulties (Green et al., 2005).     
 
Of note, and perhaps in direct contrast to how others perceive insomnia (at least as far 
as participants were concerned), chronic insomnia was reported to be a “major thing”, 
affecting several important areas of functioning.  For example, participants frequently 
described impairments in vocational/occupational functioning.  Existing data on 
insomnia and the workplace have largely focused on absenteeism, with mixed results 
(e.g. Leger et al., 2006; Phillip et al., 2006).  In the current study very few participants 
reported taking days off/missing lectures due to sleep disruption; instead they described 
“struggling through the day” with subsequent effects on productivity and performance.  
Only recently have studies documented measurable impairments in workplace 
functioning, using rating scales (e.g. David & Morgan, 2006; Erman et al., 2008); our 
sample revealed the nature of this impairment.  Specifically, work output, completion of 
tasks on time, effort, and learning were all impacted.  Interestingly, our participants 
reported awareness of compensatory techniques to minimize vocational impairment, 
allowing themselves to “gauge” their way through the day.  Such techniques included 
completing work at home, scheduling tasks to optimize cognitive and social 
performance, forced physical activity (going for a walk, making tea, rubbing eyes, 
reading text) to stave off fatigue and sleepiness, and off-setting ‘heavier’ duties to 
another day.  Given that the workplace appears particularly sensitive to the 
consequences of insomnia, and plays an important role in prompting sufferers to seek 
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medical treatment (Henry et al., 2008), there is a great need for future intervention 
studies to include occupational outcome measures. 
 
Similarly, participants complained that insomnia has a detrimental impact on social 
functioning.  Again this domain has received little attention in its own right, usually 
being assessed as a construct within overall HRQoL measurement.  Studies have 
documented lower scores on the social functioning sub-scale of the SF-36 in those with 
PI relative to normative reference values (e.g. Walsh et al., 2007).  However, this 
component sub-scale simply asks two questions relating to extent and frequency of 
social ‘interference’, failing to capture what this ‘interference’ actually is.  Focus groups 
and audio-diaries revealed an inability to plan social events because of sleep instability, 
self-imposed social inclusion due to lack of enthusiasm/energy, and reduced 
responsiveness when in social situations.                                     
 
Participants found it difficult to think of areas of functioning that escape impairment.  
This does fit with questionnaire studies demonstrating decrements in every aspect of 
HRQoL relative to controls (e.g. Leger et al., 2001), as well as cross-disease 
comparisons indicating comparable, and more wide-ranging, HRQoL impairments than 
patients with depression and congestive heart failure (e.g. Katz & McHorney, 2002).  
Indeed, it is this enduring, all encompassing nature of insomnia that is characteristically 
reported by patients during consultations.  Participants felt the burden of insomnia 
prevented them from achieving goals/aspirations in life e.g. travelling, working full- 
time, training/applying for a preferred vocation, performing in university/college 
courses, and taking up hobbies.  Importantly and not surprisingly, there was great 
diversity in the areas that individuals reported to be affected, as well as differences in 
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the relative importance of each area.  Thus, it would appear crucial that assessments of 
functioning and QoL take into account those aspects that are important to the individual.  
Previous studies using standardized measures may not have been sensitive enough to 
detect initial daytime distress, and therefore improvement, post-intervention.  This may 
explain why improvements in sleep are not always closely mirrored by improvements in 
daytime functioning (e.g. Omvik et al., 2008).  Qualitative, patient-centred 
methodologies in combination with both disease-specific and generic outcome measures 
may provide a better indication of treatment success in improving daytime functioning.    
 
This study has to be viewed within the context of several limitations.  Firstly, it is worth 
pointing out that our participants, through volunteering to take part in a qualitative study 
focusing on daytime functioning, may over-represent those with severe and pronounced 
functional impairments.  That being said, many of our themes and sub-themes can be 
linked/related to issues in the existing literature, including qualitative/quantitative, and 
clinical/non-clinical studies.  Importantly, because we adopted an IPA method to 
explore participants’ experience of insomnia, our conclusions can only be attributed to 
the 11 participants within the study - and not taken as representative of all individuals 
with PI.  Moreover, traditional exemplary methods for IPA are semi-structured 
interviews and other idiographic approaches e.g. diaries (Smith, 1999); we opted to use 
focus groups given that previous literature (Carey et al. 2005) suggests insomnia can be 
an isolating and misunderstood condition, and therefore creating a supportive 
environment was a key methodological consideration.  Focus groups also tend to 
overcome power imbalances between researcher and participants (a potential problem 
when conducting face-to-face interviews), and capitalize on shared experiences through 
everyday communication (Kitzinger, 1995).  We do realize, however, the limitations of 
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focus group methodology when attempting to explore personal, individual experience, 
particularly problems concerning participant and issue dominance; nevertheless, such 
influences can be attenuated through effective group facilitation.  Comparing and 
contrasting our findings with future studies that utilize other qualitative methods (such 
as semi-structured interviews) would be informative.  Finally, interpretation is central to 
IPA, and thus the beliefs and role of the researcher, when running focus groups and 
analyzing transcripts, inevitably influenced interpretation of data.      
 
A number of research possibilities are worth mentioning that could extend and build 
upon the present study.  For example, we included participants of working age only, it 
would be interesting to investigate, qualitatively, daytime functioning in elderly adults 
with insomnia, given there is some indication in the literature that this group may have 
less severe HRQoL impairments (see Kyle et al., 2010).  Qualitative inquiry applied to 
insomnia in the context of other medical and psychiatric illness, may also be a 
worthwhile endeavour; perhaps helping to uncover the intimate reciprocal relations 
between insomnia and co-occurring conditions.  One final implication of our research 
concerns measurement of functional impairment.  It is clear that future tools assessing 
daytime functioning and quality of life in insomnia need to include items that 
adequately tap domains relevant to patients with insomnia, as revealed in the present 
study.  Indeed, in Glasgow we are piloting a measure which goes one step further: 
asking patients to generate, in their own words, relevant insomnia-related impairments, 
which are then converted into a quantifiable metric (Kyle et al., 2009).  Such an 
approach may be a particularly sensitive way to evaluate simultaneous changes in both 
sleep and functioning.   
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In summary, the current study highlights that individuals with persistent insomnia 
encounter difficulties and impairments on a daily basis and across many aspects of 
functioning.  A lack of empathy and understanding from others, coupled with the 
inadequacy of the medical profession at getting to the ‘source’ of sleep difficulties, 
created anxiety, isolation and ‘felt stigma’ amongst participants.  Insomnia was 
described as limiting, affecting QoL variables such as work performance, careers, life 
aspirations and social functioning.  It is important that policy-makers and health care 
providers understand that insomnia is a serious condition with deleterious 
consequences, and attempts be made to integrate effective and sustainable treatments, 
such as cognitive behavioural therapy (Espie et al., 2007; Morgan et al., 2003), into 
everyday clinical practice.                   
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Chapter 4: 
 
 
 
The Development of Two New Measurement Approaches to Assessing 
Insomnia-Related Quality of Life and Daytime Functioning: the Glasgow 
Sleep Impact Index (GSII) and the Daytime Functioning and Sleep 
Attribution Scale (DFSAS) 
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4.1. Abstract 
 
Daytime dysfunction and quality of life (QoL) impairment are clearly important and 
salient consequences of poor sleep in those with insomnia.  The surprising lack of 
suitable tools to assess these two constructs limits conclusions that can be drawn 
regarding which (and if) treatments are effective in improving both sleep and non-sleep 
aspects of insomnia.  Existing measurement approaches to functional impact tend to rely 
on non-specific generic tools, non-validated scales, or single scale items; in short, they 
are sub-optimal at best and misleading at worst.  In this chapter, two new measurement 
approaches to assessing and understanding the downstream effects of insomnia on 
functioning and QoL are explored.  The Daytime Functioning and Sleep Attribution 
Scale (DFSAS) and the Glasgow Sleep Impact Index (GSII) capture impairment in (1) 
common everyday daytime functional domains, and (2) individual-specific insomnia-
related impairment, respectively.  Preliminary results indicate these measures to have 
good psychometric properties; including, high internal consistency, strong face, 
construct, and discriminant validity, and sensitivity to change, post-behavioural 
treatment.  Further work should investigate test-retest reliability, and assess sensitivity 
to change in the context of large randomised controlled trials of both psychological and 
pharmacological interventions for insomnia.  The described novel attempts to capture 
and measure functional impairment in insomnia, it is hoped, will stimulate others to 
focus on the fundamental measurement of the insomnia experience.               
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4.2. Introduction 
 
A number of studies indicate that insomnia negatively impacts several domains of 
daytime functioning (e.g. Kyle, Espie & Morgan, in press; Buysse et al., 2007; Alapin et 
al., 2000), and this, of course, is reflected in contemporary disease/disorder 
classification manuals (DSM-IV, 1994; ICSD-2, 2005; ICD, 1992; RDC, Edinger et al., 
2004).  Both qualitative and quantitative research also highlight that the functional 
impact of sleep disturbance is what drives treatment-seeking behaviour for many 
patients (Henry et al., 2008; Morin et al., 2006a). 
 
Several authors have commented on the need to better understand the waking 
consequences of insomnia (Buysse et al., 2006; Orff et al., 2007), as well the urgency to 
develop tools that are sensitive to impairments experienced by patients (e.g. Riedel & 
Lichstein, 2000; Moul et al., 2004; Gradisar et al., 2007; Krystal, 2007).  With the 
documented mixed literature on neurocognitive performance in those with insomnia 
(Riedel & Lichstein, 2000; Fulda & Schulz, 2001; NIH state-of-the-science conference 
statement, 2005; Shekleton et al., 2010), coupled with conflicting reports surrounding 
post-interventional changes in daytime parameters (Omvik et al., 2008; Means et al., 
2000), it seems increasingly important to ‘home-in’ on, and develop measures to 
adequately capture, self-report functioning,  
 
Accordingly, there has been increased emphasis on scale development.  Gradisar et al. 
(2007) created the 7-item Flinders Fatigue Scale (FFS) to probe components of fatigue, 
often the most frequently reported daytime symptom by those with insomnia.  
Preliminary data indicate good discriminant validity, high internal consistency, and 
sensitivity to treatment outcome; suggesting the FFS may be a useful measure in 
outcome studies involving insomnia populations.  Secondly, Leger and colleagues 
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(2005) developed the Hotel Dieu 16 (HD-16), a measure designed to assess ‘Quality of 
Life’ in those with insomnia, owing to the lack of an existing widely used disease-
specific tool.  Domains cover the following categories: physical role, energy, cognitive, 
social and psychological functioning.  Strengths of this measure include: appropriate 
item generation (based on patient interviews and then factor analysis); graded 
discriminant validity across ‘severe insomniacs’, ‘mild insomniacs’ and normal 
sleepers; and dimensional as well as global score calculation.  The HD-16, however, has 
several limitations; specifically concerning translational issues, complex score 
derivation, and lack of available data on test-retest reliability, concurrent validity, and 
sensitivity to treatment outcome.  Indeed, to the best of our knowledge, no single 
published study has used the instrument, other than the original validation paper. 
 
In a recent thorough review of the literature on health-related quality of life (HRQoL) in 
insomnia, Kyle and colleagues (2010; also chapter two of this PhD thesis) outline the 
need to develop measures that adequately capture QoL impairment relevant to patients.  
They highlight that the majority of studies assessing HRQoL or the more global 
‘Quality of Life’ construct, have used generic instruments, such as the Short Form 
Health Survey 36 (SF-36; Ware & Sherbourne, 1992) - a health status tool.  Reliance on 
generic and non-specific measures in insomnia outcome research may be obscuring real 
treatment effects (Omvik et al., 2008; Soeffing et al., 2008), and hence leading to classic 
type II error conclusions.  Kyle et al. also suggest that more attention be paid to the 
underlying constructs that tools are supposed to measure, such as daytime functioning, 
Quality of Life (QoL) and Health-related quality of life (HRQoL) - which are typically 
used interchangeably, indiscriminately and without definition in most of the insomnia, 
and indeed health literature.  For example, ‘daytime functioning’ has usually been 
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assessed by administering scales that measure various discrete constructs e.g. the Beck 
Depression Inventory (BDI; Beck et al., 1961) for depression, the Beck Anxiety 
Inventory (BAI; Beck et al., 1988) for anxiety, and the Fatigue Severity Scale (FSS; 
Krupp et al., 1989) for fatigue.  The problem with this approach is that, firstly, those 
with primary insomnia are excluded for co-morbid psychopathology, and so there is 
limited scope for change within the sub-clinical category; and secondly, daytime 
impairment can vary within an individual, so that only some domains are affected 
(above some personal ‘interference threshold’), while others remain unaffected.        
 
In a similar vein, Krystal (2007) reviewed work on general daytime impairments in 
insomnia, covering isolated symptoms and domains of functioning.  Although it was 
concluded that (1) daytime impairment reliably exists in those with insomnia, and (2) 
both pharmacological and non-pharmacological treatments can improve daytime 
symptoms, much of the reviewed studies used non-validated, non-specific 
questionnaires, or just single items, to assess daytime symptoms/functioning.  The 
message from both review papers is clear: the field needs to pay more attention to the 
measurement of non-sleep variables, particularly aspects of subjective functioning and 
quality of life, importantly, as they relate to insomnia patients.                          
 
Other than the HD-16, there are only two scales claiming to assess aspects of 
functioning specific to insomnia: the Quality of Life of Insomniacs questionnaire 
(QOLI; Rombaut et al., 1991) and the Insomnia Impact Scale (IIS; Hoelscher et al., 
1993).  The QOLI is a 52-item measure made up of three existing questionnaires (the 
Psychological Well-Being Index, the Leeds Sleep Evaluation Questionnaire, and the 
Jenkins Sleep Evaluation Questionnaire) plus an additional 22 items.  Although the 
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QOLI has been used in a handful of studies, with some evidence of treatment-outcome 
sensitivity (e.g. Goldenberg et al., 1994), it has a number of limitations.  These include: 
a lack of adequate data on psychometric properties; an exhaustive number of items 
covering both sleep and non-sleep domains; and varied response formats.  The IIS is a 
40-item measure assessing sleep-related impairments in functional, cognitive, social, 
occupational, emotional and physical domains.  Again basic data are lacking on this 
scale; no paper has been published documenting its psychometric properties (the initial 
validation study remains a conference abstract); items cover non-daytime functioning 
domains; ratings are made with reference to ‘experience’ or ‘belief’, making it unclear 
what construct the scale assesses; and only one research group continue to use it 
(Soeffing et al., 2008; Means et al., 2000; Ustinov et al., in press).   
 
A limitation of the IIS, and a challenge for all measures designed to probe functioning 
relevant to insomnia, is the loaded nature of items linking poor sleep to impaired 
functioning.  For example, the IIS asks participants to rate their agreement with 40 
statements, with reference to the ‘past two weeks’, such as: ‘I have problems 
concentrating and I make foolish errors after a poor night of sleep’.  Wording of items 
in this manner may, for both poor and normal sleepers, lead to artificially elevated 
scores by (1) priming the PI patient’s negatively toned cognitive set (Harvey, 2002); 
and (2) prompting the normal sleeper to reflect on a rare occasion when they did 
experience disturbed sleep, and hence, conclude that ‘poor sleep does in fact cause me 
to have problems with concentration and to make foolish errors’.  Of course, it is also 
possible that normal sleepers struggle to recollect any significant episode of poor sleep, 
creating floor effects and inflating between group differences (Riedel & Lichstein, 
2000).  Further, even if sleep and subjective functioning were to improve in a group of 
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individuals with insomnia, post-intervention, the very nature of the wording of these 
items and the response context (i.e. ‘experience’ or ‘belief’), could still generate high 
scores (indicative of impairment), as the ‘reformed’ poor sleeper recounts prior or 
occasional current episodes of sleep disturbance.  It is interesting that treatment effects 
have never been documented using this scale despite quite robust improvements in sleep 
(Soeffing et al., 2008; Means et al., 2000).   
 
Clearly, what is needed (see table 4.1) is some measure of daytime functioning that 
limits the effect of sleep- or insomnia-related priming, and which permits the collection 
of appropriate normative data by which to then gauge whether a patient has returned to 
‘normal’ levels of functioning. The attribution for poor sleep in accounting for 
functional impairment is, of course, also very important; for two main reasons.  Firstly,  
 
 
Table 4.1 – Required scale characteristics to meet existing measurement needs. 
Required scale characteristics for use with insomnia patients
1. Assessment of concerns relevant to each individual patient 
2. A measure which permits ranking of concerns in order of personal importance
3. Some measure of the attribution for poor sleep in causing daytime impairment
4. Coverage of items that are commonly reported by insomnia patients as a group
5. Brief measure that can be used in both clinical and research settings
6. Can be completed by normal and poor sleepers with limited sleep-related priming
7. Can be completed by patients with additional health conditions
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several cognitive processes have been investigated as being relevant to the development 
and maintenance of insomnia (Harvey, 2002; Harvey et al., 2005; Espie, 2002; Morin, 
1993).  For example, the tendency to catastrophize about the consequences of poor 
sleep, perhaps coupled with underlying maladaptive sleep-beliefs, may render some 
individuals with increased sleep-related threat detection, monitoring, and enhanced 
sleep pre-occupation (Harvey, 2002).  It is proposed that these individuals are likely to 
misinterpret non-significant innocuous cues as evidence of sleep-related impairment, 
fuelling daytime anxiety and dysfunction via enhanced cognitive load and 
compensatory safety behaviours.  Being able to identify those with a markedly high 
(mis-) attribution for poor sleep in causing daytime impairment may help in tailoring 
interventions for an individual, ultimately enhancing the probability of treatment 
response.  
 
Secondly, the co-occurring nature of insomnia (e.g. Sarsour et al., in press) has been put 
forward as the biggest challenge to developing scales for specific use with insomnia 
patients (e.g. Reimer & Flemons, 2003; Buysse et al., 2006).  The ability to partial out 
the effect of insomnia on everyday functioning, in the context of co-morbid pathology, 
would be desirable, and have particular relevance in the clinical context.  Above all 
though, assessment must reflect concerns and values of individual insomnia patients. 
 
This chapter describes the background, creation and development of two new tools, 
from differing theoretical perspectives, that may address the void in current functional 
assessment of insomnia.  The Daytime Functioning and Sleep Attribution Scale 
(DFSAS) explores, in a two part format, the level of daytime interference across 12 
commonly reported symptoms (part 1), and the perceived extent to which the 
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impairment is caused by poor sleep (part 2).  The Glasgow Sleep Impact Index (GSII), 
conversely, asks patients to generate their own items.  Specifically, in this patient-
centred measure, items unique to each individual are ranked on importance and 
subsequently rated in relation to perceived impact.     
    
4.3. The Daytime Functioning and Sleep Attribution Scale (DFSAS) 
 
4.3.1. Background & Aims  
 
There is a need for a scale that can be used by both individuals with sleep disturbance 
and normal sleepers.  Secondly, items need to have good face validity i.e. reflect 
concerns and experiences relevant to patients and their everyday lives.  Thirdly, there is 
a necessity to tease out the perceived impact of poor sleep in contributing to daytime 
impairment in (1) those with primary insomnia and (2) patients who suffer from 
additional co-morbidities beyond sleep disturbance.   
 
With these needs in mind we created the Daytime Functioning and Sleep Attribution 
scale (DFSAS; see figure 4.1), a 12-item, two-part scale.  Part 1 asks participants to rate 
12 impairment-related aspects of daily functioning (e.g. ‘Difficulty concentrating and 
focusing on things’) in terms of how much of a problem (0-3) it has been in the past two 
weeks.  Part 2 then asks participants to re-rate each individual item, but this time in 
relation to how much poor sleep was responsible (0-4) in generating the impairment.  
Thus, part 1 (range: 0-36) is a general assessment of everyday functional limitations and 
problems, and part 2 (range: 0-48) is a measure of how much the respondent believes 
that poor sleep accounts for the experienced impairment. 
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Figure 4.1 - Copy of the Daytime Functioning and Sleep Attribution Scale (DFSAS). 
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4.3.2. Methods 
 
4.3.2.1. Participants 
To investigate basic statistical properties of the scale, including discriminant validity, 
internal consistency, and sensitivity and specificity, we combined three samples of 
highly screened individuals with primary insomnia (PI).  PI patients who completed the 
scale were from the following University of Glasgow Sleep Centre (UGSC) studies: 
those taking part in a condensed sleep restriction intervention (n=18; see chapter five); 
those taking part in a mechanistic study (n=12) investigating adherence to stimulus 
control treatment (Crawford, unpublished); and finally, nine participants meeting 
criteria for Psychophysiological insomnia (ICSD-2), taking part in an ongoing NIH-
funded study.  Thus, number of patients with insomnia totalled thirty nine.  Normal 
sleepers (n=31) were recruited from the same aforementioned NIH study. 
 
All PI patients met basic criteria for Primary Insomnia according to research diagnostic 
criteria (RDC; Edinger et al., 2004; DSM-IV, 1994).  That is, they all had difficulties 
with initiating and/or maintaining sleep, or non-restorative sleep, lasting for at least a 
one-month period.  All subjects underwent an initial screen using the UGSC brief 
screen protocol (see Appendix E).  This records basic information on severity and 
frequency of insomnia symptoms, co-morbid medical/psychiatric/sleep difficulties, and 
medication use.  Those satisfying the brief screen then received a thorough phone 
interview using the UGSC screening questionnaire, based on a template set out by 
Morin & Espie (2003; see Appendix A), to exclude those with affective/psychiatric 
disorder, those with sleep-disruptive medical co-morbidities, and to assess sleep 
pattern/symptoms to rule out occult sleep disorders.  In keeping with diagnostic criteria 
of insomnia as a 24-hour disorder, participants also had to report experiencing at least 
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one daytime functional impairment, attributed to disturbed sleep (RDC; Edinger et al., 
2004).  Participants were all aged between 18 and 65, and recruited through media 
adverts and GP referral letters.  Additionally, those patients in the NIH study (n=9) all 
received an overnight PSG screening assessment to (objectively) rule out occult sleep 
disorder pathology, and also met criteria for Psychophysiological insomnia based on 
ICSD-2 (2005) classification.  Two (5%) out of the 39 patients were on sleep-promoting 
hypnotic medications at the time of scale completion.  
 
Normal Sleepers (NS) had no complaint of sleep disturbance, failed to meet DSM-IV 
criteria for insomnia, did not use sleep-promoting hypnotics, and reported the absence 
of medical or psychiatric illness (ascertained using the UGSC brief screening protocol).  
Additionally, all NS were required to score ≤ 5 on the Pittsburgh Sleep Quality Index 
(PSQI; Buysse et al., 1989). 
 
Participant demographics are presented in table 4.2.  The mean (SD) age of the PI group 
was 43.9 ± 13.1 years; and 31.5 ± 13.5 years for normal sleepers.  This difference was 
statistically significant [t(68) = 3.88, p<.001].  As expected, mean PSQI scores were   
 
Table 4.2 - Demographics for primary insomnia (PI) patients and normal sleepers (NS). Parentheses 
represent the standard deviation. 
PI (n=39) NS (n=31)
Age 43.9 (13.1) 31.5 (13.5)
Gender 27♀/12♂ 18♀/13♂
PSQI 12.86 (2.6) 2.97 (1.4)
ISI 17.5 (3.9) N/A
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higher for the patient group (12.86 ± 2.6) compared with normal sleepers (2.97 ± 1.4); 
this difference proved highly significant [t(59.9) = 20.13, p<.001].  Both groups had a 
greater female-to-male ratio, which was slightly more pronounced in the patient group, 
though a chi-square test for independence (with Yates continuity correction) indicated 
no significant association between gender and group status [X2 (1, n=70) = .52, p=.473].  
Mean (SD) ISI scores for PIs (17.5 ± 3.9) were in the ‘clinical moderate insomnia’ 
range. 
 
4.3.2.2. Measures and procedures 
Participants completed both the PSQI and the DFSAS to permit investigation into 
associations between global sleep quality and daytime functioning.  PI patients also 
completed the Insomnia Severity Index (ISI; Morin, 1993) to investigate relations 
between insomnia severity and daytime impairment.  Those patients taking part in the 
sleep restriction intervention (see chapter five) completed the Short-Form Health Survey 
36 (SF-36; Ware & Sherbourne, 1992) and Occupational Impact of Sleep Questionnaire 
(OISQ; David & Morgan, 2006), permitting assessment of concurrent validity.  
Sensitivity to change could also be assessed from this treatment study as patients 
completed the DFSAS at post-treatment and at 3 months follow-up.   
 
4.3.3. Results 
4.3.3.1. Item generation and face validity 
 
After several reviews of audio-diary and focus-group transcripts, collected during a 
previous qualitative investigation on daytime functioning and quality of life in insomnia 
(Kyle, Espie & Morgan, in press; see chapter three, table 3.2), several item-domains 
were identified to capture everyday functional impairments relevant to those with 
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insomnia.  Discussions between the authors (researchers and clinicians) and one 
independent researcher not affiliated with the study, coupled with exhaustive reading of 
the literature (see Kyle et al., 2010), resulted in the agreement and acceptance of 12 
items.  Response formats were modelled on the widely used Pittsburgh Sleep Quality 
Index (PSQI; Buysse et al., 1989), for part 1, and the Flinders Fatigue Scale (FFS; 
Gradisar et al., 2007), for part 2.  The time reference period, ‘in the past two weeks’, 
was chosen to parallel that of the Insomnia Severity Index, and the typical assessment 
period for subjective sleep diary parameters (10-14 days).    
 
4.3.3.2. Discriminant validity 
The ability of the DFSAS to discriminate insomnia patients (n = 39) from good sleepers 
(n = 31) was investigated.  The mean DFSAS part 1 total score for insomnia patients 
was 17.12, SD =5.67; and 6.16, SD = 3.06 for good sleepers.  Mean DFSAS part 2 total 
score was 23.81, SD=9.00, for patients; and 5.53, SD=6.03 for good sleepers.  Thus, 
both parts 1 [t(60.6) = 10.33, p<.001] and 2 [t(67) = 9.58, p<.001] readily discriminated 
the groups (figures 4.2 & 4.3 indicate the distribution of scores for both groups).  
Because of group discrepancies in terms of age, we also conducted univariate analyses 
controlling for the influence of this variable.  This revealed that age was not 
significantly related to group differences for either DFSAS part 1 [F(1, 67) = 1.42, 
p=.24, partial eta squared = .021] or 2 [F(1, 66) = .227, p=.64, partial eta squared = 
.003], and that group effects, partialling out age, remained robust (both p<.001).   
Mean scores for individual DFSAS items (parts 1 & 2) also discriminated the groups. 
Item (mean) scores and related statistical significance are detailed in table 4.3 and 
graphically represented in figures 4.4 and 4.5.   
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Figure 4.2 - Boxplots of DFSAS part 1 scores for PI patients and normal sleepers (NS). 
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 Figure 4.3 - Boxplots of DFSAS part 2 scores for PI patients and normal sleepers (NS). 
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Table 4.3 - Mean DFSAS item values for PI patients and normal sleepers (NS).  
Item PI NS t p PI NS t p
1 Difficulty concentrating and focusing on things 1.64 0.61 7.46 < 0.001 2.59 0.47 10.03 < 0.001
2 Feeling irritable 1.46 0.61 5.22 < 0.001 2.08 0.33 7.68 < 0.001
3 Fatigue or tiredness 2.13 0.87 8.17 < 0.001 3.31 0.97 9.96 < 0.001
4 Feeling 'down in the dumps'/ low mood 1.28 0.52 4.38 < 0.001 1.79 0.30 6.09 < 0.001
5 Not performing at work/or study as well as you would like to 1.45 0.45 5.53 < 0.001 2.21 0.37 7.84 < 0.001
6 Feeling tense or anxious 1.21 0.52 4.62 < 0.001 1.44 0.30 5.19 < 0.001
7 Difficulty remembering things 1.33 0.52 5.32 < 0.001 1.67 0.23 6.53 < 0.001
8 Lack of energy and motivation 1.92 0.71 7.45 < 0.001 2.77 0.97 7.32 < 0.001
9 Aches and pains 0.92 0.23 4.39 < 0.001 0.62 0.30 1.51 0.136
10 Avoiding or cancelling social acitivities 0.92 0.10 4.75 < 0.001 1.23 0.10 4.50 < 0.001
11 Feeling sleepy during the day 1.81 0.90 5.99 < 0.001 2.92 1.07 7.24 < 0.001
12 Lack of desire for physical intimacy or sex 1.13 0.13 4.83 < 0.001 1.14 0.00 5.56 < 0.001
Part 1 Part 2
 
 
Figure 4.4 - Radar plot of mean item (1-12) DFSAS part 1 scores for patients with primary insomnia (PI) 
and normal sleepers (NS). 
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Figure 4.5 - Radar plot of mean item (1-12) DFSAS part 2 scores for patients with primary insomnia (PI) 
and normal sleepers (NS).  
 
0.00
1.00
2.00
3.00
4.00
1
2
3
4
5
6
7
8
9
10
11
12
PI
NS
 
 
 
4.3.3.3. Concurrent validity 
 
Given the lack of a widely used measure to assess functioning specific to insomnia, we 
chose the SF-36 to investigate concurrent validity with DFSAS part 1 scores.  Although 
not a directly comparable measure, the SF-36 was chosen because it has been shown to 
be sensitive to insomnia impairment, as well as to change, post-behavioural and 
pharmacological intervention (for a review, see Kyle et al., 2010; chapter two of this 
thesis).  Concurrent validity was also assessed using the OISQ, a measure of sleep-
related occupational impairment.  Spearman correlational analyses revealed moderate 
negative associations between part 1 scores and the following dimensions of the SF-36: 
vitality (rho=-.51, n=18, p<.05), general health (rho=-.54, n=17, p<.05), emotional role 
limitation (rho=-.43, n=18, p=0.07), mental health (rho=-.41, n=18, p=0.09) and social 
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functioning (rho=-.40, n=18, p=.10).  The OISQ was found to be strongly and 
positively associated with DFSAS part 1 scores (rho=.76, n=16, p<.01).         
 
4.3.3.4. Relationship with sleep quality and sensitivity to treatment outcome 
To investigate associations between functional impairment and sleep quality/insomnia 
symptoms, correlational analyses were carried out between DFSAS scores and both 
PSQI and ISI values for the patient group.  Associations between PSQI and part 1 
scores were weak (rho=.19, n=38, p>.05).  Relationships between PSQI and part 2 
scores were weak to moderate (rho=.31, n=38, p>.05).  Conversely, associations 
between global ISI scores and DFSAS parts 1 (rho=.49, n=38, p<.01) and 2 (r =.61, 
n=38, p<.001) were significant and moderate to large in strength.  
 
Based on data from 18 patients taking part in the sleep restriction intervention (see 
chapter five), we assessed the sensitivity of the DFSAS to change over time with 
successful treatment.  The DFSAS was completed at baseline, post-treatment (4 weeks), 
and 3-months follow-up.  Repeated measures ANOVA were used to assess time effects, 
and post-hoc paired t tests investigated specific mean differences.  Finally, responder 
analyses were also carried out to determine whether those who responded to therapy, in 
terms of overall insomnia severity, had lower scores on the DFSAS compared with non-
responders to treatment.   
 
Mean Insomnia Severity Index (ISI) scores for the total sample indicated significant 
time effects, with a baseline average of 17 decreasing to 10 at post-treatment, which 
remained at this level at 3 months follow-up (see chapter five).  ANOVA for DFSAS 
part 1 indicated a main effect of time [F(2, 26) = 12.42, p<.001].  Post hoc t-tests (see 
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table 4.4) revealed significant improvements at post-treatment, relative to baseline, and 
a further enhancement effect at 3 months; with values being significantly lower 
(improved) compared with both baseline and post-treatment scores (see figure 4.6).  
 
Table 4.4 - Treatment sensitivity for DFSAS parts 1 and 2 in PI patients. 
M (SD) M (SD) M (SD)
     DFSAS      Part 1 16.93 5.24 11.36* 4.99   8.64**a 4.41
            Part 2 23.21 10.96 18.79 12.08 14.60* 10.36
a. contrast with post-treatment mean sig. at p <.05
Asterisks indicate post-treatment changes from Baseline: *p <.05, ** p<.01
Baseline Post-treatment Follow-up
(3 months)
 
 
Figure 4.6 - DFSAS part 1 mean (± standard error) scores over the course of intervention.  
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Part 2 scores similarly evidenced a main effect of time over the assessment points [F(2, 
26) = 4.56, p<0.05].  Paired t tests indicated significant mean reductions at 3 months 
relative to baseline, though between-subject variability remained high (see figure 4.7).   
 
     Figure 4.7 - DFSAS part 2 mean (± standard error) scores over the course of intervention. 
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A treatment responder analysis was also carried out to compare responders versus non-
responders.  Those showing at least a six point change on the ISI were considered to be 
treatment responders (Yang et al., 2009).  Twelve (66.6%) patients were found to be in 
the ‘responder’ group; the remaining six were classified as non-responders.   
 
Significant responder versus non-responder effects were found for DFSAS part 1 [U = 
6.50, z = -2.79, p<.01] and a trend was present for part 2 [U = 14.00, z = -1.91, p=.056], 
with responders having substantially lower scores (indicative of less impairment; see 
table 4.5) 
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Table 4.5 - Responder analysis for DFSAS parts 1 and 2. Median (Mdn) values are presented with the 
interquartile range (IQR) in parentheses. 
 
Mdn IQR Mdn IQR
DFSAS
Part 1 8.00 (7-10) 16.00 (14-20)
Part 2 11.00 (7-18) 28.00 (15-37)
Non-RespondersResponders
(n =12) (n =6)
 
 
4.3.3.5. Internal consistency 
Cronbach's α was 0.91 for DFSAS part 1 and 0.94 for part 2.  When the PI patients were 
investigated separately, Cronbach’s α remained high at 0.81 for part 1 and 0.89 for part 
2.  Items were then systematically removed to ascertain the stability of the DFSAS, 
reflected in the item-deletion alpha (Broomfield & Espie, 2005).  For part 1, specifically 
for the patient group, item-deletion alphas remained high (mean α = 0.80, range 0.77-
0.84).  Item-deletion alphas similarly remained high for Part 2 (mean α = 0.88, range 
0.87-0.89).   
 
4.3.3.6. Sensitivity and specificity 
Both sensitivity (the probability that an individual with the condition will be correctly 
classified as having the condition) and specificity (the probability that a person without 
the condition will be properly classified as not having the condition) were calculated for 
DFSAS parts 1 and 2 using receiver operating characteristic (ROC) curves.  The area 
under the curve was 0.945 (p<.001) and 0.954 (p<.001) for parts 1 and 2, respectively.  
A cut-off ≥ 10 on part 1 correctly identified 87.2% of PI patients and 87.1% of normal 
sleepers (see table 4.5).  In relation to part 2, a cut off ≥ 13 correctly identified 92.3% of 
PI patients and 86.7% of normal sleepers. 
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Table 4.6 - Sensitivity and specificity of DFSAS in identifying NS and PI patients. 
PI NS
Correct 34 27
Incorrect 5 4
Correct 36 26
Incorrect 3 4
Using DFSAS part 1 cut-off score of ≥ 10:
Using DFSAS part 2 cut-off score of ≥ 13:
 
 
4.3.3.7. Relationship between DFSAS parts 1 and 2 
Because DFSAS items reflect those daytime impairments associated with poor sleep (as 
reported qualitatively by patients), it was predicted there would be a relationship 
between magnitude of impairment (part 1) and attribution for poor sleep as being 
responsible for the impairment (part 2).  Accordingly, correlational analyses were 
carried out revealing a positive association between scores on part 1 and scores on part 
2 for PI patients (r =.60, n=39, p<.001).  
 
 
 
 
 
 
 
 
 
 139 
4.4. Glasgow Sleep Impact Index (GSII) 
Having presented an approach grounded in psychometric theory, where the construct 
under investigation is pre-determined, we decided next to investigate the utility and 
practicability of an individualised patient-centred measure that recruits the expertise of 
the patient when assessing insomnia-related quality of life impairment. 
 
4.4.1. Background & Aims 
Kyle et al. (2010) in their review of the insomnia and quality of life literature point out 
that in order to claim measurement of the ‘quality of life’ construct, concerns and values 
relevant to each individual patient must be considered.  The main criticism being, that 
generic measurement with, for example, the SF-36 takes little account of domains of 
functioning that are salient or specific to the individual with insomnia.  The net effect is 
that these measures may be less sensitive to picking up treatment effects because of the 
neglect of issues important to patients, coupled with the inclusion of non-relevant items.  
Of course, this is a problem that, to some extent, pervades nearly all research founded 
on traditional psychometric (nomothetic) ideology: ultimately the aim is to make rules 
and predictions about the group on some ‘global’ construct (for example, ‘depression’).      
 
Alternative approaches to symptom measurement have existed in Psychiatry and 
Clinical Psychology for some time, perhaps starting with Monte Shapiro’s (1961) 
personal questionnaire.  Dissatisfied with multi-item scales that fail to reflect the illness 
experience, or intensity of symptoms relevant to each individual patient, Shapiro 
developed a system to assess clinical change using the words of patients to describe 
their current illness state.  In a second stage, statements are constructed, again based on 
the patient narrative, which describe desired states of ‘improvement’ and ‘recovery’.  
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Over time, these states are compared and contrasted to monitor clinical change (in a 
number of symptom domains) within the individual patient.  The strength of this 
idiographic, patient-centred approach to measurement is the ability to track aspects of 
illness that are otherwise difficult to do using psychometric theory, aided by recruiting 
the patient ‘expert’ into the process.  The construct to be measured is defined by the 
individual; not the other way round, as is typically the case in psychometric research 
(Bilsbury & Richman, 2002).  Such patient-centred and clinical staging methodologies 
have recently gained renewed momentum in the psychiatric research community 
(Bilsbury & Richman, 2002), in the health-related quality of life measurement literature 
(Carr & Higginson, 2001), and for assessment of outcomes in primary care (e.g. 
Paterson, 1996).   
 
From our early qualitative work with insomnia patients (Kyle, Espie & Morgan, in 
press; chapter three of this thesis), it was clear that although common domains of sleep-
related impairment were expressed at the group level, each individual assigned different 
values of importance to particular domains of impairment, within the context of their 
own daily lives.  We therefore wanted to create a measure that would allow patients 
with insomnia to describe impairments that were most important and relevant to them, 
and hence capture insomnia-related quality of life impairment, which could 
subsequently be evaluated within both clinical and research settings.  To do this we 
modified the standard patient-generated index (PGI; Ruta et al., 1994), an individualised 
measure of quality of life.   
 
In the standard PGI, participants are asked to write down, in a structured template, the 
five most important areas of their life affected by a particular health condition (e.g. 
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pain).  They are then asked to rate the areas on a 0-100 scale, with scores ranging from 
‘the worst you can imagine’ to ‘exactly as you would like it to be’.  Finally, participants 
prioritise each generated item by assigning points (out of 60) to the area(s) considered 
most important to eradicate.  There is also an additional box referring to ‘all other areas 
of your life’, which is similarly rated and assigned points.  Overall score is calculated by 
multiplying ratings by the weighted sum of the ‘points’ value, per item, and combining 
them to give a score between 0 and 100.  The PGI is based on a model that considers 
QoL to be the gap between reality and expectations: the more pronounced the gap, the 
poorer the current state of QoL (and vice versa).  Hence the aim is for reality to be as 
close to expectations as possible (Ruta et al., 1994).          
 
4.4.2. Scale development & pilot  
We initially made only small modifications to the standard PGI, using the 
aforementioned three-part format, including item generation, rating, and point 
assignment sections.  For the ‘list areas’ section, participant instructions were to “write 
down the five most important areas of your life that are affected because of poor sleep”.  
A list of domains was provided as a ‘trigger’ list to prompt and aid participants in item 
generation (as in the initial PGI).  Subsequently, we informally piloted the scale on a 
small sample of participants who took part in a previous qualitative study (Kyle, Espie 
& Morgan, in press; chapter three), to gain feedback on face validity, ease of 
completion, and practicability.               
 
Observations from this pilot indicated three important limitations of the initial measure: 
(1) participants could not always generate five areas; (2) participants tended to copy 
areas directly from the ‘trigger’ list, particularly if they were unable to generate them 
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independently (a previously documented problem; Patel et al., 2003), and (3) the section 
‘all other areas of your life’ was confusing to patients and often left incomplete.  Based 
on this feedback we made several modifications to the scale (see figure 4.8), so that 
participants were now asked to generate three items (stage 1), rank the three items in 
terms of importance (1-3; stage 2), rate how ‘bothered’ they had been by the impairment 
in the past 2 weeks on a 100mm visual analogue scale (VAS; stage 3), and, finally, 
‘spend an imaginary £60’ on getting rid of impairments of choice (stage 4).  This final 
version of the scale was designed to allow participants to generate items without a 
trigger list, so fully in their own words; and also to enable collapsing of ranks (1-3) 
across the group, permitting within-subject analyses of change, yet at the same time 
retaining individual patient concerns.    
 
This collapsing of generated ranks (and therefore scoring) differs from the original PGI, 
where sensitivity is typically assessed using a so-called ‘blind’ version, in which ranks 
(patient concerns) are newly generated each time the PGI is completed (i.e. participants 
are not shown their previous responses).  Although this ‘blind’ format does take account 
of the fluctuating nature of ‘quality of life’ (so participants can insert new domains on 
re-completion), responsiveness to change has been poor, likely because of the 
inconsistency in rated items (Witham et al., 2008).  We wanted to introduce some 
experimental stability over what ranks/items are rated; thus when re-administering the 
scale, in say a treatment context, original ranks are inserted by the researcher/clinician 
and the patient is asked to re-rate them – a so-called ‘closed’ format (see figure 4.9).  A 
further related idea was that in future studies these generated areas of individual-specific 
concerns could be inserted into a sleep diary and measured on a daily basis, in a similar 
manner to quantitative sleep parameters assessed throughout the intervention period.   
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Figure 4.8 - Copy of the Glasgow Sleep Impact Index (GSII). 
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Figure 4.9 - Follow-up ‘closed’ version of the GSII with patient example. 
 
 145 
Based on the premise that quality of life impairment (above an individual personal 
threshold) drives treatment-seeking behaviour in those with insomnia, the ultimate aim 
of the GSII is to document a reduction in quality of life interference in parallel with 
clinically significant changes in sleep.  
 
4.4.3. Results 
 
4.4.3.1. Participant demographics 
 
The 39 primary insomnia patients that completed the DFSAS also completed the GSII at 
the same time (see table 4.2 for demographics).   
 
Based on data from PI patients, we assessed the following properties of the GSII: 
content of generated domains/ranks; how VAS ratings and ‘spend money’ scores 
compared across the three most important generated life areas (within-subjects); 
concurrent validity with SF-36 dimensions and the Occupational Impact of Sleep 
Questionnaire (OISQ; David & Morgan, 2006); relationships with global measures of 
insomnia symptoms/sleep quality; and sensitivity to treatment outcome during a sleep 
restriction intervention.     
 
 
4.4.3.2. Rank content analysis (content validity) 
 
The scale was completed appropriately by nearly all patients; missing data was small.  
Of the 39 patients involved in the three studies, three were not administered the scale by 
the relevant researcher, leaving 36 completed GSII questionnaires.  Out of these 36, two 
patients failed to enter data for one of the ranks; hence, missing data was 2 (1.85%) out 
of a possible 108 rank entries. 
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We carried out a quantitative content analysis (Hsieh & Shannon, 2005) of the 106 
remaining generated domains, across all participants and their three specified concerns.  
Each item was given a code; codes were subsequently grouped into global categories.  
The frequency of each category, reflected as a percentage of the total number of 
generated items, is reported in table 4.7.  Although likely to be highly inter-related, the 
most commonly reported categories were: ‘occupational functioning’, ‘cognitive 
functioning’, ‘mood’, ‘energy’ and ‘social functioning’.  There was no clear pattern in 
terms of generated domains and rank importance i.e. areas of functioning concern 
tended to be equally distributed across ranks 1, 2 and 3. 
 
Table 4.7 - Content domains from GSII rank content analysis. 
Category Frequency (%)
Occupational Functioning 15.10%
Cognitive Functioning 15.10%
Energy 11.30%
Mood 11.30%
Social Functioning 8.50%
Motivation 7.50%
Outlook 6.60%
Family/Partner Relationships 6.60%
Health 6.60%
Tired/Fatigue 4.70%
Appearance 2.80%
Happiness 1.90%
Sleepy 1.90%
Anxiety 1.90%
Confidence/Self-esteem 1.90%
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4.4.3.3. Relationship between ranks 
 
Ranks and ratings were collapsed across all patients, creating global group mean VAS 
scores for ranks 1, 2, and 3.  Lower VAS scores are indicative of greater perceived 
impairment in the particular area of concern.  These mean scores were investigated 
using repeated-measures ANOVA, revealing a significant main effect of rank [F(2, 62) 
= 18.44, p<.001].  Post-hoc paired t tests indicated a graded trend across the ranks (see 
figure 4.10 and table 4.8), so that rank 1 scores were significantly lower than both ranks 
2 [t(31) = -2.89, p<.01] and 3 [t(31) = -5.74, p<.001], and rank 2 scores were 
statistically lower than rank 3 values [t(31) = -3.32, p<.01].  This analysis essentially 
confirmed the ordering of generated rank importance. 
 
 
Figure 4.10 - Boxplots of VAS (mm) ratings for GSII ranks 1, 2 and 3, for all patients.  
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Scores on the ‘spend’ category further supported this pattern (table 4.8), with 
participants opting to place the highest ‘monetary’ value on eradicating rank 1 (£34.20, 
SD=14.6), then rank 2 (£16.50, SD=9.7) and finally, rank 3 (£9.35, SD=8.0).      
 
Table 4.8 - VAS ratings (mm) and spend (£) for generated ranks for all patients. 
VAS score (mm) Level of 'spend' (£)
Rank 1 22.94 (12.2) 34.20 (14.6)
Rank 2 30.69 (16.1) 16.50 (9.7)
Rank 3 41.34 (19.2) 9.35 (8.0)
 
 
4.4.3.4. Concurrent validity 
 
Relations between GSII rank scores and both SF-36 and OISQ scores, collected at 
baseline during the aforementioned sleep restriction study (n=18), were investigated 
using correlation analyses.  
  
Rank 1 was found to be significantly associated with emotional role limitation (rho=.56, 
n=17, p<.05) and moderately associated with social functioning (rho=.41, n=17, 
p=.099).   
 
Ranks 2 and 3 were both significantly (negatively) associated with occupational 
functioning as measured by the OISQ (r =-.59, n=16, p<.05; and rho=-.55, n=16, 
p<.05).  Rank 2 was strongly associated with emotional role limitation (rho=.70, n=18, 
p<.01) and moderately associated with mental health (r =.43, n=18, p=.07) and social 
functioning (rho=.37, n=18 p=.13).  Rank 3 was similarly positively associated with 
social functioning (rho=.59, n=18, p<.05), and moderately associated with emotional 
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role limitation (rho=.40, n=18, p=.10), mental health (rho=.37, n=18, p=.13), and 
vitality (rho=.37, n=18, p=.13).  
 
 
4.4.3.5. Relationship with sleep and treatment outcome sensitivity 
 
Interestingly, ranks 1 and 2 were weakly and non-significantly associated with PSQI 
and ISI values.  Rank 3, however, was negatively (moderately) associated with both 
PSQI (r =-.40, n=32, p<.05) and ISI (r =-.42, n=32, p<.05) values.   
 
The GSII was completed over the course of the sleep restriction intervention, at 
baseline, post-treatment and 3 months follow-up.  Repeated measures ANOVA revealed 
main effects of time for rank 1 [F(2, 26) = 5.31, p<.05] and rank 2 [F(2, 28) = 3.56, 
p<.05], but not rank 3 [F(2, 28) = 0.92, p=.410].  Post-hoc t tests indicated that although 
mean group scores for ranks 1 and 2 increased (improved) from baseline to post-
treatment, between-subject variability was high, and hence both failed to reach 
statistical significance.  However, both ranks 1 and 2 achieved statistical significance at 
the three month assessment point relative to baseline values (see table 4.9).   
 
 
Table 4.9 - VAS scores for GSII ranks collected over the course of intervention and at follow-up. 
M (SD) M (SD) M (SD)
GSII
34.14 (17.96) 53.14 (22.58) 58.00* (22.85)
Rank 2 39.47 (17.72) 49.93 (24.77) 57.20* (19.96)
Rank 3 50.87 (19.01) 54.60 (22.66) 58.80 (24.43)
* signficant at p  <.05, relative to baseline
         Baseline                Post-treatment            Follow-up
         Rank 1
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Finally, those categorized as ‘responders’ to sleep restriction therapy, based on ISI 
values, were found to have significantly higher (improved) scores for ranks one [U = 
13.50, z = -2.11, p<.05], two [U = 6.00, z = -2.81, p<.01] and three [U = 4.00, z = -2.92, 
p<.01], relative to non-responders (indicating less impairment; see table 4.10).     
 
 
Table 4.10 – Responder analysis for the GSII. Median (Mdn) values are presented with the interquartile 
range (IQR) in parentheses. 
Mdn IQR Mdn IQR
GSII
Rank 1 63.50 (33-73) 25.50 (18-58)
Rank 2 67.00 (51-78) 21.00 (16-35)
Rank 3 66.00 (59-78) 29.50 (16-43)
Responders Non-Responders
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4.5. Discussion 
 
In the present study, two new brief scales, the Glasgow Sleep Impact Index (GSII) and 
the Daytime Functioning and Sleep Attribution Scale (DFSAS), were developed to help 
refine measurement of insomnia-related impairment in both clinical practice and 
research settings (see table 4.11).  The DFSAS was created to address the need for a 
scale that is based on commonly reported insomnia-symptom domains; can be 
completed by both patients and non-patients; and includes (as a separate section) some 
reference to poor sleep attributions in causing daytime impairment.  The GSII, on the 
other hand, was created as an individualised measure for specifically targeting daytime 
and quality of life impairments reported by insomnia patients.  This tool addresses the 
need for a scale that records items relevant to each patient in their own unique 
vocabulary, capturing individual meaning, relevance and importance.     
 
Table 4.11 - Measurement needs and subsequent fulfilment by developed scales.   
Required scale characteristics for use with insomnia patients Met by…
1. Assessment of concerns relevant to each individual patient GSII
2. A measure which permits ranking of concerns in order of personal importance GSII
3. Some measure of the attribution for poor sleep in causing daytime impairment GSII/DFSAS
4. Coverage of items that are commonly reported by insomnia patients as a group DFSAS
5. Brief measure that can be used in both clinical and research settings GSII/DFSAS
6. Can be completed by normal and poor sleepers with limited sleep-related priming DFSAS
7. Can be completed by patients with additional health conditions GSII/DFSAS
 
4.5.1. DFSAS 
The DFSAS, based on common patient descriptors, was found to have high internal 
consistency, good discriminant validity, and, using a cut-off of 10 (part 1), was able to 
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correctly identify 87% of insomnia patients and 87% of normal sleepers.  Furthermore, 
DFSAS (part 1) demonstrated fair concurrent validity; correlating moderately with SF-
36 dimensions tapping vitality/energy, emotional well-being, social functioning and 
general health (domains that are typically the most sensitive to insomnia impairment 
and treatment; Kyle et al., 2010).  Given the global coverage of symptoms in the 
DFSAS, these moderate correlations are not surprising; suggesting that our new scale, 
as predicted, is likely to be tapping into a more global daytime functioning construct, 
over and above isolated dimensions.  Interestingly, the DFSAS was strongly related to 
the OISQ, accounting for approximately 58% of the variance in scores.  The DFSAS 
items probe a range of daytime symptoms, including items relating to work 
productivity, concentration, memory, and fatigue, all of which are likely to be important 
for optimal workplace functioning.          
 
A particular strength of the DFSAS is the ability to collect normative data on healthy 
normal sleepers, in a non-loaded fashion.  This proved useful when assessing sensitivity 
to change in PI patients during the sleep restriction intervention, where improvements 
were found to be robust and graded over the three assessment points.  Indeed, final 3 
month follow-up mean scores (part 1) were only approximately 2 scale points higher 
than those observed for normal sleeping controls.  Although a small uncontrolled trial, 
such data suggest that (1) a brief behavioural intervention can improve daytime 
functioning, and (2) these end-point scores are not markedly dissimilar from values 
indicative of normal functioning.  Clearly, the DFSAS needs to be piloted in large 
randomised controlled trials of behavioural and pharmacotherapy interventions before 
any definite conclusions can be made.   
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Part 2 of the DFSAS provides an index of the attribution for poor sleep in accounting 
for experienced daytime impairment, recorded in part 1.  Part 2 was found to have high 
internal consistency, good discriminant validity, good sensitivity and specificity, and, as 
predicted, was associated with magnitude of reported daytime impairment.  This 
attributional approach to measurement of daytime impairment has yet to be fully 
explored, but one can envisage several important implications.  For example, those 
scoring particularly high on questions relating to the subjective role of poor sleep in 
accounting for experienced daytime impairment may require focused cognitive therapy 
to challenge/alleviate maladaptive beliefs on the link between sleep and functioning (cf. 
Harvey, 2002).  That is, those who have pronounced sleep-related cognitive distortions 
and maladaptive views on sleep, which may relate to the misperception of both 
subjective sleep and impact on daytime functioning (‘daytime misperception’; Orff et 
al., 2007), could be identified as a specific sub-group.  It is interesting that the ‘non-
responders’ to sleep restriction treatment (see table 4.5) have substantially higher scores 
on part 2 than responders, and also notably higher scores than baseline values for the 
whole group.  These individuals, perhaps, may not be predicted to respond to a single 
behavioural intervention, instead requiring additional cognitive restructuring 
components to target sleep-daytime attributions (Harvey et al., 2007).  Due to the small 
numbers available to assess treatment response, these findings are necessarily 
preliminary and require further investigation. 
 
Secondly, DFSAS items probe everyday functional limitations, and are therefore likely 
to be relevant to other patient groups.  It would be interesting to administer the scale to 
other patient groups and compare, firstly, the relative magnitude of everyday functional 
impairments, and secondly, the role of sleep in its perceived causation.  This could 
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prove particularly interesting in disorders where sleep disturbance is prevalent (for 
example, depression, chronic pain, and cancer populations) to give a better 
understanding of the role of poor sleep in contributing to impairment among other 
disease-relevant contributors.  The DFSAS provides a means by which to assess poor 
sleep attributions in accounting for impairment, and how these may change post-
intervention.   
 
4.5.2. GSII             
The GSII, a patient-centred measure, was developed to quantify insomnia-related 
quality of life impairment at the individual level.  That is, life domains considered 
important and salient by the individual, which are negatively affected by insomnia, are 
recorded and subsequently rated.  By administering a ‘closed’ version (where originally 
generated items are inserted into a follow-up GSII), participants can re-rate their three 
originally generated ranks, permitting assessment of change over time.    
 
The scale was well received by patients.  Although not systematically recorded, 
conversations with patients suggested they enjoyed having their own input in the 
measurement process, which, according to some, ‘made sense’.  Moreover, completion 
rates were high.  This was important to document given the original PGI has often been 
poorly completed when not interview-administered (Ruta et al., 1994, 1999).   
 
Content analysis of generated domains validated the presence of impairments cited in 
diagnostic classification manuals, such as difficulties with fatigue, energy, motivation, 
mood, and cognitive functioning, as well as more ‘downstream’ disruption, related to 
social, occupational, and relationship functioning (ICSD-2, 2005; DSM-IV, 1994).  
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Importantly though, additional categories of impairment emerged that have not been 
described or investigated in the literature, with perhaps the exception of some recent 
qualitative work (Carey et al., 2005; Kyle et al., in press).  These included: happiness, 
outlook, confidence/self-esteem, and appearance.  It is interesting that many of these 
additional categories represent a shift in focus away from specific symptoms; instead 
capturing highly personal and difficult-to-define constructs, which only have meaning 
and relevance for the individual patient.  Overall, the breadth of generated domains 
underscores the pervasiveness of insomnia-related impairment, supporting earlier work 
using the SF-36 indicating that insomnia patients have comparable, but more wide-
ranging, functional impairments than those with depression and congestive heart failure 
(Katz & McHorney, 2002).  
 
Another emergent finding from this content analysis was that occupational functioning 
was the most frequently cited area impacted by poor sleep.  This is perhaps not 
surprising given that work-life represents a large percentage of our waking activity.  
What is surprising, though, is the small amount of literature investigating the 
relationship between insomnia and workplace functioning.  It is fair to say that the 
majority of published literature has assessed the relationship at a rather blunt, macro-
level; typically in large epidemiological studies reporting on absenteeism rates, and 
(non-validated) measures of work productivity (e.g. Philip et al., 2006; Daley et al., 
2009b).  Encouragingly, the inclusion of the Work Limitations Questionnaire (WLQ; 
Lerner et al., 2001) in two recent large randomized trials of hypnotic medication for 
insomnia revealed that work-related impairments can undergo improvements in parallel 
with sleep (Walsh et al., 2007; Erman et al., 2008).  The development of the OISQ by 
David & Morgan (2006) also looks a promising addition to the field, with a particular 
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focus on the impact of sleep quality on workplace functioning.  Of interest, ranks 2 and 
3 from the GSII were significantly (negatively) associated with scores on the OISQ, 
indicating that those with lower rank scores (reflective of greater impairment) also 
tended to experience greater occupational difficulties.   
 
It is also worth mentioning that although ‘fatigue’ is regarded as the most commonly 
associated daytime symptom of insomnia (e.g. Lichstein et al., 1997; Riedel & 
Lichstein, 2000) no single participant actually used this term when describing insomnia-
related impairments.  ‘Tired’, ‘energy’ and ‘motivation’, often synonyms for fatigue, 
were used more frequently.  Perhaps a seemingly trivial point, but daytime functioning 
scales, such as the Fatigue Severity Scale (a recommended and often-used measure in 
insomnia research), tend to be composed of items which include the term ‘fatigue’.  
This inclusion may subsequently fail to capture ‘fatigue’-related impairment in a 
meaningful way for patients.  Such data parallel work in the pain literature by De Souza 
& Frank (2000).  These authors interviewed 11 patients with chronic pain to gain 
‘insider’ accounts of how pain is perceived and understood by those who have it.  
Interestingly, patients reported less than half of the pain descriptors cited in the widely 
used McGill Pain Questionnaire.  This finding, coupled with our content analysis, 
reinforces the need for an understanding of, and appreciation for, personal semantics 
when describing health-related impairments.  The distinction between ‘sleepiness’ and 
‘fatigue’ at the beginning of the recently developed Flinders Fatigue Scale (Gradisar et 
al., 2007) indicates, to some extent, awareness of such important related issues in the 
field of sleep medicine.  
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Concurrent validity of the GSII was assessed through correlating ranks with SF-36 
dimensions.  Similar to the DFSAS, GSII ranks tended to be moderately associated with 
dimensions covering aspects of emotional well-being and social functioning.  This is 
perhaps not surprising given that ‘social functioning’ and ‘mood’ were in the top five 
most frequently generated categories of the GSII.  This could also suggest there is a 
strong affective component involved in rating insomnia-related quality of life 
impairment.  Indeed, recent work with a large number (n=160) of primary insomnia 
patients indicates that higher levels of depression (as measured with the BDI) predicted 
impairments in three factors capturing fatigue, physical health and mental health 
(Beaulieu-Bonneau et al., 2007b).  
 
Interestingly, from this study, levels of depression predicted impairments in these 
factors to a greater degree than both objective and subjective measures of sleep.  This 
may, therefore, explain why in the present study standard self-report measures of sleep 
quality and global insomnia severity tended to correlate poorly with GSII generated 
ranks.  Alternatively, the poor relationship between insomnia severity and the GSII may 
be explained by the nature of what patients are asked to report in the GSII.  Participants 
are asked to write down the three most important areas of their lives affected by poor 
sleep.  Given that each generated rank is salient, important and therefore relevant to 
each (untreated) patient, one would perhaps not expect these values to vary in a linear 
fashion with scores on a pre-determined measure of insomnia severity.   
 
In a recent review, Krystal (2007) made the important point that “successful therapy 
should improve difficulties identified prior to initiating treatment” (page 69).  He was in 
fact directing his comments towards clinicians within everyday clinical practice, where 
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quantitative measurement is not necessarily the arbiter of success.  The GSII, however, 
could fulfil this very role in both clinical and research settings; eliciting patient-relevant 
concerns in a systematic fashion.  Although requiring replication within a larger 
controlled study, preliminary data from the small number of PI patients who took part in 
the sleep restriction intervention reveals significant improvements in the two most 
importantly generated patient concerns at follow-up.  Furthermore, when dividing the 
group into responders and non-responders (a more sensitive and appropriate analysis for 
patient-centred measures; Martin et al., 2007), based on global insomnia severity, it was 
found that responders had significantly higher (improved) scores for all three ranks 
compared with non-responders.  Our modified format and collapsing of generated ranks, 
across the entire group, may account for the superior sensitivity and responsiveness of 
the GSII, relative to the often poor response rate reported in work with the original and 
revised PGI (Witham et al., 2008; Patel et al., 2003; Martin et al., 2007).  
 
Finally, although not used for score derivation, the ‘spend’ section (part 4) of the GSII 
may be particularly useful within the clinical context.  If, for example, a patient decides 
to ‘spend’ all, or most, of the allocated ‘money’ on getting rid of a specific problem 
(e.g. impairment in work performance), then the therapist/clinician may tailor the 
intervention accordingly.  This may involve elements of cognitive restructuring to 
minimize distress, behavioural experiments to test out unhelpful beliefs, and the 
development of coping strategies aimed at reducing functional impact.         
 
4.5.3. Limitations 
 
This work has several limitations.  Firstly, for scale development studies, the sample 
size was small.  This is particularly important when reviewing our data on concurrent 
validity and within-group treatment effects, which are based on a small number of 
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participants.  Concerning the sample of normal sleepers, in the analysis of DFSAS 
properties, it should be noted that they significantly differed in age compared to 
insomnia patients.  Although this age discrepancy is often reported in insomnia research 
– as sleep disturbance becomes more prevalent with age – our convenient sampling of 
normal sleepers represents a limitation of the present study.  Importantly, however, this 
discrepancy did not mediate the research findings, in that group effects remained robust 
after controlling for the influence of age.  Future validation work with the DFSAS 
should recruit matched samples across the age range.   
 
Moreover, both scales are yet to be assessed for test-retest reliability, restricting their 
immediate applicability.  The DFSAS and GSII should be completed by a sub-set of 
individuals twice within a stable time-period.  In this regard, it would also be interesting 
to assess the stability of generated quality of life impairments, which could be achieved 
by administering a ‘blind’ version of the GSII, where participants are asked to generate 
items on two separate occasions.  Such information (‘index of rank change’) may 
provide important insights on the conceptualisation/re-conceptualisation of insomnia-
related quality of life impairment over time.   
 
4.5.4. Concluding remarks and future directions 
 
Moul and colleagues (2004), in their review of self-report insomnia measures, state that 
“progress in insomnia research will depend in part on advances in questionnaire 
design” (p.194).  Here, we provide preliminary data on two new questionnaires 
developed to assess both common and individual-specific impairments relevant to 
insomnia patients.  Both have excellent face validity because they are, in different ways, 
based on the words of patents.  One can envisage the DFSAS being used to (1) highlight 
the magnitude of impairment in those with insomnia relative to normal sleepers; (2) 
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‘flag-up’ those individuals who may have ‘daytime misperception’ and hence be 
responsive to a more daytime-focused intervention; and (3) track daytime functioning 
changes and poor sleep attributions over the course of treatment in those with insomnia 
as a primary disorder, as well as in those where sleep disturbance is a co-occurring 
phenomenon.   
 
The GSII is likely to be useful for (1) the clinician working with individual patients, 
encouraging engagement in the therapeutic process, and the tailoring of interventions 
based on relevant concerns; and (2) in trials of insomnia treatment to fully capture, and 
be able to document changes in, concerns of each and every individual patient, yet at the 
same time permit group-level analysis. 
.  
What still needs to be determined, in larger validation and controlled intervention 
studies, are psychometric indices of reliability and responsiveness across different 
treatment modalities.  Relationships between both scales and objective/subjective sleep 
parameters, as well measures of affect, should be investigated in future work.  One final 
possibility, alluded to earlier in the chapter, is that patient-generated concerns from the 
GSII could be inserted into a prospective sleep diary and assessed over the course of 
treatment.  In this way, daily fluctuations in both insomnia-related quality of life 
impairment and nightly sleep parameters could be tracked prospectively.  A similar 
ecological momentary assessment methodology has been recently piloted in insomnia, 
though with pre-determined scale items (Levitt et al., 2004; Buysse et al., 2007).  
Sensitivity is likely to be increased by the inclusion of patient-specific concerns, adding 
another dimension to the assessment of insomnia-related outcomes. 
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Overall, this work presents a first step in considering alternative ways to capture and 
measure insomnia-related quality of life and daytime functioning impairments.    
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Chapter 5: 
 
 
 
The Integration of Quantitative and Qualitative Methodologies to 
Investigate the Patient Experience of Sleep Restriction Therapy (SRT) for 
Insomnia  
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5.1. Abstract 
Although clearly effective in improving subjective measures of sleep, several important 
aspects of cognitive behavioural therapy for insomnia remain poorly understood and 
under-researched.  To investigate the patient experience of sleep restriction therapy 
(SRT) for insomnia we carried out a mixed-method study employing sleep and daytime 
functioning questionnaires, prospective qualitative audio-diaries, and post-treatment 
semi-structured interviews, to gain insights from a number of different but 
complementary perspectives.  Eighteen individuals with primary insomnia participated 
in a four week sleep restriction therapy group treatment.  Questionnaire measures 
indicated strong treatment effects concerning subjective sleep parameters and daytime 
functioning/HRQoL variables.  Audio-diaries and interviews provided rich accounts of 
side-effects associated with acute sleep restriction implementation; changes to sleep 
parameters, daytime functioning, and perceptions of sleep; and general challenges 
surrounding treatment implementation and adherence.  This work has important 
implications for the delivery of SRT, particularly concerning awareness of possible 
‘adverse events’ and likely implementation challenges.  Findings also pave the way for 
testable hypotheses concerning possible mechanisms of action involved in sleep 
restriction treatment.  This study highlights the insights that can be achieved through a 
pragmatic mixed-method approach.  
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5.2. Introduction 
Cognitive behavioural therapy for insomnia (CBT-I) is widely accepted as an effective 
intervention for improving insomnia symptoms.  Moreover, CBT-I is a standard, 
recommended treatment (Chesson et al., 1999; Morgenthaler et al., 2006), and is 
commonly regarded as the treatment modality of choice (Espie & Kyle, 2009; see 
Riemann & Perlis, 2009 for a review of published meta-analyses).  There still remains, 
however, a lack of available CBT-I and behavioural sleep medicine specialists to deliver 
appropriate treatment.  Indeed, it is a common quip at scientific meetings that the only 
patients gaining access to CBT-I, are those enrolled in randomised trials (Espie, 2008).  
Ongoing work attempts to widen access to CBT-I, and behavioural sleep medicine more 
generally (Espie, 2009; Perlis & Smith, 2008).               
 
Although improvements in sleep are commonly reported post CBT-I and up to 2 years 
follow-up, there is a paucity of work documenting changes in daytime parameters and 
health-related quality of life (HRQoL; Morin, 2004, Morin, 2003; Riemann & Perlis, 
2009).  One recent review paper indicates that only a handful of randomised trials have 
included a measure of HRQoL (Kyle et al., 2010; see chapter two of this thesis).  Given 
that, by definition, insomnia is associated with disruption to patients’ daily lives (DSM-
IV; ICSD-2; Kyle et al., in press; Carey et al. 2005), and that this complaint typically 
acts as the principal motivator for treatment-seeking behaviour (Stepanski et al., 1989; 
Morin et al., 2006a), the lack of measurement of daytime functioning parameters in 
trials is an important omission.  Nevertheless, the small amount of data that does exist, 
tentatively suggests that behavioural therapy and pharmacotherapy can improve 
domains of HRQoL and daytime functioning (Kyle et al., 2010; Krystal, 2007), though 
much work is still to be done to determine reliable indices of change. 
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Equally remarkable, no study has asked patients about their experience of CBT-I.  That 
is, similar to the dearth of qualitative data on the subjective experience of insomnia, 
there too remains a gap in the literature describing the patient perspective on treatment.  
Such fundamental work is long overdue, and has potentially important implications.   
 
Firstly, although there are a number of plausible explanations as to how CBT-I exerts its 
therapeutic effect (Spielman et al., 1987b; Pigeon & Perlis, 2006; Morin, 1993; Morin 
& Espie, 2003; Edinger et al., 2008b; Edinger & Means, 2005), there are few 
experimental studies that shed light on candidate mechanisms.  Tracking the subjective 
narrative account of treatment, longitudinally, may prove fruitful in confirming, as well 
as raising additional, factors associated with CBT-I response.    
 
Secondly, it is often presumed that psychological therapies, in contrast to 
pharmacological interventions, are devoid of ‘side-effects’ (Nutt & Sharpe, 2008; Berk 
& Parker, 2009).  This may be naïve, particularly in the context of the behavioural 
treatment of insomnia.  Stimulus control and sleep restriction therapies can lead to 
significant (acute) decrements in total sleep time, and, therefore, possibly induce 
daytime dysfunction over and above baseline difficulties.  Such impairments, if they 
exist, could be particularly pronounced in those with elevated levels of sleep 
misperception, and those who fail to ‘respond’ to sleep restriction after several days.  
The presence of ‘side-effects’ are yet to be described systematically, beyond anecdotal 
report (Spielman et al., 1987b; Hoelscher & Edinger, 1988; Greene, 2008).  Fittingly, in 
their recent review, Riemann & Perlis (2009) asserted “the question of adverse events 
has not been properly addressed up to now in research on psychological/behavioural 
methods, possibly taken it for granted that no such risks exist…research on adverse 
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events for psychological treatments needs to be intensified” (p.213).  The NIH state-of- 
the-science conference statement (2005) came to similar conclusions: ‘there is no 
evidence that such treatment produces adverse effects, but thus far, there has been little, 
if any, study of this possibility’. (p.1056)  
 
If negative consequences of behavioural therapy do exist, they need to be documented, 
and their time course evaluated, to further alert practitioners and prospective patients 
prior to initiation of treatment.  The lack of investigation of CBT-I side-effects can be 
contrasted with approaches in other areas of medicine, such as pharmaceuticals where 
there tends to be rigorous recording of ‘adverse events’ during active therapy.  Adverse 
event profiles are then used as cautionary notes to inform patients when initiating 
treatment.  This is also the case for sleep apnea patients undergoing continuous positive 
airway pressure (CPAP) therapy, where side-effects have been associated with drop-out 
rates and non-adherence during clinical trials (Haynes, 2005).  The importance of 
monitoring side-effects in sleep apnea patients is further underlined in the Calgary Sleep 
Apnea Quality of Life Index (SAQLI; Flemons & Reimer, 1998), which contains a sub-
scale specifically inquiring about CPAP adverse events.  Such information may 
subsequently guide CPAP titration.   
  
A third benefit of prospective qualitative monitoring may be a contribution to our 
understanding of adherence to behavioural instructions.  To date, there is only a handful 
of published studies investigating adherence to stimulus control and/or sleep restriction, 
using a variety of adherence measures – from session attendance and therapist ratings, 
to sleep diary data.  Nevertheless, this small literature indicates that: (1) consistency of 
bed/rising times, though not necessarily sleep reduction, may be predictive of outcome 
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(Riedel & Lichstein, 2001); (2) questionnaire ratings of retrospective global adherence 
moderately relate to outcome (Vincent et al., 2008); and (3) pre-treatment sleepiness, 
dysthymia, lower self-efficacy and perceived barriers to treatment engagement, are all 
associated with reduced adherence and implementation of behavioural guidelines 
(Vincent & Hameed, 2003; Vincent et al., 2008; Perlis et al., 2004; Bouchard et al., 
2003).  Crucially, although questionnaire data indicate that behavioural aspects of CBT-
I strongly relate to outcome at one year follow-up, they remain among the least liked 
and used components of CBT-I (Harvey et al., 2002; Vincent & Lionberg, 2001).  
Qualitative data tracking patients’ implementation of behavioural instructions could 
shed light on factors relevant to therapy adherence, and potentially help refine the future 
delivery of CBT-I. 
 
Fourthly, as already stated, post-interventional functioning/HRQoL has been 
inadequately investigated.  Indeed, given the small and mixed literature on functional 
assessment and outcome, some authors have questioned whether improving sleep in 
those with insomnia will in fact modify self-reported daytime functioning (e.g. Means et 
al., 2000; Omvik et al., 2008; Horne, 2010).  Explanations for this apparent 
incongruence include concerns with measurement (Kyle et al., 2010), and theoretical 
interpretations surrounding physiological arousal (e.g. Horne, 2010; Bonnet & Arand, 
1997) and dysfunctional cognitive processes (e.g. Semler & Harvey, 2006; Espie et al., 
2006; Orff et al., 2007).  One potential way to shed light on sleep and functioning 
(treatment) relationships is to simply ask participants to describe, in their own words, 
the impact of insomnia treatment on domains of functioning.              
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Qualitative methodologies are increasingly being recognised for their ability to explore 
topics that are poorly dealt with using conventional quantitative tools.  Some recent 
examples in medicine and health care include: understanding adherence/non-adherence 
to medical regimes (PLoS Medicine editors, 2007; Tolmie et al., 2003); experience of 
illness (e.g. chronic pain; Osborn & Smith, 1998); the phenomenology of emotional 
(blunting) side-effects of anti-depressants (Price et al., 2009); development and 
refinement of QoL measurement (Hawker, 2009); factors that prompt/delay patients in 
seeking medical advice (e.g. breast cancer patients; Burgess et al., 2001); and how to 
improve patient recruitment into clinical randomised controlled trials (Donovan et al., 
2002). 
 
Although slow to filter into sleep medicine, perhaps given the infancy of the field, 
qualitative work has recently appeared in the sleep apnea literature.  For example, using 
case study methodology and phenomenographic analysis, Brostrom and colleagues 
(2008) tracked a single male patient (and partner) through OSA diagnosis and 
subsequent CPAP management, interviewing at four different time points - pre-CPAP, 
2, 3, and 6-months post-treatment.  Such data provided valuable insights into the impact 
of untreated OSA on sleep and daytime functioning; the treatment process and related 
issues of compliance and side-effects; and finally, quality of life and health-related 
improvements, post-intervention.  How CPAP initiation was ‘negotiated’ in the patient-
partner relationship was also an important emergent theme from their analysis.  The 
same group also used qualitative methods to good effect in a recently published study 
focusing on CPAP adherence (Brostrom et al., in press).  Semi-structured interviews 
(qualitative content analysis) with apnea patients provided important information on 
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inhibitory and facilitatory factors related to CPAP adherence, spanning biological, 
psychological and social domains.   
         
In light of the aforementioned potential benefits of qualitative inquiry, we adopted a 
mixed-method design to improve understanding of the implementation, experience, and 
impact of a condensed sleep restriction intervention.  Sleep restriction therapy (SRT) 
was chosen because of its strong relationship with outcome, relative ease of 
administration, and reliance on adherence to prescriptive guidelines.  The treatment 
‘journey’ was investigated using (1) audio-diaries, to capture in vivo proximal 
reflections, and (2) post-treatment face-to-face semi-structured interviews, to provide a 
global experiential account.  In addition to exploring the subjective experience of sleep 
restriction, our design permitted the evaluation of self-reported changes in daytime 
functioning, forming a secondary aim.  Although single-component sleep restriction 
(Friedman et al., 2000) and sleep compression (Lichstein et al., 2001b) interventions 
have proven successful in terms of modifying sleep parameters, comprehensive 
assessment of daytime functioning impairments is lacking.  Thus, in keeping with a 
‘stepped care’ model of CBT-I delivery (Espie, 2009), we also sought to evaluate 
whether our brief intervention could improve daytime as well as (predicted) sleep 
outcome variables.                               
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5.3. Methods 
5.3.1. Participants 
Individuals meeting research diagnostic criteria (RDC; Edinger et al., 2004; DSM-IV, 
1994) for primary insomnia (PI) were recruited into the study.  Participants, therefore, 
reported difficulties with initiation and/or maintenance of sleep, lasting for at least a 
one-month period.  Individuals were excluded if they had a co-morbid active psychiatric 
disorder, or medical disorder that was related to sleep disturbance (i.e. participants 
could have co-morbid medical ailments but they had to show temporal separation, and 
attributional independence, from the insomnia disorder).  Additionally, in keeping with 
diagnostic criteria of insomnia as a 24-hour disorder, participants had to report at least 
one daytime impairment attributed to disturbed sleep (RDC; Edinger et al., 2004).   
 
Participants were aged between 18 and 65, and recruited through two avenues: (1) those 
completing non-interventional University of Glasgow Sleep Centre (UGSC) projects; 
and (2) those responding to local and national adverts, seeking individuals with sleep 
disturbance to take part in UGSC research.  Finally, those taking prescription sleep 
medication were accepted into the study only if they maintained a stable regime i.e. 
weekly intake was less than or equal to three days per week, and they had not 
undergone a modification to treatment strategy in the four weeks prior to treatment 
initiation. 
 
The study was approved by Greater Glasgow & Clyde NHS local ethics committee. 
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5.3.2. Treatment protocol  
Treatment was conducted in groups of three or four, and delivered by the researcher.  
Following a seven-day baseline period, treatment took place over four weeks, 
comprising two group sessions and two individualised phone conversations (see figure 
5.1 for session time-line).  Sleep restriction therapy content (see table 5.1) was based on 
Morin & Espie (2003) and the Glasgow Sleep Centre protocol for CBT (Espie et al., 
2007; Espie et al., 2008).  Specifically, calculated sleep window was based on the 
average total sleep time for the baseline period, and was positioned according to the 
individual schedule of each patient (accounting, also, for circadian factors).  If the 
patient felt that their calculated window was unachievable, then there was some 
negotiation to try to facilitate adaptation and adherence.   
 
The sleep window was titrated in the following ways: if sleep efficiency for the week 
was ≥ 90%, then the sleep window was increased by 15 minutes; if sleep efficiency was 
< 85 %, then the sleep window was decreased by 15 minutes; and if values fell between 
85 and 89% there was no change to the schedule.  Downward adjustments were not 
made until the end of the second week.  The minimum possible sleep window duration 
was set at 5 hours.   
 
Prior to attending session 1, participants were sent a seven-day sleep diary to complete 
each morning.  They also completed baseline questionnaires (see below) covering 
aspects of sleep and daytime functioning.  SRT was delivered using PowerPoint© 
presentation slides (Appendix F), and calculations were completed using handbooks and 
sleep-efficiency grids.   
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Baseline: 7-day diary
(~ 45-60 minutes)
week 1
(~ 30-45 minutes)
week 2
(~ 5-10 minutes)
week 3
(~ 5-10 minutes)
week 4
Session 1, Sleep Centre: Treatment rationale & instructions
                              (keep audio-diaries)
Session 2, Sleep Centre: Review & planning
Session 3: weekly phone call to monitor progress/titrate
                                      Session 4: weekly phone call to monitor progress/titrate
Final meet, Sleep Centre: semi-structured interview & debriefing           
    3 month follow-up: complete questionnaire pack
Figure 5.1 - Session time-line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 - SRT session content. 
Session Content
Session 1
Participants attended the UGSC in the evening and received treatment rationale.  
Treatment covered the following areas: sleep need & variability, sleep homeostasis & 
timing, calculation of total sleep time, setting ‘threshold’ & ‘rising’ times, sleep 
efficiency, motivation to change, and frequently asked questions in relation to 
treatment implementation. 
Session 2
Participants again attended the UGSC. The purpose of this session was to review
progress, calculate average sleep efficiency, and then set schedule for the forthcoming
week.
Session 3 & 4 Brief weekly phone calls to monitor/review weekly progress, and assist with sleep
window modifications.
Session 5
Final meet at the UGSC to review progress, provide final instructions on how to
continue to use SRT and titrate sleep window as required. Participants also took part
in a semi-structured interview with the first author.
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5.3.3. Screening instruments 
All subjects underwent an initial screen using the Glasgow Sleep Centre brief screen 
protocol (see Appendix E).  This records basic information on severity and frequency of 
insomnia symptoms, co-morbid medical/psychiatric/sleep difficulties, and medication 
use.  Those satisfying the brief screen then received a thorough phone interview using 
the Glasgow Sleep Centre screening interview schedule, based on a template set out by 
Morin & Espie (2003; see Appendix A), to exclude those with affective/psychiatric 
disorder, those with sleep-disruptive medical co-morbidities, and to assess sleep 
pattern/symptoms to rule out occult sleep disorder pathology.   
 
5.3.4. Outcome questionnaire measures 
The following measures were completed at baseline, post-treatment (four weeks), and 
three-month follow-up.  As well as constituting an outcome variable, sleep diaries were 
completed each day throughout the treatment phase to guide implementation and 
titration.  See table 5.2 (p177) for a tabulated guide to the timing of measures and 
assessment points over the course of the intervention 
 
5.3.4.1. Sleep 
Sleep Diary.  The sleep diary used was based on a template set out by Espie (1991) and 
Morin & Espie (2003), assessing the previous night’s sleep parameters and sleep quality 
(see Appendix G).  The main variables of sleep-onset latency (SOL), number of 
awakenings (NAW), wake time after sleep-onset (WASO), total sleep time (TST), sleep 
efficiency (SE), and subjective sleep quality (SQ) were extracted.   
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Insomnia Severity Index (ISI; Morin, 1993).  The ISI is a seven-item scale assessing 
the severity of insomnia night-time symptoms and interference with daytime 
functioning, in the previous two weeks.  Scores range between 0-28, and four clinical 
cut-offs have been identified: 0-7 (no insomnia problem); 8-14 (sub-clinical insomnia); 
15-21 (clinical insomnia, moderate severity); and 22-28 (clinical insomnia, severe).  The 
ISI has satisfactory internal consistency (Cronbach’s alpha = .76-.78; Bastien et al., 
2001) and is a recommended measure for use in outcome research with insomnia 
populations (Buysse et al., 2006).    
 
Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 1989).  The PSQI is a 19-item 
questionnaire that assesses sleep quality over the preceding month.  The questionnaire 
yields a global score of ‘sleep quality’, in addition to seven individual component 
scores: subjective sleep quality; sleep latency; sleep duration; sleep efficiency; sleep 
disturbances; use of sleeping medication; and daytime dysfunction.  The global score 
ranges from 0 to 21, with higher scores being indicative of poorer sleep quality.  The 
PSQI has high internal consistency (Cronbach’s alpha = .85), and a score of greater than 
five achieves maximum sensitivity and specificity for insomnia (Backhaus et al., 2002).       
 
Glasgow Sleep Effort Scale (GSES; Broomfield & Espie, 2005).  The GSES is a 7-
item scale (range 0-14) assessing the application of voluntary effort towards sleeping.  
Preliminary data indicates that it has satisfactory internal consistency (Cronbach’s alpha 
= .77) and reliably discriminates between normal sleepers and primary insomnia 
patients (Broomfield & Espie, 2005).   
 
 
 175 
5.3.4.2. Daytime functioning 
Occupational Impact of Sleep Questionnaire (OISQ; David & Morgan, 2006).  The 
OISQ is a 24-item scale (range 0-96) assessing the impact of sleep quality on various 
aspects of work-related tasks and productivity (see Appendix H).  The tool appears to 
discriminate between those with insomnia and good sleepers (Morgan & David, 2006), 
has high internal consistency (Cronbach’s alpha = .95), and has also been shown to 
correlate, positively, with global PSQI scores (Verster et al., 2008).         
 
Glasgow Sleep Impact Index (GSII; Kyle et al., unpublished).  The GSII was 
developed (see chapter four) to quantify insomnia-related impairments relevant to each 
individual patient.  Participants write down in their own words the three most important 
aspects of their life impacted by poor sleep.  These are subsequently ranked (1-3), rated 
on a 100mm visual analogue scale, and then assigned a sum of ‘money’ based on the 
patient’s desire to eradicate the problem (i.e. prioritise).  A ‘closed’ version is 
administered at post-treatment and follow-up, where original generated items are 
inserted by the researcher/clinician to ensure stability in the scoring of identified ranks. 
  
Short-Form Health Survey 36 (SF-36; Ware & Sherbourne, 1992).  The SF-36 is a 
generic health status tool, assessing functioning across eight core domains: physical 
functioning (PF), role-physical limitations (RP), mental health (MH), role-emotional 
limitations (RE), vitality and energy (VT), social functioning (SF), bodily pain (BP), 
and general health (GH) perception.  Each dimension has a satisfactory to high level of 
internal consistency (Cronbach’s alpha = ≥.76; Jenkinson, Coulter & Wright, 1993).  
The SF-36 is recommended as an outcome measure in insomnia research (Buysse et al., 
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2006), and appears sensitive to change post-behavioural and pharmacological 
intervention (e.g. Espie et al., 2006; Dixon et al., 2006; Walsh et al., 2007).  
 
Daytime Functioning and Sleep Attribution Scale (DFSAS; Kyle, et al., 
unpublished).  The DFSAS was developed (see chapter four) to assess impairments in a 
range of symptoms commonly associated with insomnia disorder (part 1).  Part 2 of the 
scale asks participants to rate each item again, though this time in relation to how much 
poor sleep was responsible for the impairment reported in part 1 (poor sleep 
attribution).  Preliminary data indicates good discriminant validity and high internal 
consistency (Cronbach’s alpha = .81 for part 1, and .89 for part 2).  
 
5.4.3.3. Treatment-related process measures 
Side-effects checklist and interference scale (unpublished).  This scale asks patients to 
check, from a list, those symptoms experienced as a consequence of sleep restriction 
therapy (see Appendix I).  Owing to the lack of an existing tool specific for CBT-I 
‘adverse events’, we generated items spanning a mix of somatic, cognitive and 
emotional domains that may be perturbed by sleep deprivation and alterations to sleep 
timing.  Checked symptoms are rated in terms of their interference with daytime 
functioning (0-4), following a similar format to existing published side-effects 
questionnaires used in pharmacological assessment (e.g. antidepressants; Uher et al., 
2009).    Additional space at the end of the scale also allows patients to qualitatively 
report domains of impairment not listed.  The scale was completed during session 2, one 
week after the commencement of treatment. 
 
 177 
Sleep Restriction Adherence Scale (SRAS; unpublished).  The SRAS was created for 
the present study (see Appendix J), owing to the lack of available instruments to assess 
adherence to behavioural components of CBT-I.  The scale is roughly based on the 
Medical Outcomes Study general adherence scale (MOS-A; Kravitz et al., 1993).  
Although previous work has modified this scale for use with insomnia patents (e.g. 
Vincent et al., 2008), we made further modifications to make it more relevant to sleep 
restriction therapy, and to probe adherence at a ‘local’ level.  The 5-item SRAS assesses 
self-report global adherence, and adherence to set ‘threshold’ and ‘rising’ times on both 
weekends and weekdays (1-6 Likert item response format).  The SRAS was completed 
at 3-months follow-up.  Total adherence score can be calculated for items 2-5 (range: 4-
24).          
 
Table 5.2 - Time-line of assessment and data collection points. 
Baseline Week 1 Week 2 Week 3 Week 4 Post-treatment
Follow-up                  
(3 months)
Sleep Diary Sleep Diary Sleep Diary Sleep Diary Sleep Diary - Sleep Diary
ISI - - - - ISI ISI
PSQI Audio-Diary - - - PSQI PSQI
GSES - - - - GSES GSES
DFSAS
Side-effects 
Checklist - - - DFSAS DFSAS
SF-36 - - - - SF-36 SF-36
GSII - - - - GSII GSII
OISQ - - - - OISQ OISQ
- - - - -
Semi-structured    
Interview SRAS
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5.3.5. Qualitative methodologies 
5.3.5.1. Audio-diaries 
Handheld dictaphones (Olympus© WS-200s) were utilised to track subjective 
experiences during the first week of treatment.  Participants were asked to make two 
entries per day, according to open-ended semi-structured guidelines (see Appendix K).  
In brief, on awakening (within ~ 30 minutes), participants described their experience of 
implementing treatment instructions for the preceding sleep period.  Similarly, in the 
evening, approximately 2 hours before going to bed, participants reflected on the course 
of the day and how their previous night’s sleep (with reference to their new schedule) 
affected their ability to function, for better or worse.  Evening entries were completed 
sufficiently prior to the sleep-onset period to avoid creating excessive sleep 
preoccupation, or pre-sleep anxiety, proximal to sleep-initiation.  Guidelines were 
purposely kept open to facilitate recording of relevant and interesting topics.     
 
The study rationale was presented to participants as an investigation into the experience 
of sleep restriction.  There was no priming in terms of what information we were 
particularly interested in; rather, it was emphasised that we wanted to know as much as 
possible about the experience of SRT implementation, from the individual perspective.     
 
5.3.5.2. Semi-structured interviews  
Four weeks after treatment initiation (session 5), participants were interviewed by the 
researcher on their overall experience of treatment.  The interview format and schedule 
was based on published guidelines (Smith & Osborn, 2003) and consisted of open-
ended fixed questions, with supplementary prompts (Appendix L) - again permitting 
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exploration of additional interesting and relevant topics.  Core questions covered the 
following areas:  
- understanding and expectations 
- implementation of sleep schedule 
- impact on sleep and daytime functioning 
 
5.3.6. Data preparation and statistical analysis 
5.3.6.1. Outcome variables 
Dependent variables were screened for extreme outliers and assessed for normality 
using histograms and boxplots.  Extreme outliers were replaced with the respective 
group mean (this was done for only two data points for two variables), and logarithmic 
transformations performed to correct skewed distributions.  The trial aspect of the study 
was viewed as an intention-to-treat analysis; hence, the last observation carried forward 
(LOCF) method was used to impute missing data values.  Imputation was almost 
exclusively confined to the three patients who were lost between post-treatment and 
follow-up assessment points.   
 
Changes in sleep diary variables (SOL, NAW, WASO, TST, SE, SQ), sleep-related 
questionnaires (ISI, PSQI, GSES), and daytime functioning measures (GSII, DFSAS, 
SF-36, OISQ), across the three time points, were assessed using repeated measures 
ANOVA.  Multivariate statistics (Wilks’ Lambda) are reported because they provide the 
most conservative way of interpreting factor effects when sphericity assumptions are 
violated (Pallant, 2007).  Significant main effects were followed up using paired t-tests.  
Finally, correlational analyses were conducted to investigate relationships between 
changes in sleep and daytime functioning.  Partial eta squared (η2) and Cohen’s d 
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(Cohen, 1988) are reported to provide an indication of effect size (ES) magnitude for 
repeated measures ANOVA, and baseline to follow-up changes, respectively.     
  
5.3.6.2. Audio-diaries & semi-structured interviews 
Audio-diaries and interviews were transcribed verbatim, including pauses, laughter and 
false starts.  Audio-diaries and interviews were analysed separately, and according to 
the framework of thematic analysis (Braun & Clarke, 2006).  Thematic analysis is a 
flexible method for locating patterns (themes) within qualitative data sets, and is 
applied, to varying degrees, within major established analytic approaches (such as 
grounded theory and IPA).  Recent structured guidelines (Braun & Clarke, 2006) 
establish thematic analysis as a flexible method in its own right, unconstrained by 
theoretical and epistemological underpinnings.  Applications of this method in the 
medical and psychological-based literature include investigations of self-monitoring of 
blood glucose levels in type 2 diabetes (Peel et al., 2007) and the psychosocial 
consequences of developmental prosopagnosia (Yardley et al., 2008). 
 
Analysis was a recursive process involving several stages (Braun & Clarke, 2006).  
First, transcripts were read through several times to gain a sense of the whole 
phenomenon under investigation.  On subsequent readings of individual transcripts, 
significant words and/or phrases were highlighted, and bullet points entered in the 
margins, creating preliminary coding schemes.  After several further reviews of the 
transcripts, initial notes and codes were collated into themes.  Themes were compared 
across individuals, looking for common recurrent themes as well as inconsistencies and 
contradicting cases.  Themes were refined throughout the analytic process via 
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discussions with another insomnia researcher (also a clinician) and from feedback 
during data presentation at lab seminars.   
 
Given that the focus was on generating descriptions of the Sleep Restriction Therapy 
experience, emphasis was initially placed on identifying themes at the semantic or 
explicit level (Braun & Clarke, 2006).  These were then subsequently related to, and 
interpreted in light of, contemporary literature on the behavioural management of 
insomnia, as well as additional questionnaire findings from the present study.    
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5.4. Results 
5.4.1. Participant demographics 
The intention was to run 6 treatment groups of 3-4 participants each, allocating one half 
to the qualitative component.  Twenty three insomnia patients were initially enrolled 
into the study, but five failed to complete the treatment phase (see table 5.3 for 
participant demographics).  Reasons for cessation included: falling pregnant (n=1); 
side-effects were too impairing (n=2); and, for the remaining two, reasons could not be 
ascertained.   
 
Participant demographics for those completing all treatment sessions (n=18) are also 
presented in table 5.3.  The mean age of the sample was 41.9 (13.2), with a range of 18-
64 years.  Five (28%) participants were male (13 female), and the average insomnia 
duration was 17 (14.4) years.  Three participants had problems initiating sleep only, 
three had difficulties with maintaining sleep only, and the remaining 12 suffered from 
both initiation and maintenance difficulties.  Finally, 2 participants (11%) were on 
prescribed sleep-promoting hypnotics at treatment intake.  Additionally, three 
participants were lost to follow-up (3 months). 
 
Table 5.3 – Participant demographics. 
Demographics PI patients enrolled PI patients completing treatment 
(n =23) (n =18)
Age (yrs) 40.2 (13.0) 41.9 (13.2)
Gender 5 male / 18 Female 5 male / 13 female
Insomnia Duration (yrs) 14.9 (13.8) 17.0 (14.4)
Insomnia Sub-type:
Inititiating 3 3
Maintaining 5 3
Mixed 15 12
Medication 5/23 (22%) 2/18 (11%)
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5.4.2. Sleep outcomes 
Table 5.4 provides an indication of main effects of time, post-hoc comparisons between 
assessment points, and related statistical significance. 
 
Sleep Onset Latency (SOL) 
There was a significant change over time in mean subjective SOL.  As is evident from 
table 5.4, mean SOL for the group decreased significantly by 21 minutes, from 41 
minutes pre-treatment to 20 minutes at the post-treatment assessment.  This 
improvement was sustained, and remained significant, at 3-month follow-up (ES=0.80).   
 
Total Sleep Time (TST) 
Subjective TST remained similar from baseline (320 minutes) to post-treatment (323 
minutes).  At 3 months, mean TST significantly improved, relative to baseline figures, 
by 47 minutes (ES=0.67).    
 
Number of awakenings (NAW) 
Number of nightly awakenings significantly decreased from baseline (2.97) to post-
treatment (1.42).  This effect was maintained at 3-months (M=1.69; ES=0.69). 
 
Wake time after Sleep-Onset (WASO) 
A significant effect of time was again found with mean WASO values.  Mean WASO of 
72 minutes at baseline significantly reduced by 43 minutes to 29 minutes at post-
treatment.  These improvements were sustained and remained significant at 3 month 
follow-up (ES=1.06).      
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Table 5.4 - Treatment effects and post-hoc comparisons for sleep diary and questionnaire variables. 
M (SD) M (SD) M (SD) df F p Partial η2
Diary
SOL (mins.) 41.12 30.63 19.70** 13.84 21.27** 17.30 (2, 16) 7.18 .006 0.473
TST (mins.) 319.79 75.31 323.07 48.80 367.08**a 65.56 (2, 16) 6.12 .011 0.433
NAW 2.97 2.20 1.42*** 1.18 1.69*** 1.44 (2, 16) 13.28 <.001 0.624
WASO (mins.) 71.97 55.64 29.03** 35.91 26.30*** 25.22 (2, 15) 10.94 .001 0.593
SE (%) 64.20 14.44 85.25*** 10.52 80.88*** 13.85 (2, 16) 19.15 <.001 0.705
Sleep Quality (0-4) 1.42 0.63 2.13*** 0.65 2.23** 0.87 (2, 16) 11.69 .001 0.594
Questionnaire
ISI 17.19 3.76 9.67*** 5.15 10.07*** 6.08 (2, 16) 16.00 <.001 0.667
PSQI 12.63 2.96 7.97*** 2.02 7.82*** 3.36 (2, 15) 21.25 <.001 0.739
GSES 9.28 3.27 5.31*** 2.52 5.61*** 3.48 (2, 16) 13.96 <.001 0.636
                                        Asterisks indicate post-hoc significant changes from Baseline: *p <.05, **p <.01, ***p <.001
                                        a . contrast with post-treatment mean sig. at p <.05
(3 months)
Baseline Post-treatment Follow-up
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Sleep efficiency (SE) 
Mean SE significantly increased by an average of 21% from 65% at baseline to 86 % 
post-treatment.  Three month average SE (81%) values remained highly significant 
relative to pre-treatment assessment, with a net improvement of 17% (ES=1.18). 
   
Sleep Quality (SQ) 
Small but significant improvements were recorded for subjective sleep quality, from 
baseline to post-treatment.  These benefits were statistically maintained at 3-month 
follow-up (ES=1.07).   
 
Insomnia Severity Index (ISI) 
Baseline mean ISI values (17.2) indicated the presence of clinical insomnia of moderate 
severity, according to scale cut-offs.  Post-treatment reductions in ISI scores were 
significant (mean of 9.7 – ‘sub-clinical insomnia’), and were maintained at 3 month 
follow-up (ES=1.41).  In terms of clinical significance, 6/18 (33%) participants scored 
in the ‘no insomnia’ range (‘remitters’) at post-treatment.  The number of ‘remitters’ at 
follow-up increased to 8/18 (44%).  Treatment ‘response’ rates were calculated based 
on recently published minimally important difference data for the ISI (Yang et al., 
2009).  The number of individuals evidencing a change of at least six ISI scale points at 
post-treatment was 66.6% (12/18).  This rate of treatment response remained the same 
at follow-up (66.6%). 
 
Pittsburgh Sleep Quality Index (PSQI) 
Similar to the ISI, mean PSQI scores significantly decreased from baseline (13) to post-
treatment (8).  This improvement was also sustained at the three month assessment 
point (ES=1.52). 
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Glasgow Sleep Effort Scale (GSES) 
Mean GSES score changes between baseline (9) and post-treatment (5) were highly 
significant.  Again this pattern remained robust at three-month follow-up (ES=1.09). 
 
5.4.3. Daytime functioning outcomes 
Table 5.5 provides an indication of main effects of time, post-hoc comparisons between 
assessment points, and related statistical significance. 
  
Daytime Functioning and Sleep Attribution Scale (DFSAS) 
Mean scores on part one of the DFSAS significantly reduced from baseline (18) to post-
treatment (12) – see table 5.5.  Comparisons between post-treatment and 3-month 
follow-up indicated further reductions in associated daytime impairment, which again 
reached statistical significance, above and beyond post-treatment effects.  Effect size 
magnitude for baseline to follow-up change was large (ES=1.42).  Concerning part 2, 
the attributional component, repeated measures ANOVA indicated a main effect of 
time.  Mean values significantly improved post-treatment, which were found to be most 
robust at follow-up (ES=0.99).       
 
Glasgow Sleep Impact Index (GSII) 
Both GSII ranks 1 and 2 indicated main effects of time.  Post-hoc testing for rank 1 
revealed significant effects at post-treatment and follow-up, with effects being most 
pronounced at final assessment (ES=1.21).  Rank 2 similarly demonstrated 
improvements across the three assessments, though effects achieved significance only at 
the 3-month follow-up (ES=1.04).  There was no within-subjects effect for rank 3, with 
mean values remaining quite stable over the assessment points. 
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Table 5.5 - Treatment effects and post-hoc comparisons for daytime functioning and HRQoL variables. 
M (SD) M (SD) M (SD) df F p Partial η2
     DFSAS      Part 1 17.86 5.31 12.06** 5.84 9.94**a 5.86 (2, 16) 8.63 .003 0.519
            Part 2 24.75 10.21 18.94* 12.05 14.39** 10.65 (2, 16) 6.78 .007 0.459
GSII         Rank 1 31.41 17.33 53.29* 24.61 57.29** 24.87 (2, 15) 5.55 .016 0.425
Rank 2 36.00 18.00 51.00 26.05 57.06** 22.27 (2, 16) 5.85 .012 0.423
Rank 3 47.39 19.55 52.00 23.10 55.50 24.98 (2, 16) 1.23 .320 0.133
OISQ 42.75 18.43 26.78* 13.23 26.66** 24.78 (2, 14) 6.72 .009 0.490
SF-36
PF 91.11 10.08 91.39 9.52 91.27 8.73 (2, 16) 0.02 .980 0.002
SF 69.47 25.77 74.31 24.43 77.11 24.30 (2, 16) 1.35 .287 0.145
RP 76.75 21.84 86.36 12.65 83.93 15.45 (2, 16) 2.41 .122 0.232
RE 73.15 21.30 77.77 16.67 82.63* 18.32 (2, 16) 5.04 .020 0.387
MH 62.78 14.97 68.33 13.50 73.33* 16.36 (2, 16) 3.62 .051 0.311
VT 39.72 12.85 46.48* 16.82 52.98** 18.77 (2, 16) 7.65 .005 0.488
BP 75.83 23.83 78.89 26.86 78.53 27.60 (2, 16) 0.88 .916 0.011
GH 63.82 16.73 66.47 18.77 69.41 14.88 (2, 15) 1.59 .236 0.175
                             Asterisks indicate post-hoc significant changes from Baseline: *p <.05, **p <.01, ***p <.001
                             a . contrast with post-treatment mean sig. at p <.05
Baseline Post-treatment Follow-up
(3 months)
 
 
PF = physical functioning; SF= social functioning; RP = role-physical limitations; RE = role-emotional limitations; MH = mental health; VT = vitality/energy; BP = 
bodily pain; GH = general health perception. 
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Occupational Impact of Sleep Questionnaire (OISQ)  
The OISQ was completed by 16 (89%) working participants in the study.  Mean OISQ 
values significantly improved at post-treatment by, on average, 16 points.  This effect 
remained robust and significant at three month follow-up (ES=0.74).  
 
Short-Form Health-Survey 36 (SF-36) 
Three dimensions of the SF-36, ‘vitality/energy’ (VT), ‘role-emotional limitations’ (RE) 
and ‘mental health’ (MH), evidenced main effects of time, with moderate effect sizes.  
Both RE (ES=0.48) and MH (ES=0.67) dimensions achieved statistical significance at 3 
months (relative to baseline values).  For the Vitality dimension, both post-treatment 
and 3 month values (ES=0.82) indicated significant improvements relative to baseline 
levels.  There was no effect of time or trends for the other five dimensions. 
 
5.4.4. Relationship between sleep and daytime functioning changes 
To determine whether changes in daytime functioning were associated with 
improvements in sleep symptoms, correlation analyses were carried out on those 
variables demonstrating significant improvements over the course of the intervention 
period and follow-up.  Change scores (baseline to follow-up) were calculated for each 
variable of interest, and standardised so that positive values indicated relative 
improvement on all variables.  Correlation coefficients and an indication of significance 
level are presented in table 5.6. 
 
Improvements in insomnia severity, as measured by the ISI, were positively and 
significantly associated with improvements in daytime functioning (see table 5.6), 
across several measures, including DFSAS (part 1), GSII rank 2 (see scatterplot, figure 
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5.2) and the vitality/energy dimension from the SF-36; all ≥ .67 in strength.  Likewise, 
PSQI improvements were similarly associated with improvements in aspects of 
functioning; specifically scores on the GSII rank 2, DFSAS and Vitality (all >.74).  
Sleep diary variables of WASO, number of awakenings, and SOL tended to be weakly 
(and non-significantly) associated with daytime functioning improvements.  TST, SE 
and Sleep Quality, however, tended to be strongly and significantly related to 
improvements in functional outcomes across the DFSAS, GSII ranks 1 and 2, the OISQ, 
and the vitality dimension from the SF-36.     
    
 
 
 
Table 5.6 - Relationship between changes in daytime functioning variables and sleep variables (baseline 
to follow-up).
ISI PSQI SOL No. Awak. WASO TST SE SQ
DFSAS (1) .831** .855** .011 -.026 .085 .595** .578* .494*
GSII rank 1 .475 .350 .361 .598* -.218 .384 .392 .650*
GSII rank 2 .674** .633** .282 .232 .031 .576* .655** .643**
OISQ .455 .418 .021 .066 .326 .604* .357 .196
RE .109 .019 .465 .168 -.316 .291 .202 .087
MH .354 .586 .069 .054 .073 .288 .381 .422
VT .715** .748** -.037 .150 .147 .643** .589** .669**
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
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Figure 5.2 - Relationship between GSII rank 2 change scores and ISI change scores.         
 
 
 
5.4.5. Treatment side-effects  
As presented in table 5.7 and figure 5.3, ≥ 50% of participants reported sleep restriction-
related side-effects, in eight out of the twelve listed domains.  The three most 
commonly reported symptoms were ‘fatigue/exhaustion’ (100%), ‘extreme sleepiness’ 
(94%), and ‘reduced energy/motivation’ (89%).  Subsequent ratings of the extent of 
‘side-effect’ interference revealed that ‘fatigue/exhaustion’, ‘extreme sleepiness’, 
‘feeling irritable’ and ‘changes in hunger/appetite’, interfered ‘somewhat’ to ‘much’ 
(mean ratings 2-3) with everyday functioning (table 5.7).    
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Table 5.7 - Side-effect frequency and interference for entire sample. 
Symptom 
% of sample reporting 
symptom 
Daytime functioning 
interference rating (0-4)
Low Mood 61 1.55
Fatigue/exhaustion 100 2.56
Extreme sleepiness 94 2.58
Feeling agitated 50 1.78
Bodily pain 33 1.17
Headache/migraine 72 1.31
Euphoria/intense increase in mood 39 1.29
Reduced motivation/energy 89 1.88
Changes in hunger/appetite 72 2.00
Blurred vision 22 1.00
Dizziness 28 1.40
Feeling irritable 61 2.09
 
Figure 5.3 - Graphical representation of % of sample reporting each listed side-effect. 
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Six (33%) participants added, qualitatively, additional domains of impairment.  These 
spanned the categories of: pain/discomfort, temperature regulation, word-finding 
difficulties, social interaction impairment, illness, ‘hangover’-like effects, problems 
with concentration, and fatigue at unusual times. 
 
Figure 5.4 - Scatterplot of relationship between PSQI change scores and number of experienced side-
effects. 
 
Exploratory correlation analyses were carried out between number of experienced side-
effects, relative daytime interference ratings for side-effects [i.e. (interference score for 
checked symptoms/total possible score for checked symptoms)*100], and sleep 
improvements (baseline to post-treatment).  Interestingly, it was found that a higher 
frequency of side-effects was associated with a greater magnitude of change on the 
PSQI (r =.51, n=17 p<.05; see figure 5.4) and, to a lesser (non-significant) degree, sleep 
efficiency (r =.44, n=18, p=.065) and ISI (r =.33, n=18, p=.185) values.  Other 
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measures of sleep continuity were weakly and non-significantly related to side-effect 
frequency.  Greater relative daytime interference ratings were significantly related to 
both improvements in PSQI scores (r =.54, n=17, p<.05) and reductions in sleep effort, 
as measured by the GSES (r =.48, n=18, p<.05).  
 
5.4.6. Self-report adherence 
Fifteen (83.3%) participants completed the adherence questionnaire at 3-months follow-
up.  The sample mean for ‘global adherence’ to sleep restriction instructions, post-
treatment phase, was 3.87 (1.41), reflecting adherence ‘a good bit of the time’ (range 1-
6); see figure 5.5 for distribution of scores.  Subsequent ratings of specific ‘threshold’ 
and ‘rising time’ adherence, across both weekdays and weekends, also indicated similar 
levels of adherence behaviour (see table 5.8); with mean ratings falling between the two 
categories of ‘some of the time’ and ‘a good bit of the time’.  
 
Figure 5.5 - Histogram showing distribution of global adherence ratings.  
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Correlations between ‘total score’ adherence ratings and sleep diary/questionnaire 
parameters (in terms of change scores) were found to be small and non-significant. 
 
Table 5.8 - Group mean scores for adherence to SRT guidelines on weekdays and weekends. 
Rising Time Threshold Time
Weekdays 4.00 (1.71) 4.29 (1.44)
Weekends 3.43 (1.87) 3.86 (1.83)
 
 
5.4.7. Qualitative results 
At the outset of the study, the intention was to recruit approximately 50% (~12) of the 
total sample into the qualitative component of the trial.  Participants were initially 
selected based on random allotment, within each treatment group, but because of time 
constraints and recruitment difficulties all participants within the final few treatment 
groups were selected to take part.  Hence, 14 (78%) participants (4 male; 10 female) 
completed both audio-diaries and interviews, which was slightly more than predicted 
from the outset, though within standard limits for qualitative research.   
 
5.4.7.1. Audio-diaries 
In week one of SRT, participants, in total, recorded 179 diary entries.  Transcription 
produced ~ 29,100 words of data.  Thorough analysis of both morning and evening 
entries revealed three major themes, each with respective sub-themes/categories (see 
table 5.9).  Direct quotes are presented to support generated themes and pseudonyms are 
used to protect patient identities.  
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Table 5.9 - Major themes from thematic analysis of audio-diary entries. 
Theme Sub-themes
Daytime side-effects: 'it's made it worse'  On awakening
 Throughout the course of the day
Adjustment to new sleep schedule  Challenges to adherence
 Coping strategies to help facilitate adherence 
Evolving changes to the sleep experience  'Unusual' feelings of sleep pressure
 Changes to sleep quality: could this be working?
 
Daytime side-effects: ‘it’s made it worse’ 
Participants described, on the whole, feeling and functioning worse during week one of 
therapy, relative to pre-treatment.  A reduction in sleep opportunity typically translated 
into less total sleep time, which had implications for the remainder of the day.  
Although impairment perhaps indicated that the therapy instructions were being 
followed and possibly beginning to work - in the sense that sleep pressure was being 
applied - this was clearly not without consequences.  Indeed, these consequences were 
conveyed on awakening, proximal to the sleep-period, with common references to 
‘zombie’ or ‘hangover’-like states: 
 
“…I feel like I’m drunk at the moment, my head’s quite swimming, and em not thinking 
very straight at all, I find it quite hard to write in this bit of paper too.”  [Bill, 68-70] 
 
“ I feel really groggy, in fact…I can hardly concentrate just now…got quite a sore 
head, em, pain in the back of my head just now, from [being] really tired…” [Jim, 41-
42] 
 
 196 
“ In terms of sort of quality of sleep, em I actually feel this morning as if I’ve got a 
hangover, and I didn’t drink anything last night, em I’ve got a headache and actually I 
feel quite sick.”  [Jennifer, 23-25] 
 
Sleep restriction therapy negatively impacted on numerous daytime functioning 
domains.  On an elementary level, participants reported feeling exhausted and fatigued, 
experiencing difficulties with concentration and memory, as well as depressed mood.  
These symptoms, combined, had the net effect of impairing aspects of job performance 
and ability/effort to interact socially.  Furthermore, 5/14 patients (36%) made reference 
to impaired driving abilities at least once during the course of the week. 
 
“Hi, it’s Sunday night, about ten o clock and I’m absolutely exhausted, I’ve had a really 
bad day and never left the house the whole day, just felt so bad, em, I don’t  know if I 
can stay up till one o’ clock…I just feel totally, at the moment, terrible” [Gillian, 58-60] 
 
“I had about four hours, four hours thirty minutes last night, and I felt the thing that 
affected me today was my memory, my job entails a lot of analysis of patient speech on 
the spot, which I was able to do, but often I have to back up what I see and explain it to 
the families, and I couldn’t remember the specific example of what the patient was 
saying to back up my hypothesis of their diagnosis.”  [Hannah, 220-224]  
 
“Woke up bright and breezy, half six, Tuesday morning, raring to go, got into the 
car…and within twenty minutes I was absolutely  exhausted, so bad that I swear I was 
nearly falling asleep all the way to work…it was torture, I was cross-eyed, em, eyes 
drooping, driving…” [Sarah, 122-126] 
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“The restrictive programme has affected my ability to function, it’s made it worse for 
me working, its been very hard at work to focus and be as sharp as you should be” [Bill, 
187-188] 
 
Adjustment to new sleep schedule 
This theme captured the practical experience of implementing set threshold and rising 
times.  Participants reported a number of issues that made adhering (rigorously) to the 
programme incredibly challenging, and which frequently led to non-adherence.  Such 
factors included: spending extended amounts of time on own, particularly at weekends; 
running out of activities to do during extra hours (boredom); inability to stave off 
sleepiness until set bed time; fear of disrupting partner by entering the bedroom after 
they had initiated sleep; staying out late, drinking and socialising; feeling pressure to 
‘perform’ when going to bed so late, and having a short period of time to obtain 
adequate sleep; and, finally, no indication of re-bound sleep over several nights of 
adherence, in parallel with accumulating daytime difficulties.         
       
“When I went to bed last night I was conscious of thinking ‘oh god, you’ve got to be up 
in five hours’ and that felt like a bit of pressure and I think it took me just a little bit 
longer to sleep because of that.’ [Sarah, 51-53] 
     
“I’m sitting at my computer and I’m listening to some nice quiet, soothing music.  To 
try and keep me awake, AC/DC is going on, hopefully that will do the trick, keep me 
going for another hour or so, sit and ponder life, quite lonely because you don’t have 
anyone with you, even the dog’s went to his bed.” [Bill, 256-259] 
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“ I’m not driving tomorrow, em, but frankly in order to function at work tomorrow, em, 
I’m seriously considering going to my bed probably about twelve tonight, that’s about 
as late as I can cope [with], because I can’t do another, em, morning I suppose like 
today – that was really grim, it was absolutely dire…” [Sarah, 132-135] 
 
“…this regime would be quite easy to do if you didn’t have any social life, em, as soon 
as you’re going out late, or drinking, or whatever, it does sort of seem to go to pot a 
bit…I’ll certainly restart it again tonight…I think that’s the difficulty come the weekend, 
it all goes a bit haywire, so whether that’s undoing any good that it’s done through the 
week, em, I possibly would think so…” [Jennifer, 196-198]  
 
“Em, just talking about the experience of implementing my new bedtime routine, I feel 
it’s just been really negative so far, and although I can understand that it probably will 
work eventually, at the moment I just feel really bad…I’ve had about an hour and a half 
to two hours sleep last night, and just feel really bad today, and already just worrying 
about how on earth I’m gonna stay up till one o clock this morning…” [Gillian, 65-71] 
 
A sub-theme captured strategies that patients put in place to facilitate adjustment and 
promote adherence to sleep restriction instructions.  These again were numerous and 
varied, but included the following: sleeping in a separate room from partner; partner 
staying up late to accompany and motivate the participant to adhere; scheduling 
activities or making modifications to activity levels to promote alertness, and to fend off 
sleep prior to set threshold time; reducing alcohol intake and late nights out; and 
seeking out others experiences of sleep restriction via the internet for additional 
reassurance/motivation.          
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“I made a point of staying with a friend to keep me awake for a while tonight...they’re 
off work…it’s made me stay awake and not be tempted to go to bed earlier than I should 
do.” [Jim, 55-57] 
 
“ It’s only when you stop you realise you’re tired, so if you’re having a dance or 
whatever then you feel fine, sitting talking to someone I suppose it’s fine, it’s only when 
you stop talking and you just sit there quietly, eh that’s when it, that’s when you really 
feel tired, as long as I’m doing something, I’m okay, but just sitting would be a ‘no-no’ 
right now (laughs)” [Bill, 224-230] 
 
“ I’ve watched more television in the last five days than I’ve watched in years at this 
time of night, however, I think that’s what keeps me awake” [Maria, 71-72] 
 
“ I put more lights on than I normally would cos normally I would have it sort of quite 
dark in the lounge but em I reckon more light is probably a good thing, just to keep me 
awake - and I think it’s working” [Sarah, 39-41] 
 
“from about 6 o’clock to 8.15, which is now, I’ve been really tired, like fighting the 
tiredness, I sat down on the couch…and I think my couch is going to have to be a no-go 
zone area because I get too comfy and I just want to nap.  I closed my eyes for a second 
when I was watching the news, but it was literally just a second and I was awake and 
got a fright…I thought ‘I really can’t nap’…so I’m going to do a few chores to keep 
myself up…” [Hannah, 48-54] 
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“…I did do a bit of checking late at night last night on the internet for other people who 
have done this em sleep restriction thing, and most of them seem to think it was worth 
persevering (laughs), some said it only took a couple of nights till they slept for the time 
they were allowed to be in bed, at least one said it took longer than that, so I’m hopeful 
that I’m not the only person who takes so long to sleep the amount of time I’m allowed” 
[Jane, 80-84] 
 
Evolving changes to the sleep experience 
Finally, participants reflected on how sleep quality, feelings of sleep pressure, and 
views on sleep, were beginning to change.  These comments were made, in nearly all 
cases, towards the end of the first week as improvements in sleep became apparent.  
Changes in sleep pressure were conveyed with reference to the perceived ability to sleep 
longer than usual (past set rising time), and, in particular, ‘unusual’ feelings of 
‘tiredness’ and involuntary napping.   
 
“ didn’t do much on Saturday, went to the cinema, and was really tired and thought I 
was going to fall asleep for the first time ever, half-way through, em a movie…went out 
for a walk and came back in again, and I was absolutely fine” [Lisa, 81-83] 
 
“this afternoon I was very dosey and sort of quite tired em because I had sort of 
struggled a little bit with sleep last night, em, I got about three and a half hours all in, 
and em, this morning found it quite hard to get up…which [is] a little bit unusual for 
me” [Jim, 46-48] 
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“I got really tired about three o’clock but not the usual tired that I get - just can’t be 
bothered doing anything - but more I could fall asleep at my desk and my eyes really 
gritty tired” [Lisa, 49-50] 
 
“these napping situations, it’s not like I’m sitting down wanting to nap but it’s just that 
I’m tired and I’m watching the telly and I’m drifting off and that’s so unlike me” 
[Hannah, 118-119] 
 
“I’ve been sort of fighting myself to stay awake, eh for most of the day” [Jim, 88-89] 
 
This pressure was linked to self-reported improvements in sleep, particularly reduced 
sleep latencies and less frequent and lengthy awakenings.  It was thus towards the end 
of week one that patients were beginning to realise that the programme may actually be 
working; that the acute exhaustion and increased wake time may be a worthwhile 
endeavour.        
 
“Sunday morning, I think it’s day 4, and eh, feel quite good, quite a good sleep last 
night, but eh I knew I would because I was so tired yesterday, em, so that’s a good sign, 
pretty much slept right through, and eh, yeah, feeling quite good” [David, 46-48] 
 
“It’s eh Friday morning, I managed to sleep right through the night last night, didn’t 
wake up at all, and woke up this morning, before the alarm for the first time this week, 
so I feel a lot brighter and don’t feel as groggy or kind of spaced out this morning” 
[Lisa, 54-56] 
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“I’ve got to admit, despite being up twice during the night, I’m having a deeper sleep 
than I normally get and that’s been the same for the last couple of nights, although it’s 
shorter, it’s actually deeper” [Maria, 60-62] 
 
“I do feel that the quality of my sleep last night was better than before I started the 
programme” [Sarah, 142-143] 
 
“I’m feeling quite good today, and I had a good sleep last night, em, I didn’t wake up at 
all during the night, and I went out like a light at twelve thirty which was very unusual 
for me, but I think it was because the whole night I was craving sleep” [Hannah, 144-
145] 
 
“I still feel sleep deprived, em, and every time I walk past my bedroom, I just look 
longingly at my bed, I just want to be in there, this is ridiculous, Saturday morning 
watching breakfast news, before seven o clock, is there any need? Eh, anyway, all in all, 
if only I woke up once, it’s maybe not that bad” [Sarah, 53-56] 
 
“..had a pretty good night, again woke up a couple of times, as per usual, but, you 
know, felt as if perhaps the quality of my sleep is better than it used to be.” [Sarah, 157-
158] 
 
“I did have a good sleep last night, but I still took a...nearly an hour to get to sleep, but 
I wasn’t really, I wasn’t lying there fretting or anything, it’s almost like being semi-
comatosed, em and then I woke twice, em and didn’t go to the bathroom which was 
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really good, and then I woke up finally at em seven o’ clock, I reckon it was pretty good 
sleep” [Louise, 48-53] 
 
“In general I just feel I’ve been a lot [more] tired...a lot more tired this week than usual 
and could probably have slept more than what I’ve restricted myself to em despite em 
oversleeping twice, em, fingers crossed that’s a good sign” [Jim, 129-131] 
 
5.4.7.2. Interviews 
The same 14 participants also took part in a face-to-face interview with the researcher at 
the post-treatment assessment point.  Verbatim transcription produced ~ 66,400 words 
of data.  Following strict coding, a number of themes were generated, capturing 
impressions and experiences of sleep restriction therapy (see table 5.10 for a summary 
of main themes). 
 
Table 5.10 - Major themes from thematic analysis of semi-structured interviews. 
Themes 
 'At the end of my tether'
 'This is  a sleep restriction  programme'
Adherence & adjustment
 'I actually want  to go to bed now'
Daytime functioning: a thermometer for success?
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‘At the end of my tether’ 
Participants discussed why they had decided to take part in the sleep restriction 
intervention; descriptions tended to be dominated with references to daytime and quality 
of life impairments, as key catalysts.   
 
“…just my mood and em kinda temperament and it affected my everyday life, I thought, 
quite badly…and I thought things could be better if my sleep was better, and it seems to 
be working.” [Ross, 6-7] 
 
“I got it into my head that I was a bad sleeper, and I thought ‘oh god, I’m still really 
young, I have to make a change or else this is going to be me’, and I don’t want this to 
be me…I had a wee bit of a fright about a few months ago, I didn’t fall asleep at the 
wheel, I would say I did, but it was almost too quick…I was just really tired, and I 
remember the music was blasting, window was down, and I must have felt drowsy, and 
then for a second my head was down and then I woke up, and I touched the kerb with 
the car, and I think I got a fright and I just thought I have to do something about this” 
[Hannah, 17-20/24-27] 
 
“…because I was at the end of my tether, em, I felt that it was interfering in not just my 
personal / social life, but it was also interfering in work life” [Sarah, 11-13]   
 
Related to this, it emerged that patients had tried a range of other treatments, including 
medication/herbal strategies; that had, for the most part, failed to effectively alleviate 
insomnia symptoms.           
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“I’ve tried herbalism…yeah just trying herbs and things, potions, but as I say I think it’s 
a whole lot of rubbish…somebody told me it would work, it worked for them, so you go 
and try it, it didn’t work.” [Bill, 41-43] 
 
“I’ve only ever tried sleeping pills, and obviously sort of watching the diet and stuff like 
that, and eh people have recommended sort of various herbal medicines, which I… 
kinda had never worked for me, nothing else has worked for me, at all really.” [David, 
26-28] 
 
“I’d tried herbal medicine, I tried Chinese medicine, I tried… (laughs) which was sort 
of boiling up a lot of sticks, I’ve tried, (laughs)...tasted absolutely disgusting, and it 
were no good at all…I tried homeopathy…I mean I looked up sort of you know, 
homeopathic doctors, I tried herbal stuff, I have tried, I don’t really, I mean I have some 
sleeping pills but I don’t think they are very successful, I remember years ago having 
temazepam which I reckon were pet pills, I mean I don’t sleep at all with those…” 
[Jane, 23-28] 
 
‘This is a sleep restriction programme’ 
Initial subjective impressions of SRT were that it was ‘logical’, and ‘made sense’; yet, 
for some, it did still feel ‘counter-intuitive’, relative to how they have typically tried to 
cope with their insomnia (i.e. extending time in bed/’catch-up’ sleep).  Others, although 
again finding it logical, thought it seemed ‘too simple’ to be effective (‘insomnia is a 
chronic problem’).  This perceived ease or simplicity failed to translate into actual 
experience, as the first 1-2 weeks of the programme were described as incredibly 
difficult, and, by some, as ‘hell’ and even ‘torture’.  As noted in audio-diary entries, 
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participants similarly reflected on the negative side-effects encountered in the early 
stages of the programme, particularly relating to extreme fatigue and sleepiness, 
impairing nearly all aspects of daytime functioning, including subjective driving ability.  
These impairments were of greater magnitude than pre-treatment functioning levels.   
 
“…telling somebody with insomnia ‘stay up late’ is like turkey’s voting for Christmas, 
don’t be ridiculous” [Sarah, 432-433] 
 
“..the sort of limited amount of sleep that you were giving us in the first night sounded 
pretty horrific, and it was, the first week was really tough, eh, but I think I could see the 
sense then, but I didn’t see it immediately you know, it didn’t hit me immediately that it 
was going to work, that sort of came in the second week’ [David, 16-19] 
 
“as the week went on you realise it was quite a task and it was quite an inconvenience 
to people, it’s got other issues attached to it I guess, and by the time you’ve done a week 
then you realise, eh, it is a sleep restriction programme.” [Bill, 63-65] 
 
“ the first few days, I remember, I was on a real buzz about it, because I thought this is 
really going to work, I’m loving it, and I just, I got out of bed with a spring in my step, 
and then about the third day, I was just like ‘oh my god, this is hell’, I want more sleep, 
and it was by that point that I would’ve wanted to break the rules, and sleep in a wee bit 
or go for a nap.” [Hannah, 89-91] 
 
“it was torture, like one of these reality TV programmes when they sort of torture 
people [laughs], it was absolutely awful because I knew I had a lot of things on that 
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week, work wise…and various things that I wanted to do…I knew I was going to be 
completely shattered when I was doing them, and I was, basically.” [David, 39-39] 
 
“…that week one needs to come with a health warning” [Sarah, 154] 
 
“It’s depriving yourself of sleep at night and being constant during the day; it’s quite a 
hard cycle” [Maria, 271-272] 
 
“driving was a nightmare, and I’ve never ever had an issue with driving before” [Bill, 
84] 
 
Adherence and adjustment 
Adherence to set rising and threshold times was affected by a number of variables.  
These included, but were not restricted to, the following: experiencing pressure to sleep 
in such a condensed period, coupled with concern for next-day-functioning; external 
fluctuating stressors and commitments; actual felt impact of restricted sleep opportunity 
on daytime functioning; and boredom associated with extra hours of wakefulness.  
Weekend adherence was particularly difficult for participants, being adversely impacted 
by: socialising/alcohol consumption; the prospect of being alone and awake for such a 
lengthy period of time; and the awareness of returning to work at the beginning of the 
week (catastrophizing about possible daytime consequences and coping).   
 
“if you don’t sleep and you know it takes you a while to get to sleep, you’re just 
concerned ‘oh my god, I’ve only got like three hours left, I better get to sleep’, you 
know, this type of thing, whereas if you had that extra hour that’s maybe an hour for 
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you to chill out, get to sleep type thing, and then the rest is for sleeping…” [Jennifer, 
327-330] 
 
“I suppose rationally and logically, it did seem a good idea, but then I think the first 
week of actually doing it, I felt worse, and so you kinda, there’s a temptation there to 
think ‘och this is not working’, like ‘give up now’” [Lisa, 17-19] 
 
“…some nights when I was really just so tired, I went to bed earlier, or if I knew I had 
to do something the next day…I was slightly concerned, when I was really tired, about 
driving, I really did feel that driving was a danger” [Jane, 145-148]   
 
Despite these obstacles, participants developed strategies to help promote adherence, 
such as refraining from going out/socialising late at night; not allowing self to relax in 
comfortable positions prior to ‘threshold time’ (to prevent ‘dosing’/napping); keeping 
active and setting chores; and negotiations/discussions with partner to facilitate 
adjustment.   
 
“my husband was determined I was sticking at it, you know, cos he, when I was sitting 
at night-time, and I was like almost falling asleep…he kept shouting at me ‘get up’, 
‘wake up, don’t go to sleep’, you know it was kinda like that, but I felt it very difficult to 
get up and do anything, I was actually too tired to” [Gillian, 135-138] 
 
“a couple of parties and things… I was still aware that I wasny gonna get too 
drunk…or stay up too late, cos I wanted to kinda keep my sleeping pattern, cos I didn’t 
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want to break it, because it was beginning to kinda, it was beginning to kinda form, so I 
didny really want to start messing about with it” [Ross, 45-49] 
 
Another factor that emerged was that non-adherence (mostly sleeping-in and napping) 
contributed to sleep-onset problems the subsequent evening, when attempting to 
‘restart’ the programme.  This ‘experimental feed-back’ acted as a negative reinforcer, 
helping to reduce non-adherence and motivate continued implementation of treatment 
instructions. 
 
“…there were times where I napped and then regretted it because it had an effect” 
[Hannah, 95] 
 
 
“…there’s been a few mornings where you’re em, oh you’re thinking, especially like 
Saturday and Sunday, ‘there’s just no way I want to get out of my bed’, but em, then you 
think ‘well no’, especially at the weekend cos then if I lie long this morning then I don’t 
get to sleep tonight, it’s just going to start the whole thing again, that’s, I suppose, the 
motivation, the fact that you think ‘well if this makes you sleep five hours through the 
night, then just get up’” [Lisa, 273-278]   
 
‘I actually want to go to bed now’ 
For the majority of participants significant changes to sleep tended to occur in the 
second or third week of treatment.  These related to commonly-measured sleep 
parameters, such as reduced sleep latency, decreased wake-time after sleep-onset, and 
decreased number of awakenings.  Changes to sleep, however, also extended to more 
‘subjectively’ expressed aspects of sleep, such as quality and depth of sleep, 
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predictability that sleep will happen, and unusual feelings of sleep pressure and 
‘craving’.  Interestingly, for many participants, this ‘paradigm shift’ to ‘looking 
forward’ to going to bed reduced sleep anxiety/distress and pre-occupation, both at 
sleep-onset and during awakenings. 
   
“I’m sleeping longer, and going into a deeper sleep, I think, when I wake during the 
night it’s only…it’s less frequent, and it’s easier to get back over again…previously if I 
woke up during the night I’d be worried about trying to get back over again, and I’d be 
thinking about it, but because you’re so tired by this sort of programme then you 
actually get back over much quicker and it seems to work” [David, 62-66]  
 
“…now, with the light off, I compose myself for sleep and then I’ll say to myself ‘right, 
I’ll give myself a wee mindless job to do in my head, right think this or something’, and 
I find it difficult to concentrate on it which is quite good because that’s, you know, it 
shows that I’m not really able to…I’m not really fully conscious, but before I used to 
find myself anxiously looking at the clock to see what time it was” [Louise, 138-142] 
 
“…I feel a lot more confident like, and my sleeping like…I don’t worry about ‘am I 
going to get to sleep’, I just go to bed and pretty much hope for the best, I’m not always 
looking at the clock and stuff.” [Becky, 122-124] 
 
“I just, I suppose I feel a bit of a weight’s taken off my shoulder, em, I almost feel 
liberated from the constant thinking off ‘am I going to sleep?’ ” [Sarah, 406-407] 
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“ I would say number one is that I actually want to go to bed now, which is really good 
for me, before it was something like a chore that I felt like I had to do, or never got 
enough of, and now I look forward to bed which is a completely new experience for me” 
[Hannah, 124-126] 
 
“I think I’ve altered my, I just seem to have gone onto a different plain when it comes to 
my attitude to sleep, em, another thing though I’ve realised is that em it’s possibly true 
that I just don’t need 8 hours of sleep or even seven and a half hours sleep or even 
seven, possibly I only need about six and a half hours sleep.” [Louise, 78-81]  
 
“you’re so knocked that you don’t have the anxiety to be anxious at that time of night, 
really, I’m so looking forward to going to my bed, when I get to whichever hour my 
times up, I say ‘Yes, times up, going to bed’ [laughs] so that’s probably the highlight of 
the day” [Bill, 167-170] 
 
“I’m not concerned, I’m not worried about not sleeping, because I know that when I go 
to bed I will sleep” [Sarah, 188-189] 
 
“..normally if I’ve got something important the next day, then that’s the sort of thing 
that would keep me awake, but as I say I’m so tired by the time it gets to quarter past 
twelve or whatever, then em I don’t even worry about the following day, I know I’m 
going to sleep” [David, 114-118] 
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“it’s a different kind of tiredness it’s more of a…there’s periods during the day when 
you think I could put my head down on the desk and fall asleep, whereas before it was 
go away and leave me alone and just don’t annoy me” [Lisa, 298-299] 
 
Indeed, even for those few participants who felt they hadn’t benefited from the sleep 
restriction programme, they did, however, describe changes to their attitude towards 
sleep, particularly sleep need.  Having encountered side-effects during restriction, they 
tended to have a ‘response-shift’ to their own sleep duration; engendering ‘this could be 
worse’ phenomenon, which seemed to relieve some pre-occupation/concern with sleep.   
 
“I think with just looking at this overall, I sort of think well okay if I only sleep for four 
hours it’s no big deal, I seem to function okay, I mean I will maybe get to the point in 
the weekend where if I have maybe a couple of extra hours, that’s enough sort of thing, 
and it seems to recharge the batteries, and you know, you can carry on, so it’s maybe, 
maybe I came in to this thinking ‘oh my god, I don’t sleep properly’ and blahdy blah, 
but actually I just think well that is probably what’s normal for me..” [Jennifer, 200-
205] 
 
For most participants, improvements were considered to be ongoing, and their 
perceived-capacity to obtain more sleep, and build on gains, was a prime motivator for 
continuing with the programme (after formal monitoring ceased).  
 
“It’s the first time, as I say, that I’ve actually had a positive experience from something 
like this, em, and after ten years of sort of just dealing with it and being told there’s 
nothing much that can be done about it, it’s given me a slightly sort of 
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difference…attitude towards it...that there might be a, you know, some sort of light at 
the end of the tunnel with it, and I also appreciate that I might not become an eight or 
nine hour-a-night person, If I can quite simply stabilise at five to six, or even seven 
hours, then for me that’s gonna have a huge impact on me personally” [Jim, 238-242] 
 
“I just have a very positive feeling about it, and I know that it’s early days and you‘ve 
got to remember that it’s such a long time since I’ve had a good nights sleep, that it 
won’t change overnight, you know, and so I’ve got to keep working at it…so, and I think 
it’s the most positive thing I’ve done or felt is going to work, medication never really 
worked” [Gillian, 221-224]   
 
Daytime functioning: a thermometer for success? 
Although improvements in functioning tended not to be as robust as changes to sleep, at 
least at the time of interview, many participants reported positive modifications to 
aspects of daily living, such as having more energy, being more organised, being less 
anxious, enhanced coping skills, adopting a more positive outlook, and even comments 
by significant others concerning physical appearance.  These improvements were 
typically just evolving 1-2 weeks prior to interview, in a slight time-lag behind sleep 
symptom changes. 
 
“…I do think having the sleep sorted out has helped me [to] be calmer and more 
relaxed” [Louise, 179-180] 
 
“I’ve got much more energy now than I had before” [Sarah, 242-243] 
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“see when you’re not sleeping you just don’t want to do anything, you’re just sitting, 
you don’t want to really talk to people, but now I’m going about, going out more and 
stuff, so good.” [Becky, 185-187] 
 
“much more sort of…quite motivated for work and stuff, eh, it definitely has had a very 
positive effect on my sort of daily life” [David, 87-88] 
 
“ I think now I’m more likely if I’ve planned something for after work, to do it, em, I’m 
meant to, I’ve paid for most of this year west Dunbartonshire council money for a gym 
membership, that I [‘ve] never been in, em, so I’m now back three times a week!” [Lisa, 
185-187] 
 
“my sister has commented em that I don’t look like a panda anymore…with my big 
black eyes” [Lisa, 236-237] 
 
“I do feel like a normal sleeper, which is bizarre and great, this has been huge for...like 
driving, I feel like I’m calmer you know I don’t get road rage, I don’t…I’m not as bad 
as what I was, I’m taking less risks in the car, I’m not in a rush, because I’m not as 
anxious, I’m not on edge, I’m just a bit more chilled I think, and I think the sleep helps 
to centre yourself…”  [Hannah, 353-357] 
 
“[it’s] bizarre thinking well I actually have to get out of bed, and I could still sleep 
another couple of hours, but I’ve actually also slept quite a few hours so that’s quite 
liberating, I do feel I’ve got more energy” [Sarah, 407-409] 
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Impact on functioning was considered a thermometer by many to gauge therapy 
success.  The continuation of a journey, an ongoing treatment process, was often made 
with reference to obtaining future improvements in aspects of functioning.   
 
“ If I can build it up to six and a half I think, six and a half hours, I’m gonna feel like I 
can function, right, so I guess I’m thinking in my head that’s where my functioning 
range is, six and a half hours is gonna allow me to function, eh, if I can better that then 
I’m hoping that’s where the energy and the zest for life is going to come from” [Bill, 
325-329] 
 
“I think...[I] still need that extra bit of sleep, which might come just the next couple of 
weeks, because I felt quite irritable this morning and that was because I didny have 
enough sleep” [Ross, 297-298] 
 
“I’ve had some mornings where I felt really good, you know, and feeling the 
positiveness coming back again, thinking this is really going to work and that hasny left 
you know, I still think there’s room for improvement in that, so that’s what I’m heading 
for” [Gillian, 120-123] 
 
Those individuals who considered SRT to have been unsuccessful in terms of 
improving night-time sleep, or that only reported minimal improvements (at least up 
until the interview), voiced that functioning was detrimentally affected during times of 
adherence (both acutely and throughout the four-week period).  In extreme cases this 
meant a subsequent shift towards baseline sleep schedules, accompanied by a return to 
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‘normal’ levels of functioning; while others voiced determination to commit to the 
programme despite negative daytime experiences.    
 
“ I got quite excited, cos I felt although I wasn’t sleeping long, that I felt that I had slept 
better, but then I think that was three nights in all the three and a half weeks that I’d 
done it, that I felt like that, otherwise some nights I felt sort of always semi-awake, other 
nights I slept really badly, so it was only three nights that I felt ‘oh I really slept 
soundly’, so that was rather disappointing…I haven’t done it since the grandchildren 
are staying because I need to be on sparkling form all day with them” [Jane, 164-
168/172]    
  
“I was alright the first sort of few nights, and then I started feeling a wee bit down 
about it actually, I remember I said that on the dictaphone as well, that I started 
thinking hmm I can’t sort of comply with this and I can’t really…I don’t think I can do it 
properly, you know, that sort of thing, and I don’t like doing things sort of half-
heartedly” [Jennifer, 138-140/145-146] 
 
“I actually do feel worse during the day than what I previously did, whilst I’ve managed 
to recover some of the sleep that I wasn’t previously getting, em, I feel more exhausted 
during the day than what I did previously, em certainly in the mornings, and in the mid 
afternoons, em, I am not as alert as I used to be, em unless I’m actually working on a 
project or have a group of people to work with” [Jim, 173-176] 
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5.5. Discussion 
The aim of this mixed-method study was to investigate, using both quantitative and 
qualitative methodologies, the patient experience of sleep restriction therapy for 
insomnia.  Sleep-diaries, questionnaires, audio-diaries and semi-structured interviews 
were combined in an attempt to understand the impact of SRT on sleep and functioning, 
but also to gain an ‘insider’s perspective’ (Conrad, 1987) on treatment implementation 
and process.   
 
5.5.1. Sleep-related changes 
All major sleep diary variables significantly improved from baseline to post-treatment 
(excluding TST), and these improvements were maintained at three months.  By three 
months, TST demonstrated a gain of 47 minutes, on average, relative to baseline values.  
Overall, sleep changes were comparable (and for some variables, larger) in terms of 
magnitude, to those obtained in full CBT interventions (Riemann & Perlis, 2009; Smith 
et al., 2002) and previously published trials of sleep restriction therapy (e.g. Friedman et 
al., 2000).  Moreover, global insomnia disorder severity (assessed using the ISI) 
indicated mean values for the group to be in the ‘sub-clinical insomnia’ range at post-
treatment and follow-up, relative to baseline levels in the ‘clinical moderate’ range.  The 
clinical significance of these changes was confirmed with 44% and 67% of patients 
being classified as ‘remitters’ and ‘responders’, respectively, at three month follow-up. 
 
Semi-structured interviews with patients, post-treatment, supported these changes in 
nightly sleep parameters; specifically concerning reduced sleep-onset latencies, 
decreased number of awakenings (also reported as a reduced ability to remember 
awakenings), and decreased amounts of wake-time during the night.  Interviews also 
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revealed changes in subjective sleep quality; with participants providing rich 
descriptions of sleep as being ‘deeper’ and ‘more efficient’, as well as reporting 
dampened mentation at sleep-onset, and during middle-of-the night awakenings.  Such 
‘qualitative’ changes and increased predictability of sleep are likely related to the 
harnessing of homeostatic pressure and circadian re-alignment; both desired targets of 
sleep restriction therapy (Perlis & Pigeon, 2006; Spielman et al., 1987b; Cervena et al., 
2005; Edinger & Means, 2005).   
 
Importantly, participants described simultaneous modifications to how they perceived 
sleep.  The feeling of ‘craving’ sleep – as a consequence of it being ‘denied’/restricted - 
represented a significant shift from how participants typically viewed the sleep-onset 
and sleep period.  In turn, this led participants to describe having reduced anxiety and 
worry when initiating sleep, and during middle-of-the-night awakenings.  A recent 
study by Spiegelhalder and colleagues (2010) found, somewhat surprisingly, that 
increased sleep-related attentional bias (measured using a visual dot-probe paradigm) 
prior to sleep, was subsequently positively associated with markers of improved sleep 
continuity (greater sleep efficiency, slow wave sleep, and total sleep time, as well as 
reduced awakenings).  The authors interpret these findings as suggestive of a 
homeostatic craving for sleep in PI patients.  Sleep restriction may work, in part, then 
by modifying - through partial sleep deprivation - the evolved threat value that sleep 
and associated bedtime routine have come to represent in those with primary insomnia.  
Although speculative, this notion could also relate to the natural variability of ‘good’ 
and ‘poor’ nights in PI patients (e.g. Perlis et al., in press B), where a good night has 
been found to follow one to three nights of poor sleep: an eventual build up of sleep 
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pressure may help to defuse sleep-related anxiety, associated arousal, and selective 
attention, ultimately restoring sleep automaticity.  
 
The knock-on effect of craving sleep, in terms of reduced pre-sleep anxiety and arousal, 
and increased nightly sleep predictability, may well relate to the robust decreases in the 
application of ‘sleep effort’ (as measured by the GSES), a concept central to recent 
cognitive models of psychophysiological insomnia (cf. Espie et al., 2006; Broomfield & 
Espie, 2005).  Furthermore, it was also interesting that some patients underwent an 
adjustment process with respect to their sleep need during the first week.  Functioning 
worse than they previously had done, a few patients began to feel perhaps their sleep 
problem was not as problematic or obstructive as once thought – which seemed to 
provide some level of reassurance, despite no obvious or immediate improved 
modifications to sleep.   
 
To build on Edinger & Means’ (2005) description of ‘pathways’ implicated in CBT 
response (see figure 5.6), the present study suggests, based on participant descriptions, 
that SRT may have secondary or parallel effects on both ‘inhibitory factors’ 
(particularly conditioned arousal) and ‘cognitive factors/dysfunctional beliefs’, thought 
to be important in the aetiology and maintenance of insomnia [see additional red (dash) 
lines superimposed on figure 5.6].  This, of course, requires additional empirical testing 
in the context of isolated component intervention studies. 
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Figure 5.6 - CBT-I treatment targets. Taken from Edinger & Means (2005) and modified (red lines) based 
on present study findings.          
 
       
 
5.5.2. Side-effects and Daytime Functioning/HRQoL 
Functioning fluctuated over the course of the four-week period.  Responses from our 
newly developed side-effects checklist indicated that at least one half of participants 
experienced eight of the 12 listed symptoms, as a consequence of sleep restriction 
therapy during week one.  Fatigue, extreme sleepiness, and reduced motivation/energy 
were the most commonly experienced difficulties, and, along with irritability and 
changes to hunger/appetite, negatively interfered with daytime functioning (to the 
greatest degree).  In vivo diary reflections corroborated these accounts, with participants 
describing, at length, impairments in occupational performance, social functioning and 
everyday duties, citing exacerbated levels of fatigue and sleepiness and their subsequent 
downstream effects on cognition, as the main culprits.  Of particular prominence, more 
than one-third of our sample described, during diary entry recordings, concerns with 
driving ability (these were again discussed during interviews).  With numbers of this 
magnitude, it is clear that SRT is not an intervention with just mild and trivial effects, 
and it remains to be determined if such a treatment approach (at least acutely) is 
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associated with a ‘spike’ in automobile accidents (as reported with hypnotic use: 
Gustavsen et al., 2008; Engeland et al., 2007).  Clearly the risk exists.  It would be 
interesting to qualitatively track patients assigned to active hypnotic therapy to compare 
patient narratives and experiences across treatment modalities.   
 
According to a recently published 6-month study on the efficacy of nightly Eszopiclone 
3mg in those with primary insomnia (Walsh et al., 2007), adverse event rates were as 
follows for Eszopiclone versus placebo: somnolence (•8.8% v 3.2 % ), myalgia (•6.0% 
v. 2.9 %) and headache (15.0% v. 15.0%).  Another study by Scharf et al. (2005), over a 
more similar time-period to the present study, revealed the following rates for 
Eszopiclone 1mg, 2mg and placebo: somnolence (6.9% and 3.8%, vs. 8.8%) and 
headache (15.3 % and 15.2%, vs. 15%).  It is abundantly clear that rates in the present 
study are substantially higher, and it is important to note that the above recorded 
adverse events in the pharmacological studies usually include multiple events from a 
single patient.  Also of interest, two out of the five individuals who discontinued 
treatment did so because ‘side-effects’ (presumably) outweighed any sleep 
gain/benefits.  CBT-I treatment studies rarely report (and/or record) reasons for attrition, 
perhaps because they are often difficult to ascertain, but if approximately 10% (in this 
study) drop-out due to an exacerbation of baseline impairments, this represents a 
significant challenge for CBT uptake and therefore effectiveness.   
 
It is also worth pointing out that in the current study the minimum sleep window was set 
at five hours; other CBT-I programmes set a bottom limit of as little as four hours (e.g. 
Perlis et al., 2001c), which might be expected to produce more pronounced impairments 
                                                 
•
 significantly different from placebo  
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than those reported here.  One also has to remember that about 25% of insomnia 
patients may have high pre-existing excessive sleepiness levels (Day et al., 2001); these 
individuals may be a particularly high-risk group during the acute sleep restriction 
period.      
 
To the best of our knowledge, side-effects encountered during CBT have not been 
adequately described or investigated in previous literature.  Perlis and colleagues (2004) 
in their randomised trial of modafinil as an adjunctive to CBT, indicated that during 
week one of treatment, sleepiness, as measured by the Epworth Sleepiness Scale (ESS), 
approached pathological levels (ESS = ~10.5 versus a baseline of ~7); an effect that was 
in fact attenuated in the CBT plus modafinil group.  Similarly, an abstract presented at 
the 2003 meeting of the Associated Professional Sleep Societies (APSS), in Chicago, by 
Fortier-Brochu and colleagues, reported on weekly questionnaire data (assessing 
daytime functioning symptoms) collected during the course of CBT-I.  Results indicated 
a worsening of symptoms during the early stages of CBT, including elevated levels of 
fatigue, sleepiness and irritability – which coincided with the introduction of sleep 
restriction and stimulus control components.  The present study is the first to reveal, in-
depth, the descriptive nature and magnitude of experienced ‘side-effects’, that were 
attributed to the programme.  Interviews suggested that for the majority of participants, 
side-effects sub-sided 1-2 weeks into treatment initiation, as sleep parameters began to 
stabilise and improvements in sleep quality evolved. 
 
One intriguing finding was that number of checked side-effects positively correlated 
(moderate strength) with ISI, PSQI, and sleep efficiency change scores, from baseline to 
post-treatment.  Side-effect daytime interference ratings were also significantly 
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associated with PSQI and GSES change scores (again moderate strength).  It may be 
that side-effects provide an index of adherence to set threshold and rising times and 
hence mediate this relationship; the association with decreased sleep effort gives further 
credence to this argument.  Of note, however, this ‘side-effect-outcome’ account runs 
partially counter to the findings of Perlis et al. (2004), who found that 
blocking/attenuating sleepiness using modafinil did not interfere with CBT-I efficacy; 
concluding that sleepiness may not be essential for CBT outcome.  This finding, of 
course, does not rule out additive effects of modafinil properties beyond simply its 
stimulant action, such as the blockade of dopamine transporters (Volkow et al., 2009) 
and possible mood-enhancing effects, as well as increased levels of activity.  
Interestingly, the authors also reported a tendency for this group to be more adherent to 
bed-time instructions.  Future studies must examine the mechanisms of sleep restriction 
and predictors of response.     
 
With respect to daytime functioning outcomes, significant improvements were observed 
on the DFSAS (parts 1&2), GSII (ranks 1&2), OISQ, and three domains of the SF-36 
(role emotional, mental health and vitality/energy) – all with moderate to large effect 
sizes.  Overall, improvements tended to be most robust at three months than post-
treatment, which may reflect the overlap between questionnaire reference period and 
experienced side-effects during the acute stages of treatment.  This is an important 
consideration when assessing CBT gains directly following the ‘active’ phase.  From 
semi-structured interviews, participants were beginning to notice improvements in 
domains of functioning, three to four weeks into the programme, describing positive 
changes in energy levels, fatigue, but also aspects of work life and social functioning.  
To add credence to these improvements being related to the intervention itself, strong 
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relationships were found between changes in sleep symptoms and daytime 
improvements – an association rarely found (or left unreported) in insomnia research 
(Means et al., 2000; Omvik et al., 2008; Kyle et al., 2010).  Intriguingly, changes were 
most pronounced on our newly developed scales (DFSAS, GSII), which may suggest 
enhanced sensitivity of these measures – both based on words/experiences of insomnia 
patients – in detecting daytime difficulties relevant to those with insomnia disorder.  
 
5.5.3. Adherence 
Our use of qualitative methodologies provided insights into how participants adjusted 
and adapted to their new sleeping schedule.  Audio-diary entries were particularly 
interesting because we were able to track experiences over time, from day 1, and gain 
access to moments of adherence and, importantly, non-adherence.  Recent work by 
Vincent and colleagues (2008) revealed that perceived barriers to sleep restriction and 
stimulus control treatment engagement (measured with a non-validated questionnaire 
post-CBT) predicted self-report adherence; here we were able to capture the nature of 
encountered barriers, in real time.  Specifically, negative impact on functioning, an 
inability to stave off sleepiness prior to bedtime, and boredom and loneliness during 
extra hours were all prominent reasons for non-adhering.  Such factors also affected 
those who were adherent, representing general challenges of sleep restriction therapy 
implementation.    
 
Side-effects interacted with going to bed late, so that impaired daytime functioning not 
only made staying up until a late set bed time incredibly difficult, but also created 
pressure and anxiety for participants when attempting to initiate sleep.  They were faced 
with both the prospect of only having x hours to ‘obtain’ sleep, and the experience of 
continued, and possibly enhanced, impairments the following day.  Thus, for some, the 
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normal catastrophizing about daytime consequences (Wicklow & Espie, 2000) was in 
fact exacerbated during the early stages of sleep restriction, which discouraged rigorous 
adherence.  It would seem important, therefore, to identify those who do not respond in 
the first few days of treatment, to prevent complete or partial disengagement from 
treatment instructions.  Indeed, a few participants, during interviews, did indicate that if 
there were to be increased therapist contact during active treatment, it would be in the 
first week.   
   
In this regard, it would also be a worthwhile research endeavour to extend the early 
work by Perlis and colleagues (2004), to determine if additional stimulant therapy can 
attenuate daytime impairments, improve adherence, and (possibly) enhance outcome.  
Of course, activation therapies may not necessarily be restricted to pharmacological 
intervention.  For example, some components of fatigue interventions used with cancer 
patients undergoing chemotherapy could also be applied, such as specific exercise 
activities (Escalante & Manzullo, 2009).  Interestingly, during interviews and audio-
diary entries, participants described a number of counter-measures they had developed, 
which included keeping active, engaging in discussion, and setting chores, all with the 
primary aim of improving alertness to promote adherence. 
 
Another, perhaps unsurprising, finding from audio-diaries and interviews, was that 
adherence was most difficult on weekends compared with weekdays.  Weekends tended 
to be viewed (prior to SRT) as designated time for catch-up sleep and rest.  Participants 
commented on how ‘long’ and ‘lonely’ weekends had become, particularly because of a 
lack of stimulation and interaction during Saturday and Sunday mornings.  Socialising 
also negatively impacted adherence and effectiveness through three main routes: firstly, 
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staying out late tended to shift bed time and the sleep window forward; secondly, 
proximal ‘stimulation’ too close to set bed time created ‘over arousal’, and hence sleep 
initiation more difficult; and finally alcohol intake negatively interfered with sleep 
quality.  It would seem important to discuss, more thoroughly, weekend adherence with 
patients during CBT-I sessions.  Emphasis could be placed on the importance of 
organising social activities in advance of weekends to help put in place a routine which 
supports adherence to threshold and rising times, and lessens the associated boredom 
(Vincent et al., 2008).  
 
It should be noted that we did not find any evidence of a relationship between our 
questionnaire measure of adherence at 3 months and magnitude of outcome (pre-
treatment to follow-up).  The use of a non-validated scale, small sample, and time-frame 
(reference to adherence ‘in the last three months’) may all account for the null effects.  
Nevertheless, it is important to consider the possibility that rigorous adherence to sleep 
restriction is not necessarily (linearly) associated with outcome.  Patients classified as 
‘remitters’, for example, may no longer feel the need to rigorously implement set times; 
they are, after all, now considered to be in the normal sleeping range (Harvey et al., 
2002).  Moreover, patient narratives from the present study indicate other secondary 
effects of sleep restriction, such as reduced pre-sleep anxiety and sleep pre-occupation, 
increased sleep predictability, and even a ‘response shift’ to insomnia severity.  Perhaps 
these parallel effects also contribute unique variance to explaining outcome.  It is 
interesting that the few studies to assess relations between behavioural adherence and 
outcome tend to find either quite weak to modest associations (e.g. Vincent et al., 2008; 
Vincent & Hameed, 2003) or that sleep window consistency may be a better predictor 
than sleep reduction per se (e.g. Riedel & Lichstein, 2001).  Perhaps stabilising set bed 
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and rising times, with a mild sleep reduction, as in fixed sleep restriction studies with 
elderly participants (e.g. Hoch et al., 2001), may be enough to obtain clinical 
improvements without inducing significant daytime disruption.  It seems important for 
the field to investigate (1) conventional and modified (compression; Lichstein et al., 
2001b) sleep restriction interventions; (2) predictors of adherence; and (3) the 
development of standard ways to assess adherence, including the use of objective 
measures such as actigraphy.  
 
5.5.4. Implications for clinical practice and future research 
There are several implications for clinical practice arising from this work.  Firstly, 
patients need to be made fully aware of how difficult the sleep restriction programme 
can be, as well as the possible risks/dangers associated with the acute stages.  Our 
participants’ initial perceptions of the programme when explained – although positive 
and logical – were, typically, far removed from the reality of implementation.  Perhaps 
vignettes from real participants, like those in the present study, would give the 
prospective CBT-I patient an insight into some of the challenges involved.  
 
This also raises the issue of whether the ‘expert patient’ (Department of Health, 2001) 
may have a role in treatment preparation, as a way of reducing attrition and enhancing 
adherence.  That is, in addition to vignettes, participants (‘graduates’) who had 
previously taken part in CBT-I (and benefited) could speak with prospective patients 
about the treatment experience and implementation.  This could be in the form of a 
recorded video clip, for example, shown to patients during CBT-I sessions.  A similar 
approach is currently used in some respiratory clinics to inform sleep apnea patients of 
the benefits of CPAP therapy, prior to initiation (e.g. Wiese et al., 2005).  Finally, 
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supplementary motivational interventions may also have a place in the behavioural 
management of insomnia; preliminary data suggests motivational interviewing, for 
example, is effective in improving CPAP adherence (Aloia et al., 2004).  Application to 
CBT-I is worthy of investigation.     
  
Although admittedly a small sample, results indicate that a brief sleep restriction 
intervention can, in isolation, improve aspects of functioning and sleep.  This supports 
other published controlled studies that have used similar brief CBT-I packages (two 
sessions), documenting substantial treatment gains (Edinger & Sampson, 2003; 
Germain et al., 2007).  Though more work is required, this literature and the present 
findings suggest that a brief (low-resource) behavioural intervention may be delivered 
as a first line treatment, in an attempt to widen access to evidence-based non-
pharmacological insomnia treatments (Espie, 2009). 
 
This work also has important implications for research.  For example, the finding that 
SRT modifies sleep-related anxiety, arousal and perceptions, demands greater attention 
in future work, with a range of assessments.  In particular, serial measurement of 
attentional bias and self-report questionnaire measures of pre-sleep mentation and 
applied sleep effort, over the course of sleep restriction, would be a worthwhile 
endeavour.  Furthermore, does sleep restriction modify physiological arousal prior to 
sleep and also during the day?  And what is the relationship, if any, with daytime 
functioning outcomes?  It would also be informative to assess objective (cognitive) 
functioning throughout the intervention period, helping to establish whether acute 
restriction is associated with measurable impairments (as our qualitative reports 
suggest), and also whether therapy reverses possible baseline neurobehavioural deficits.      
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5.5.5. Limitations  
The results of the present study have to be viewed in the context of several limitations.  
In relation to the diary and questionnaire data, particularly in light of the strong results, 
it needs to be borne in mind that this was an uncontrolled study, and that non-specific 
and other placebo-related effects cannot be ruled out without the inclusion of an 
adequate control group.  Similarly, procedural aspects of the treatment protocol may 
have impacted results in two important ways.  Firstly, audio-diary entries may have 
acted as a proxy for therapist contact, enhancing motivation/support to adhere with the 
programme, and ultimately moderating outcome.  Secondly, post-treatment interviews 
were conducted by the therapist (also the researcher: SK), which may have created 
‘demand characteristic’ behaviour on the part of interviewees.  On this point, however, 
it was made explicit to participants that we were interested in their experience, ‘good or 
bad’, and that all information was interesting and relevant.      
 
We also did not use polysomnography (PSG) to diagnose our patients as having primary 
insomnia.  Although reliance on subjective self-reports to ‘diagnose’ sleep disturbance 
is standard for PI populations (Buysse et al., 2006), it remains possible that some of our 
participants experienced (significant) sleep state misperception, which may have 
exacerbated experienced side-effects during the intervention period. 
     
Moreover, although not systematically recorded, the sample was largely white, middle 
class, and well-educated; these may be important factors when considering aspects of 
SRT implementation, motivation and adherence.  Such potential moderating variables 
should be investigated in future trials.  The generality of the findings may, therefore, be 
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restricted.  In addition, several of the questionnaires used in the present study were non-
validated and require further testing with larger samples of individuals with insomnia.   
 
Finally, numerous statistical tests were performed, increasing the likelihood of type one 
error outcomes.  Because of the small sample size and a predominant focus on 
integrating measures of participant ‘experience’, it was considered appropriate to not 
adjust the alpha level, balancing the likelihood of type I and type II errors.  
Nevertheless, further supplementary analysis of sleep and daytime functioning outcome 
data, applying the Bonferroni correction within each variable (α / 3 = 0.017), indicates 
that all carried out comparisons remain robust at the adjusted level, except for two 
variables (baseline to post-treatment comparisons for DFSAS part 2 and the SF-36 
vitality dimension).   
 
5.5.6. Concluding remarks 
The present study provides novel data on the implementation and experience of sleep 
restriction therapy for insomnia.  The triangulation of quantitative and qualitative 
methodologies gives considerable credence to the findings.  This data has several 
important implications concerning SRT mechanisms of action, experienced side-effects 
and adverse events, factors impacting adherence and, finally, perceptions of benefit.  
This work underlines the value of using mixed methodologies to explore poorly 
understood and/or under-researched phenomena.  
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Auditory P300 and Neuropsychological Performance in Poor and Normal 
Sleepers: A Controlled Comparative Study 
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6.1. Abstract 
 
Individuals suffering from insomnia typically report daytime difficulties with aspects of 
cognition.  There are however mixed findings concerning the ‘objectivity’ of their 
subjective complaint.  On the whole, previous studies assessing neurocognitive 
variables have recruited small and poorly defined samples, and differed in the range and 
sensitivity of measures used to probe cognition.  To further understand the relationship 
between sleep disturbance and daytime information processing, we compared the largest 
investigated sample to date of poor sleepers (PS; n=58), meeting DSM-IV symptom 
criteria for primary insomnia, with 59 well-matched normal sleepers (NS) on several 
measures of neuropsychological performance and event-related potentials (ERPs) 
during an auditory oddball task.  We found no evidence of performance impairment in 
the PS group, relative to NS, on any domain of the cognitive test battery.  Results from 
the oddball task revealed no differences in terms of P300 amplitude, but the PS group 
had significantly reduced P300 latencies, specifically at Cz and Pz (p<.05).  Taken 
together, our findings point towards increased arousal and/or applied task effort; both of 
which may help maintain behavioural performance on relatively ‘simple’ 
neuropsychological tests.  The field would benefit from directing research efforts 
towards assessing the moderating effects of sleep, arousal, and effort on task 
performance.  The utility of an international standardized database to probe aspects of 
insomnia is also considered.    
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6.2. Introduction 
 
Cognitive impairment features as a potential daytime consequence of insomnia in the 
major sleep disorder classification manuals (i.e. ICSD-2, 2005; DSM-IV-TR, 2000).  
Telephone surveys, qualitative studies, clinician reports, and prospective diary 
investigations, have all documented that individuals with insomnia report deficits in 
different facets of cognition; including memory, concentration, attention, and executive 
functioning (e.g. Roth & Ancoli-Israel, 1999; Carey et al., 2005; Moul et al., 2002; 
Buysse et al., 2007).  These isolated, proximal symptoms may culminate in more 
‘downstream’ consequences, such as impaired work performance (e.g. Erman et al., 
2008; Daley et al., 2009b; Kyle et al., 2008), and increased risk of being involved in 
road traffic accidents (e.g. Leger et al., 2006).    
 
However, studies utilising objective measures of cognitive functioning, typically 
through computerised assessment and traditional neuropsychological testing, are 
inconclusive (Riedel & Lichstein, 2000; Fulda & Schulz, 2001; Orff et al., 2007).  Some 
cognitive models of insomnia have instead explained the subjective-objective 
discrepancy in terms of elevated pre-occupation with sleep, and misattributions and 
monitoring for sleep-related consequences, rather than there actually being any real 
deficit (e.g. Semler & Harvey, 2006; Harvey, 2002).  More recently, however, a meta-
analysis of all studies assessing neuropsychological performance in insomnia, revealed 
small to modest effect sizes for impairments in attention, episodic and working 
memory, and executive functioning domains (Fortier-Brochu et al., 2008).  Such data 
suggest that deficits do exist, but that methodological factors may be obscuring their 
identification.  A recent systematic review of the neurobehavioral literature came to 
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similar conclusions: people with insomnia show performance impairments (more often 
than not) on tasks assessing attention and working memory (Shekleton et al., 2010).   
      
It has been suggested that many of the early studies assessing objective performance in 
insomnia suffered from a number of design limitations, such as small and poorly 
characterised samples, and limited and/or insensitive test batteries (Edinger et al., 
2008a; Shekleton et al., 2010).  Others have also suggested that the absence of deficits 
may be explained by the poor sleeper’s ability to exert ‘compensatory effort’ during 
testing, potentially masking performance decrements (e.g. Bastien et al., 2003; 
Varkevisser et al., 2007; Orff et al., 2007; Espie & Kyle, 2008).        
 
One way to assess alterations in cortical function, in the absence of recorded 
behavioural output, is through the measurement of event-related potentials (ERPs).  
ERPs are small amplitude fluctuations in the scalp-recorded EEG, elicited by either an 
external physical stimulus or an internal psychological event.  ERPs thus provide high 
temporal resolution on the timing of sensory and cognitive processing.  A number of 
positive and negative components have been identified and associated with specific 
brain processes.  For example, early components occurring within 100 ms post-stimulus 
presentation reflect early sensory processing; components peaking at about 100 ms 
relate more to attentional processes (e.g. encoding, selective attention); and later 
components occurring 300-600 milliseconds post-stimulus typically index higher order 
cognitive processing, such as memory updating and detection of semantic deviance 
(Colrain & Campbell, 2007; Banich, 2004).   
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The most studied ERP phenomenon is a late positive component peaking at about 300 
ms (referred to as the P300 or P3b) in response to stimulus change, across a number of 
sensory modalities (Duncan et al., 2009).  P300 is an endogenous component, which is 
typically elicited during discrimination tasks (so-called oddball paradigms), where high 
probability (‘background’) stimuli are interspersed with low probability (‘target’) 
stimuli.  The P300 wave therefore occurs when the subject detects the presence of a rare 
‘target’ tone (in the case of an auditory task).  The memory trace is much less formed 
for such stimuli compared with the frequently presented ‘background’ tones, and thus 
the generated centro-parietal wave is thought to reflect attentional processing and 
hippocampal-mediated updating of working memory (e.g. Linden, 2005; Polich, 2007).  
 
Relatively consistent findings from the sleep deprivation literature reveal decreased 
amplitude and increased latency of the target P300 compared with healthy normal 
sleeping controls (e.g. Lee et al., 2003).  Thus the speed at which the brain evaluates 
and updates the deviant or rare stimulus, and the amount of processing resources 
allocated to carrying out this operation, appears to be compromised under the load of 
sleep deprivation.  Similar alterations have also been reported in sleep apnea patients 
(Rumbach et al., 1991; Sforza & Haba-Rubio, 2006), in healthy subjects during 
continuous sleep restriction protocols (sleep time reduced by one third of habitual total 
sleep time; Cote et al., 2008), and the transition from wake-to-sleep, reflecting changes 
in level of arousal (cf. Colrain & Campbell, 2007, for a review of sleep and ERPs).  It is 
also worth pointing out that P300 abnormalities have been documented in a number of 
psychopathologies; including individuals with depression, schizophrenia, various sub-
types of dementia, traumatic brain injury, and childhood developmental disorders (see 
Duncan et al., 2009, for a clinical review).    
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To the best of the author’s knowledge, there are approximately 11 published ERP 
studies using insomnia samples.  Most have been interested in assessing aspects of 
‘hyperarousal’ at sleep onset, during NREM sleep, on awakening, or during the day; 
predominantly focusing on earlier components of attention and sensory processing 
(Bastien et al., 2008; Yang & Lo, 2007; Regestein et al, 1993; Wang et al., 2001; Milner 
et al., 2009), though not exclusively (e.g. Devoto et al., 2003; Devoto et al., 2005).   
 
This latter work by Devoto and colleagues (2005) is particularly worth mentioning 
because they specifically focused on P300 measurement during an oddball task, 
immediately pre-and post-sleep, in a small number of individuals with primary 
insomnia (n=7) and matched normal sleepers.  The study was carried out over several 
nights permitting distinction between ‘good’ and ‘bad’ nights.  Results indicated 
increased P300 amplitudes in the patient group relative to controls when pre and post 
sleep measurements were averaged for a ‘poor’ night of sleep, supporting earlier pilot 
data based on laboratory recordings the morning after a self-defined ‘poor’ night of 
sleep (Devoto et al., 2003).  The data, overall, were interpreted as evidence for 
increased arousal, present only for poor nights of sleep (i.e. state hyperarousal).  Such 
results conflict with compromised P300 parameters reported in healthy individuals 
during sleep deprivation.   
 
Because oddball performance was measured prior to sleep, and immediately on 
awakening, results may not be relevant to the full daytime period, but instead might 
reflect an acute triggered threat-detection state directly proximal to experiencing, or 
anticipating experiencing, poor sleep.  It is notable that increases in P300 amplitude 
have been reported in patients with anxiety disorders (e.g. Enoch et al., 2008).  
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Moreover, group differences in the Devoto study were only found at electrode site Fz; 
inconsistent with the topographical distribution of the evoked P300.  Instead such a 
finding may be suggestive of a frontal measured P3a, representing inhibition of novel 
stimuli (Colrain, 2005).  This study, therefore, awaits replication.        
 
A small number of studies report on the potentially negative impact of insomnia 
symptoms on daytime cognitive processing.  For example, Anderer and co-workers 
(2003) found significantly delayed latency and decreased amplitude of the P300 in 
postmenopausal woman with insomnia (prior to undergoing hormone replacement 
therapy), relative to healthy postmenopausal controls.  In a secondary analysis, using 
low resolution electromagnetic tomography (LORETA) to localize scalp electrical 
activity, Anderer et al. (2004) reported decreased source strength of standard (N1, P2) 
and target (N2, P300) components.  Similarly, Szelenberger & Niemwicz (2001), again 
using LORETA, found reduced source density during the continuous attention task 
across both early and late attentional components (i.e. P1, N1, N2, P3) in 14 individuals 
with primary insomnia (PIs), with differences particularly pronounced in orbitofrontal, 
medial prefrontal, and anterior cingulate regions.  Moreover, Bruder and colleagues 
(1991) reported, in a group of depressed individuals, significant positive associations 
between P300 latency (during an audiospatial task) and sleep item scores on the 
Hamilton rating scale for depression i.e. longer latencies for those with greater sleep 
disturbance.  In contrast, however, Sforza & Haba-Rubio (2006) found no evidence of 
altered P300 amplitude or latency during pre- and post-sleep recordings, in a well-
screened sample of PIs relative to healthy controls.    
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In summary, this small literature tentatively points to potential information processing 
deficits in those with insomnia, at least at the cortical level.  Importantly though, 
available studies suffer from small and/or diluted groups, and/or the failure to assess 
both ERPs and neuropsychological variables within the same sample.  In collaboration 
with the Brain Resource International Database (BRID) the present study sought to (1) 
better understand the impact of sleep disturbance on information processing by 
comparing a relatively large sample of poor sleepers (meeting putative symptom criteria 
for DSM-IV Primary Insomnia) with a well-matched group of normal sleepers; and (2) 
as a by-product of this approach, consider the merits of a standardized database to probe 
specifics aspects of insomnia.  Group differences were investigated on behavioural 
measures assessing a number of neuropsychological variables, as well as latency and 
amplitude of the late P300 component during an auditory oddball paradigm.   
 
Based on the mixed and small literature this study was necessarily exploratory in nature, 
but we hypothesized a number of possible outcomes: (1) poor sleepers would show 
impairment on both neuropsychological tests and the P300 component; (2) poor sleepers 
would not show overt performance deficits but would have impaired measures of P300 
amplitude and latency; (3) poor sleepers would not display neuropsychological 
impairment and have P300 markers suggestive of ‘arousal’ (i.e. increased amplitude 
and/or decreased latency); and finally (4) there would be no alterations on any 
neurocognitive dependent measure between poor and normal sleepers.                     
 
 
 
 
 
 
 239 
6.3. Method 
6.3.1. Participants 
We identified 58 participants from the normative BRID, meeting our defined criteria for 
poor sleeper (PS).  The BRID is an international collaborative effort which uses 
standard uniform brain and behavioural measurements, and exclusion/inclusion criteria, 
across approximately fifty different labs (Gordon, 2003; Gordon et al., 2005).  BRID 
represents an integrative neuroscience platform, collecting data using a number of 
methods, including: self-report questionnaires, quantitative EEG, ERPs, fMRI, and 
genetic swab analysis.  The normative healthy dataset currently has over 2000 
participants, all of whom have undergone a standard thorough protocol, and have been 
excluded for major medical, psychiatric, neurological, and substance abuse disorders.  
Specifically, exclusion criteria are determined using BRID personal history and 
screening instruments, which include the Somatic and Psychological Health Report 
questionnaire (SPHERE-12; Hickie et al., 1998) and the Patient Health Questionnaire 
(PHQ-9; Kroenke et al., 2001), as well as additional items to assess medical and 
psychiatric history.  All participants give informed consent to have their (anonymised) 
data uploaded to a centralised database. 
 
As part of the screening/informational procedure, participants complete a basic (non-
validated) sleep questionnaire (see Appendix M).  To be included in our PS group, 
participants had to indicate that they experienced difficulties ‘initiating’ and/or 
‘maintaining’ sleep at least 3-4 times per week in the last month.  Participants were also 
required to respond below a certain criterion (1-2 times per week, or less) on 
questionnaire items assessing symptoms of sleep-disordered breathing and restless legs 
syndrome.  Thus, participants met symptom criteria for DSM-IV primary insomnia, free 
from psychiatric and medical co-morbidities.  None of the sample reported taking sleep-
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promoting hypnotics.  Our matched normal sleepers (NS; n=59) reported no difficulty 
with sleep initiation, maintenance, or sleepiness during the day.  For each poor sleeper, 
a normal sleeper was selected and matched, as much as possible, in terms of age, 
gender, and years of education.    
     
6.3.2. Materials & Procedure 
6.3.2.1. Neuropsychological assessment 
All participants within the BRID complete the touch screen IntegNeuro™ test battery, 
assessing performance in a number of cognitive functions – including sensori-motor, 
memory, attention, executive functioning, and language domains.  Subjects complete 
ten tasks in a sound attenuated room, taking a total of ~50 minutes.  Tests are 
administered using pre-recorded, automated task instructions (.wav files via 
headphones).  An IBM touchscreen records participant responses and .wav files record 
spoken answers in tasks requiring a verbal response.  The battery has been validated 
against more traditionally used measures of neuropsychological functioning, revealing 
highly significant correlations (Paul et al., 2005). 
   
Immediately prior to testing, participants complete information pertaining to basic 
demographics, and also record their sleep duration for the previous night.  As part of the 
screening procedure, data are also recorded on depression, anxiety and stress, using the 
depression, anxiety, and stress scales (DASS; Lovibond & Lovibond, 1995).  We 
selected four broad domains for analysis that have some support in the existing 
literature for being impaired in those with insomnia: attention and motor speed, verbal 
fluency, executive functioning, and verbal learning and memory functioning (see table 
6.1 for a description of tests used).    
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Table 6.1 – IntegNeuro standard neuropsychological test descriptions (taken and modified from Paul et al., 2006). 
Test Description
Choice Reaction Time
One of four circles was illuminated on the screen. Immediately following presentation, the subject is required to touch the 
illuminated circle as quickly as possible. Twenty trials were administered with a random delay between trials of 2–4 
seconds. The dependent variable was the mean reaction time (ms) across trials.
Sustained Attention/Working 
Memory
A series of letters (B, C, D or G) were presented to the subject, one-by-one, on the computer screen (for 200 
milliseconds), separated by an interval of 2.5 seconds. If the same letter appeared twice in a row (target letters), the 
subject was asked to press buttons with the index finger of each hand. Speed and accuracy of response were equally 
stressed in the task instructions. There were 125 stimuli presented in total, 85 being non-target letters and 20 being 
target letters. The dependent variable was mean reaction time (ms) to target stimuli and number of errors.
Executive Maze
The subject was presented with a grid (8 × 8 matrix) of red circles on the computer screen. The object of the task was to 
identify the hidden path through the grid, from the beginning point at the bottom of the grid to the end point at the top. 
The subject navigates around the grid by pressing arrow keys on the touchscreen interface. The subject was presented 
with one tone (and a red cross at the bottom of the screen) if they made an incorrect move, and a different tone (and a 
green tick at the bottom of the screen) if they made a correct move. The purpose of the task was therefore to assess how 
quickly the subject learned the route through the maze and their ability to remember that route. The trial ended when the 
subject completed the maze twice without error or after 10 minutes had elapsed.  Dependent variables were time to 
complete full maze for the first time (secs) and number of trials in total to complete the task (maze completion twice 
without errors).
Stroop Task
Participants were presented with colour words printed in incongruent ink and they were required to name the colour of 
the ink rather than read the word.  In a second part participants were this time asked to name the word and ignore the 
background colour. Total number of correct trials was the dependent variable for both parts.
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(table 6.1 continued) 
Switching of Attention
This modified version of the Trail Making Test consisted of two parts. The first required the connecting of numbers in 
ascending sequence (1-2-3- etc). On the first test (switching of attention 1), 25 numbers, in circles, were placed on the 
touchscreen and the subject was instructed to press them in the correct order. This tests the basic ability to hold 
attention on a simple task. The second test (switching of attention 2) required the connecting of numbers and letters in 
an ascending but alternating sequence (1-A-2-B etc.). The numbers 1–13 and the letters A–L were presented in circles 
on the touch-screen.  Dependent variables of interest were time taken to complete both parts 1 and 2.
Verbal Fluency
Subjects were required to generate words beginning with the letters F, A, and S. Sixty seconds were allotted for each 
letter and proper nouns were not allowed. The total number of correct words generated across the three trials was the 
dependent measure.  In a second related test animal word generation was assessed by asking subjects to name as 
many animals as possible within sixty seconds.  Total number of animals generated was the dependent measure.
Verbal Learning and Memory
Participants were read a list of 12 words, which they were asked to memorize. The list contained 12 words from the 
English language. Words were closely matched on concreteness, number of letters and frequency. The list was 
presented four times in total and the subject was required to recall as many words as possible after each presentation. 
The subject was then presented with a list of distractor words and asked to recall them. The subject was then asked to 
recall the 12 words from the original list. The dependent variable was the number of words correctly recalled across the 
four learning trials, learning rate over the trials, number of intrusions, words recalled from the distractor list, and short 
and long-term delay recall.
Digit Span
Subjects were presented with a series of digits (for example, 4,2,7…) presented individually for 500 ms and separated by 
a one second interval. The subject was then immediately asked to enter the digits on a numeric keypad on the touch-
screen, either in forward order or backwards (reverse digit span task). The number of digits in each sequence was 
gradually increased from 3 to 9. The dependent measure was the maximum number of digits the subject recalled 
(forward and backwards) without error.
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6.3.2.2. Oddball task 
The oddball task is completed as part of the LabNeuro test battery.  In the auditory 
oddball task, participants are presented binaurally, via headphones, with a series of high 
and low tones, at 75 dB, and lasting for 50ms, with an inter-stimulus interval (ISI) of 1 
second. Rise and fall times of the tones was 5 ms.  Participants were instructed to press 
designated buttons with the index finger of each hand in response to ‘target’ tones 
(presented at 1000 Hz).  They were asked not to respond to ‘background’ tones 
(presented at 500 Hz).  The task took place in a sound, temperature and light controlled 
room.  Participants were given a brief practice session to clarify the distinction between 
target and background stimuli.  Speed and accuracy were stressed equally in the task 
instructions.  There were 280 background and 60 target tones presented in a quasi-
random order, with the only constraint being that two targets could not appear 
consecutively.  Duration of task was six minutes and reliability of the task, similar to the 
neurocognitive test battery, has been documented (Williams et al., 2005).    
     
6.3.2.3. EEG/ERP acquisition 
A QuickCap (Neuroscan) was used to acquire EEG data from electrode sites according 
to the 10-10 international system.  Data were recorded relative to the average of A1 and 
A2 (mastoid) electrode sites.  EEG data were screened visually for artefacts, normal 
variants and changes in alertness.  For the oddball task, ERP data were extracted from 
EEG recordings. Conventional ERP averages were formed at each recording site in 
relation to each target stimulus.     
 
All target stimuli with a correct button response (only) were included in the target 
average.  Before averaging, each single-trial waveform was filtered at 25Hz with a 
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tukey (cosine) taper to 35Hz, above which frequency no signal was passed.  For the 
target stimuli waveforms, the peak (amplitude and latency) of the P300 component was 
identified (relative to a pre-stimulus baseline average of -300 to 0 milliseconds) at each 
site.  ERPs were scored using an automated algorithm, which were then validated by 
experienced scorers.  The algorithm uses pre-determined latency windows as a guide to 
determining component peaks; specifically, 270-550 ms post-stimulus for the P300 
component (e.g. Williams et al., 2000).  Between group effects were assessed in terms 
of latency (msec) and amplitude (µV) of the target P300 at electrode sites Fz, Cz, and 
Pz (elicited P300 is maximal over midline scalp sites; Duncan et al, 2009).  We also 
extracted behavioural responses (button press) for each participant, in terms of average 
reaction time (RT) to target stimuli.   
 
6.3.2.4. Analyses 
Student t tests and non-parametric equivalents were used to compare groups on 
demographic variables of interest, including age, education, sleep duration, stress, 
depression, and anxiety.  Gender distributions were assessed using a 2x2 chi-square test. 
   
Dependent variables were screened for extreme outliers and assessed for normality 
using histograms.  Extreme outliers (>3 SD above the mean) were replaced with the 
respective group mean, and logarithmic transformations performed to correct skewed 
distributions.  Replaced outliers made up less than 5% of data points for any single 
dependent variable.  
 
The four domains from the neuropsychological test battery were investigated separately 
using one-way (between-groups) MANOVA models.  Given the small amount of 
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published work investigating P300 parameters in insomnia, univariate analyses were 
conducted at each midline electrode site (Fz, Cz, Pz) for both amplitude and latency.  To 
balance likelihood of type I and II errors, the Bonferroni correction method was applied 
within each domain (i.e. α =.05/3 = .017).  Effect sizes (Cohen’s d; Cohen, 1988) were 
also calculated.  Behavioural reaction time (RT) data for target stimuli were assessed 
using univariate ANOVA.   
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6.4. Results 
6.4.1. Participant characteristics 
As expected, poor and normal sleepers had practically identical mean age, years of 
education, and gender distributions (all non-significant; see table 6.2).  PS reported 
significantly less sleep duration for the night prior to testing, relative to the control 
group of normal sleepers [t(115) = -3.98, p<.001], and significantly greater scores for 
depression [U = 1301, z = -2.30, p<.05], stress [U = 1129, z = -3.22, p<.01] and anxiety 
[U = 1363, z = -2.05, p<.05] scales of the DASS (see table 6.2).  These small but 
reliable differences emerged despite subjects within the ‘normal’ database scoring well 
below clinical cut-offs.     
 
Table 6.2 - Participant demographics. Presented are group means and standard deviations (in 
parentheses). N.B. Median scores are presented for depression, anxiety and stress (DASS) scales, with the 
accompanying interquartile range in parentheses.  
PS (n=58) NS (n=59)
Age (SD) 38.0 (14.1) 38.3 (14.2)
Gender 41 female/17 male 42 female/17 male
Education (yrs) 14.0 (3.0) 14.4 (2.6)
Sleep Duration (hrs) ***6.2 (1.4) 7.2 (1.2)
 Depression *2.00 (0-3) 1.00 (0-2)
 Anxiety *1.00 (0-2) 0.00 (0-1)
Stress **3.00 (2-5) 1.00 (0-4)
***p <.001, **p <.01, *p <.05
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6.4.2. Neuropsychological testing 
MANOVA did not reveal any group differences (or trends) for the domains of verbal 
fluency [F(2, 107) =.574, p=.565; Wilks’ Lambda =.99; partial eta squared =.01],  
attention and motor speed [F(7, 94) =1.40, p=.214; Wilks’ Lambda =.91; partial eta 
squared =.09], verbal learning and memory [F(6, 51) = 1.06, p=.401; Wilks’ Lambda 
=.89; partial eta squared =.11] or executive functioning [F(4, 100) = 1.37, p=.248; 
Wilks’ Lambda =.948; partial eta squared =.05].  Thus, no group differences in 
performance were present on any test of the battery (see table 6.3 for group means and 
standard deviations for each test).  
   
Table 6.3 - Mean (not transformed) scores (SD) for neuropsychological tests for poor sleepers (PS) and 
normal sleepers (NS). 
PS NS
Verbal Fluency
                               Animal (words) 23.4 (6.9) 22.2 (5.3)
                                   FAS (words) 15.2 (4.7) 14.5 (3.7)
Attention & Motor Speed
                             Choice RT (ms) 705.4 (90.7) 691.8 (91.5)
Sustained att. (no. errors) 1.26 (1.6) 1.86 (1.7)
                                 Sustained att.(ms) 474.6 (86.5) 506.8 (89.2)
          Switching att. (numbers; secs) 19.5 (5.3) 20.8 (4.4)
          Switching att. (mixed; secs) 46.6 (15.8) 48.0 (15.9)
                         Digit span (words) 6.2 (1.4) 6.4 (1.3)
           Reverse digit span (words) 4.9 (1.4) 4.8 (1.4) 
Executive functioning
                    Stroop Word  (no. correct) 18.6 (2.3) 18.4 (3.4)
                   Stroop Colour (no. correct)  11.7 (3.8) 11.8 (4.5)
   Total no. of trials to complete maze 9.0 (4.1) 9.0 (3.9)
Maze completion time (first time; secs.) 213.5 (155) 184.4 (115)
Verbal Learning and Memory
             Memory recall (trials 1-4) 33.1 (5.3) 33.1 (4.6)
                              Learning rate 0.99 (0.55) 1.24 (0.48)
            Number of intrusions (1-4) 1.40 (1.7) 1.16 (1.4)
         Distracter list (no. of words) 4.8 (1.8) 5.1 (1.4)
Delayed recall (short delay; words) 8.3 (2.5) 7.9 (1.9)
Delayed recall (long delay; words) 7.9 (2.6) 7.7 (2.5)
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6.4.3. Oddball task (ERPs) 
One hundred and ten of the original 117 participants completed the auditory oddball 
task (54 poor sleepers, 56 normal sleepers).  In terms of P300 amplitude (see table 6.4), 
no group differences were present at site Fz [F(1, 104) =.739, p=.375; Cohen’s d=0.11], 
Cz [F(1, 101) =.312, p=.578; Cohen’s d=0.12], or Pz [F(1,103) =.244, p=.623; Cohen’s 
d=0.10].  For P300 latency, univariate analyses at each electrode site revealed that 
latencies were significantly reduced in PS compared with NS at Cz [F(1, 101) =6.53, 
p=.012; Cohen’s d= 0.50] and Pz [F(1, 103) =5.52, p=.021; Cohen’s d=0.46], though 
not Fz [F(1, 104) = 2.16, p= .144; Cohen’s d=0.29].  Thus, after Bonferroni correction, 
latency group differences remained statistically significant at electrode site Cz (see table 
6.4 and figure 6.1). 
 
 
Table 6.4 - Mean P300 amplitude and latency for both groups at each midline electrode site. 
PS NS
Amplitude (µV)
Fz 8.7 (7.4) 7.5 (6.4)
Cz 9.2 (8.4) 8.3 (7.7)
Pz 14.3 (7.5) 13.6 (6.7)
Latency (msec.)
Fz 335.9 (24.6) 343.0 (24.7)
Cz 334.0*a (28.6) 347.8 (26.5)
Pz 346.0* (24.5) 357.0 (23.5)
* sig. at p <.05
a
 sig. after Bonferroni adjustment
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Figure 6.1 - P300 latencies (mean plus standard error) for poor and normal sleepers. 
P300 latency
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There were no differences in terms of behavioural reaction time (button press to target 
tones) between the two groups [F(1, 107) = .343, p=.559; Cohen’s d= 0.11]: poor 
sleepers M=335.2, SD=41.0); and normal sleepers M=339.7, SD=40.6. 
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6.5. Discussion 
We found no direct evidence of neuropsychological impairment across several cognitive 
domains in poor sleepers meeting DSM-IV symptom criteria for primary insomnia 
using a battery of standardised tests.  This parallels a number of studies that have failed 
to find objective evidence to corroborate the typical subjective daytime complaint of 
cognitive dysfunction in insomnia (e.g. Orff et al., 2007; Varkevisser et al., 2007; 
Omvik et al., 2008; Riedel & Lichstein, 2000; Fulda & Schulz, 2001).  Our poor 
sleepers did not differ from normal sleepers on domains of attention and motor speed, 
verbal fluency, executive functioning, or verbal learning and memory.  
 
Such data may accord with recently published work indicating that impairments in 
performance, in complaining patients, only become apparent in ‘complex’ load-
intensive tasks, invoking a series of parallel cognitive processes (e.g. Edinger et al., 
2008a; Altena et al., 2008a).  In more ‘basic’ tasks, like the ones used in the present 
study, the poor sleeper may be able to mobilise adequate compensatory effort to mask 
performance decrements.  The ability to compensate for the effects of sleep loss on task 
performance during sleep deprivation studies has been relatively well described at the 
neural level.  Although contingent on task type, a compensatory system which involves 
stronger activation and/or additional recruitment of regions in the prefrontal cortex and 
parietal lobes may assist in maintenance of performance (e.g. Drummond et al., 2000; 
Drummond et al., 2004).  Although preliminary, recent work also indicates that similar 
neural compensation may occur in insomnia. PI patients were shown to demonstrate 
increased cerebral activation in task-specific neural networks, including the right middle 
frontal gyrus, relative to normal sleepers during a working memory (n-back) task, 
despite no evidence of overt performance impairment (Orff et al., 2009).   
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In terms of the oddball task, there were no group differences in P300 amplitude.  
Interestingly though, we did find a significant group effect for peak latency; with the PS 
group evidencing reduced latencies at sites Cz and Pz (the typical scalp distribution for 
the P300 component).  Although latency differences were small, they are similar in 
magnitude to differences recently reported between patients with major depression and 
healthy controls - though in the opposite direction - from the very same database (Kemp 
et al., 2009).  Indeed, effect sizes (d) were found to be in the moderate range for Pz and 
Cz.  There was, therefore, no evidence of a slowing or reduction in brain processing 
capacity during (context) updating of rare tones, as has been reported in the sleep 
restriction literature (e.g. Cote et al., 2008) and in previous studies recruiting patients 
with insomnia symptomatology (e.g. Anderer et al., 2003, 2004; Bruder et al., 1991).  
Instead, the pattern of data may be explained by at least two possible mechanisms, 
which could also help understand neuropsychological performance.  
 
6.5.1. Arousal 
Firstly, reduced latencies may indicate increased levels of ‘arousal’, or ‘arousability’, 
within the sample of poor sleepers.  This would be in line with a number of studies 
(using active and passive oddball paradigms) that report increased levels of cortical 
arousal across both early (Bastien et al., 2008; Milner et al., 2009; Regestein et al., 
1993) and late ERP components (e.g. Devoto et al., 2003, 2005) - typically reflected in 
increased amplitude.  This is the first study to suggest a reduction in P300 peak latency.  
Although often negatively related, P300 amplitude and latency may be differentially 
affected by aspects of arousal.  For example, increased heart rate and body temperature 
in healthy individuals is associated with shortened latencies, but not increased 
amplitude (for a review see Polich & Kok, 1995).  This is particularly relevant to 
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insomnia as both heart rate and body temperature have been reported to be increased in 
patients compared with normal sleepers (for a review see Bonnet & Arand, 2010).  
Although speculative, alterations to these physiological parameters may have 
contributed to a shortening of P300 latency in the present sample.  The P300 finding 
may, therefore, reflect ‘hyperarousal’ in both autonomic and central nervous systems - 
consistent with contemporary perspectives on insomnia (Riemann et al., 2010).  The 
inability to document altered P300 amplitudes, as reported by Devoto and colleagues 
(2003, 2005), may relate to differences in sample characteristics concerning measures of 
arousal.  It should also be mentioned that Devoto et al. (2003, 2005) only found group 
differences for the ‘worst’ night of sleep.  We were unable to ascertain from this sample 
of individuals whether sleep the night before testing was considered ‘poor’ quality.       
 
Nevertheless, and although requiring replication, our P300 finding tentatively supports 
the notion that documented hyperarousal and enhanced sensory processing at sleep-
onset and during NREM sleep (e.g. Nofzinger et al., 2004; Perlis et al., 2001b; Milner et 
al., 2009; Bastien et al., 2008), may extend right across the 24-hour period.  
Interestingly, anxiety disorder patients, who are typically considered to be 
dysfunctionally aroused, also demonstrate increased P300 amplitudes and reduced 
latencies (Enoch et al., 2008; Hanatani et al., 2005).  Indeed, in the former of these 
studies, greater P300 amplitudes were associated with enhanced performance on a digit 
symbol task assessing attention and working memory (though only for anxious patients; 
Enoch et al., 2008).  Alternatively, it might be that reduced P300 latencies, indicative of 
speed of stimulus evaluation, and perhaps a reflection of arousal, may help to maintain 
performance in those with insomnia in certain controlled tasks.  Related to this, elevated 
‘arousal’ has been proposed, in a recent study, as the explanation for why complaining 
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PI patients performed significantly faster (RT) on a simple test of vigilance (Altena et 
al., 2008a), and showed impairments only in tasks demanding greater cognitive load, 
compared with good sleepers.  This apparent ‘inverted U’ performance curve, where 
hyperarousal may be facilitatory on some tasks, and obstructive when cognitive load is 
manipulated in a systematic fashion, could lead to a masking of any obvious impairment 
during tests typically sensitive to sleep loss (Horne, 2010). 
 
Reduced whole brain gamma-aminobutyric acid (GABA) levels in PIs (Winkelman et 
al., 2008), though speculative and requiring further investigation, may lead to attenuated 
inhibitory action on aspects of alertness, emotional reactivity, and ultimately cognitive 
functioning.  In relation to possible GABA abnormalities, it is notable that stimulation 
of GABAergic receptors in healthy controls, through the administration of GABAA 
receptor agonists (e.g. barbiturates, benzodiazepines), leads to an attenuation of P300 
amplitude (Watson et al., 2008), and a lengthening of latency (Fowler & Mitchell, 
1997).  This, of course, reflects a general dampening of cortical information processing; 
conversely, therefore, enhanced cortical arousal may lead to, and be reflected by, a 
shortening of latencies.  To fully conclude an increased cortical arousal account, with 
respect to evoked potentials, earlier components of attention (N1, P2) to both target and 
non-target stimuli will require to be recorded several times throughout the course of the 
day in patients with PI. 
 
6.5.2. Effort 
A second plausible explanation is that reduced P300 target latencies may be a marker of 
increased effort or motivation.  Recent work in sleep deprivation provides some support 
for this account.  Hsieh and colleagues (in press) sleep deprived 24 healthy volunteers 
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and randomised half to receive monetary incentives for improved accuracy on a 
modified flanker task.  After each trial, points would appear on the screen conveying to 
participants how well they had performed.  Participants were told that total number of 
obtained points would be converted into currency.  P300 was recorded during the 
Flanker task.  Two important findings emerged.  It was found that subjective effort level 
decreased in the group with sleep deprivation plus ‘no incentives’, relative to when the 
same group completed the task after a regular night of sleep.  Conversely, there was no 
recorded decrement (sleep deprived versus rested) in subjective effort in the sleep 
deprived plus ‘incentives’ group.  Thus the usual decrease in subject effort induced by 
sleep deprivation was attenuated with the provision of incentives.  Importantly, P300 
latencies were also found to be significantly reduced in those who were offered 
monetary rewards (compared to the ‘no incentives group’), suggesting that the effects of 
sleep deprivation on attentional processes involving stimulus categorization and 
evaluation can be attenuated by the deployment of effort/motivation.  
 
Additional evidence for the effects of motivation on P300 parameters comes from work 
by Carrillo-de-la-Pena & Cadaveira (2000).  In this study, healthy participants 
completed the auditory oddball task (similar to the present study) twice.  Directly after 
run 1, participants were instructed to do as well as they could in a next subsequent run.  
They were also told that their results would be compared with their peer group 
(classmates).  Motivational instructions resulted in an increase in amplitude and a trend 
towards decreased P300 latency.  A repeat of the study one year later in the same 
subjects (without motivational instructions) ruled out a simple repetition explanation for 
the findings.  It is possible, however, that motivational instructions concerning peer 
comparison may have induced anxiety-arousal responses, subsequently modifying P300 
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parameters.  Nevertheless, in light of this work, combined with evidence from sleep 
deprivation, and preliminary neural compensation imaging data in insomnia patients 
(Orff et al., 2009), reduced latencies in the present study may indicate that participants 
are ‘working harder’ to try to maintain performance.  From previous qualitative work by 
our group (Kyle et al., in press) it is clear that patients with primary insomnia report 
deploying more effort to complete daily tasks; whether or not this translates to 
controlled performance testing and notable modifications to ERP parameters, remains 
unclear.  No subjective measure of effort was included in the present study but future 
research should consider investigating both subjective and objective markers of 
cognitive effort during testing as well as naturalistic conditions.  
 
6.5.3. Limitations 
Conversely, a general inability to observe deficits in the poor sleeper group may also 
relate to several intrinsic limitations of the study.  Although the selected poor sleepers 
met questionnaire criteria for insomnia symptoms, we cannot be sure they have a self-
defined ‘problem’ with sleeping (i.e. have a clinical complaint).  Furthermore, we do 
not, for example, have data on duration of sleep disturbance (beyond a minimum of one 
month) or self-reported daytime impairment attributed to significant sleep disturbance.  
Importantly, however, mean age, gender bias towards females, reduced prior night sleep 
duration, and significantly increased scores – despite an enforced ceiling for clinical 
cut-offs – on depression, stress and anxiety scales, all mirror the characteristics of a 
primary insomnia sample (e.g. Orff et al., 2007; Morin et al., 2003).    
 
Concerning severity of insomnia, it is worth mentioning that a recent study (Fernandez-
Mendoza et al., in press), assessing the largest number of insomnia patients to date (n= 
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116; duration ≥1 year), failed to find evidence for impairment across a number of 
domains (attention, visual memory, word fluency, psychomotor speed) compared with 
normal sleepers (n=562).  The strength of this study, however, was that all participants 
underwent PSG recording, allowing further sub-grouping.  Four groups were evaluated 
in terms of performance: insomnia patients with normal objective sleep duration (≥6 
hours; n=65); insomnia patients with < 6 hours objective sleep duration (n=51); normal 
sleepers with ≥ 6 hours of sleep duration (n=343); and finally normal sleepers with < 6 
hours sleep duration (n=219).  The comparison between objectively ‘short sleeping’ 
insomnia patients, normal sleeping healthy controls, and short sleeping healthy controls, 
revealed impairments in insomnia patients (compared with both groups) in processing 
speed, set-switching attention, and short-term visual memory.  It might be, therefore, 
that objective impairment is most pronounced in (objectively) short sleeping individuals 
with insomnia (see, also, Edinger et al., 2008a), though this remains to be documented 
at the subjective level.  The sample investigated in the present study, similar to many 
other studies assessing performance in insomnia, may have included a heterogeneous 
group in terms of ‘severity’, preventing documentation of ‘true’ performance deficits. 
   
Another major limitation of the present study is that we cannot be sure that time of 
testing was similar for all participants, and therefore circadian effects in terms of 
alterations to vigilance and alertness, may have confounded both neuropsychological 
(Schmidt et al., 2007) and ERP (Polich & Kok, 1995) findings.  Finally, our ‘bottom-
up’ statistical approach, using univariate analyses to assess ERP parameters, may be 
considered liberal.  Given the small literature in this field, it was thought best to take a 
pragmatic view to balancing type I and II errors.  However, applying the Bonferroni 
correction and calculating effect size magnitude, while still not the most conservative 
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approach, minimises the opportunity for misleading conclusions.  It should also be 
noted that adjusting the alpha level within both amplitude and latency variables 
separately, as compared with adjusting across the six comparisons, may potentially 
contribute to an increased likelihood of type I error outcomes.  This latter more 
conservative approach, however, also increases the likelihood of type II error 
conclusions (Perneger, 1998), and hence adjusting within the variables separately was 
considered the most reasonable approach.  
 
6.5.4. The role of a standardized database in insomnia research 
This is the largest investigated sample in terms of ERPs and primary insomnia 
symptomatology.  The standardization of methods and inclusion/exclusion criteria 
across several international labs made it possible to select large and extremely well-
characterised and matched samples, thus minimizing the influence of extraneous 
variables on task performance.  In spite of these obvious benefits, the present study 
lacks specificity to insomnia because the database was not set up to investigate sleep 
disturbance.  It is however worth reflecting, briefly, on the benefits of such a method 
and how it could be applied to insomnia research. 
 
The insomnia field has struggled for years to compare results of investigations because 
of poor characterisation of patients and reporting of statistics, as well as heterogeneity 
of measures used to assess and monitor outcomes.  Recent expert consensus work 
groups have tried to overcome some of these issues with the creation and publication of 
standard research diagnostic criteria and assessment procedures (Edinger et al., 2004; 
Buysse et al., 2006).  It may be worthwhile going one step further, to create a system 
where data is collected by participating labs using existing standard assessment 
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procedures and dependent measures, as well as additional uniformly agreed 
instruments/protocols.   
 
The ability to investigate a large number of individuals with insomnia, who have 
undergone a standard protocol, may prove important in confirming existing hypotheses 
concerning insomnia mechanisms and treatment, but also elicit new insights and 
discoveries.  Some potential topics, out of many, that may benefit from such a database 
approach include: a better understanding of insomnia sub-types, their pathogenic 
features and responsiveness to different treatment modalities; prospective monitoring of 
insomnia as a risk factor for psychopathology and medical co-morbidity; consequences 
of insomnia in terms of integrated measures of brain structure, function and behaviour; 
how treatment modifies associated morbidity of insomnia; candidate genes linked to 
insomnia susceptibility, or specific sub-types of insomnia; and finally, powerful 
psychometric assessment of existing and newly developed insomnia scales and 
instruments.  Concerning this latter point on psychometrics, it is worth mentioning that 
a recent multi-lab collaboration gathered and compared (retrospective) data on the 
Dysfunctional Beliefs and Attitudes about Sleep (DBAS; Morin et al., 2007) scale, on 
over 1000 patients with various sub-types of insomnia disorder (Carney et al., 2010).  A 
prospective standardised approach to data collection would ensure greater comparability 
among participating labs, bolstering the power to address many important questions 
surrounding pathogenic features involved in insomnia.     
 
6.5.5. Future directions and concluding remarks    
Given the heterogeneity of daytime (and night-time) symptoms in insomnia, particularly 
hyperarousal versus hypoarousal, research should further delineate the mediating roles 
 259 
of both effort and arousal (and their interaction) in explaining task performance.  
Multiple ERP recordings/paradigms and cognitive assessments across nights, pre-and 
post sleep (e.g. Bastien et al., 2008; Devoto et al., 2005; Sforza, & Haba-Rubio, 2006; 
Turcotte & Bastien, 2009), and at several time-points throughout the day (Varkevisser 
& Kerkhof, 2005), will further aid in elucidating relationships between sleep quality, 
arousal, and daytime performance.      
 
Tasks found to be sensitive to insomnia impairment in recent studies, particularly those 
tapping, and challenging, attentional and executive functioning systems (Edinger et al., 
2008a; Fernandez-Mendoza et al, in press; Altena et al., 2008a), should be used in 
future studies, including intervention research, to confirm sensitivity and possible 
predictor variables of change.  Individual variability in terms of susceptibility and 
resilience to the effects of sleep loss should also be investigated in future work (so-
called ‘trototypes’; Van Dongen et al., 2005).  The collection of stress system markers, 
such as cortisol (Lee et al., 2007), prior to and during testing, may also help in 
understanding moderators of cognitive performance in those with insomnia.  Finally, 
greater attention should be paid to the clinical complaints of patients: do current 
neuropsychological tests adequately capture the subjective self-report?  A recent study 
using ethnographic observational methods, at home and in the work-place, suggests that 
many of the problems patients report are not covered by common testing procedures 
(Fox et al., 2007).  It would seem important, therefore, to also consider how laboratory 
tests can better approximate ‘real-world’ functioning (e.g. Leufkens et al., 2009).        
 
In sum, the current study did not reveal any evidence of cognitive impairment in a large 
sample of poor sleepers meeting PI symptom criteria, relative to normal sleepers.  P300 
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latencies were however significantly reduced in the PS group, specifically at electrode 
site Cz.  Our data may be interpreted as evidence for daytime cortical hyperarousal, 
and/or applied task effort, both of which may help to maintain cognitive performance 
and behavioural output during simple tasks designed to reveal gross brain abnormalities.  
Research groups should consider the merits of creating a large standardized database to 
further probe specific aspects of insomnia, particularly neurocognitive phenomena. 
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7.1. Thesis findings: a synthesis  
 
This thesis set out to explore daytime functioning and quality of life in individuals with 
chronic insomnia, from a number of different perspectives.  Historical neglect of 
investigating, and measuring, insomnia-related functioning has been commented on by 
leading researchers in the field (e.g. Buysse et al., 2006; Morin, 2003; Riemann & 
Perlis, 2009).  The body of work presented here attempts to further research and 
understanding in this important area; specifically through the application of several 
methodological approaches, employed across a number of different ‘experiential’ levels.     
 
Table 7.1 - Key findings from thesis. 
Chapter Key Findings & Insights
2 Review and clarification of issues relevant to HRQoL measurement in insomnia
Outlining of extensive research agenda and parameters to help standardise reporting of 
HRQoL scores
3 In-depth description of the limiting nature of insomnia
First use of audio-diaries with insomnia patients
Novel insights into aspects of insomnia illness experience
4
Development of two new scales to assess insomnia-related daytime functioning and 
quality of life impairment
Preliminary demonstration of good psychometric properties and treatment responsiveness
Consideration of alternative approaches to understanding and measuring impairment in 
insomnia patients
5 First application of qualitative methods to assess experiences of CBT-I
First comprehensive documentation of CBT-I side-effects
Effectiveness of brief behavioural intervention on both functioning and sleep  
Shed light on possible mechanisms of SRT and barriers to adherence in real time 
6 Largest investigated sample in terms of ERPs and insomnia symptomatology
First report of reduced P300 latencies in poor sleepers compared with normal sleepers
Consideration of a database method that may help standardise insomnia assessment
 
Table 7.1 details the key findings from each chapter.  The utilization of novel 
methodologies, even within each study, generated new insights surrounding, in 
particular, the impact of chronically disturbed sleep; development of alternative 
approaches to measuring functional impact; how daytime functioning and sleep 
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quality/perceptions fluctuate over the course of behavioural treatment; and how patterns 
of objective neuropsychological performance may be influenced and explained by 
moderating factors.  Furthermore, additional important findings emerged from this 
work, specifically concerning: general aspects of the insomnia illness experience; 
implementation of, and adherence to sleep restriction therapy for insomnia; and newly 
identified pathways associated with treatment response. 
 
Results from each chapter informed and complemented subsequent data collection.  For 
example, reviewing the insomnia-HRQoL literature revealed several inadequacies with 
current approaches to defining, measuring, and framing HRQoL, as applied to 
individuals with insomnia.  To fundamentally gauge important daytime issues relevant 
to insomnia patients, focus-groups and audio-diaries were combined in a further study.  
Transcripts and phenomenological analysis then helped shape and guide novel scale 
development - recruiting features of both traditional nomothetic assessment and 
idiographic patient-centred measurement.   
 
Given the insights obtained from the early phenomenological study (chapter three), 
qualitative techniques - audio-diaries and semi-structured interviews - were again 
utilized to probe the patient experience of sleep restriction therapy for insomnia.  The 
newly created scales were also assessed for responsiveness in this study, providing 
methodological triangulation alongside sleep-related assessments, prospective 
qualitative diaries, and post-treatment interviews.  Staying within the broad domain of 
daytime functioning, a next step was to investigate neuropsychological performance and 
P300 parameters in poor and normal sleepers.  Earlier qualitative research from chapter 
three complemented this work: helping to formulate hypotheses that may possibly 
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explain neuropsychological and ERP findings.  Finally, the database approach 
uncovered in this last experimental chapter may have particular relevance to the 
insomnia field; providing a method to collect data in a standardized manner across the 
various ‘levels’ of brain and behavioural measurement.  Such a database approach may 
not only help further our understanding of insomnia pathophysiology but could also 
herald in a ‘personalised medicine’ perspective on the management of insomnia 
phenotypes.                 
 
7.2. Limitations: some reflections on methods and design 
As this thesis demonstrates, there are clearly a number of strengths to applying 
qualitative, patient-centred approaches in combination with commonly-used 
quantitative designs.  However, it is also worth discussing some potential limitations to 
such an approach, specifically surrounding the present body of work.            
 
Typical of qualitative research, results are based on a small number of participants and 
hence unlikely to be representative of all individuals with primary insomnia.  It is 
important to note, though, that qualitative research does not seek to be generalisable; 
instead focusing more on the idiographic perspective.  This is why the fusion of mixed 
methods can be informative, strengthening perspectives on a given topic (Whitley, 
2007).  The incongruence between these two methodological approaches may also be of 
important value, perhaps suggesting a need for refinement in current assessment 
practices.  In this regard, it will be interesting to re-visit individual accounts of patients 
who qualitatively voiced experiencing ‘improvement’ or ‘no improvement’ (or a 
worsening of symptoms) during sleep restriction therapy (chapter five), and compare, 
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on a case-by-case basis, subjective narratives with questionnaire and sleep diary 
measures.              
 
One often-cited limitation of qualitative research is the inherent reliance on the primary 
researcher.  The quality of data generated, particularly in a face-to-face context, is 
contingent on the ability of the researcher to engage with participants, making them feel 
comfortable enough to share their experiences in a ‘valid’ way.  The researcher also 
inevitably influences results, because questions, and therefore analysis, can be 
constrained by prior knowledge, experience, and beliefs about the phenomenon under 
investigation.  A further relevant limitation relates to possible participant self-
censorship during interviews because of an established relationship with the researcher.  
In this case (chapter five), the author assumed the role of both therapist and 
interviewer/researcher; thus, if possible, it may be desirable in future work for another 
member within the research team to conduct interviews with patients, limiting demand 
characteristic behaviour on the part of the interviewee. 
 
The central role of the researcher and emphasis on participants’ subjective experience in 
qualitative research is often considered a trade-off for the enhanced validity and insights 
of obtained findings.  Analysis and results must be credible, with transparent stages of 
analysis and supporting quotations (Braun & Clarke, 2006).  All quotations in the 
present thesis were independently checked for credibility.  Further checks may have 
enhanced credibility, such as asking participants to read over findings (so-called 
‘member-checking’), or requesting additional researchers to code and thematically 
analyse transcripts independently, and subsequently compare findings.  There are also, 
however, limitations to these approaches that may not necessarily lead to increased 
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rigour; instead perhaps reflecting a naïve notion of ‘technical essentialism’ (Barbour, 
2001, 2003).   
 
The decision to use qualitative or mixed methodologies should be fundamentally 
determined by the research question; and not a hierarchy of evidence or methods 
(O’Cathain et al., 2009; Barbour, 2003).  Clearly, if one wishes to primarily investigate 
whether sleep restriction therapy is effective in improving sleep, as a single component 
intervention, relative to say a simple educational pamphlet, then such a question is 
perhaps better addressed within the context of a randomised controlled trial.  
Conversely, if the topic is poorly understood, under-explored, and involves highly 
personal factors, such as beliefs and lived experience, then qualitative patient-centred 
methodologies are likely best placed to provide a foundation knowledge base to aid 
future hypothesis testing.  Of note, the GSII reflects an approach which bridges both 
qualitative and quantitative paradigms; recording patient-relevant concerns in unique 
personal vocabulary, but still allows for the investigation of treatment effects at the level 
of the group.  More emphasis should be placed on this type of integration in future 
health services research.                              
 
Additional salient caveats to drawing conclusions based on the present thesis findings 
relate to sample size and the need for more elaborate psychometric testing (chapter 
four), as well as sample composition issues (chapter six).  Ideally, both the DFSAS and 
GSII would have been completed by a larger number of participants to thoroughly 
assess psychometric properties, including factor structure and test-retest reliability.  
Nevertheless, although small numbers, both PI patients and normal sleepers were well-
defined, adding some credence to the preliminary findings.  Future studies with larger 
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and more heterogeneous samples may help in addressing questions concerning possible 
insomnia sub-type differences and relationships with nightly sleep parameters.  Finally, 
it may be important, also, to collect scale data on insomnia patients presenting for 
treatment in the primary care setting; the majority of participants taking part in the 
present research were recruited through study adverts, further limiting the 
generalisability of results.  
 
Concerning chapter six, focusing on neurobehavioural and ERP parameters, it is 
important to bear in mind that our defined ‘poor sleepers’ may not necessarily have a 
problem with sleep.  It is well documented that individuals with ‘poor sleep’, at least 
according to sleep diaries, may not consider sleep to be a significant issue and hence 
never feel the need to seek treatment (i.e. non-complaining poor sleepers; McCrae et al., 
2003).  Thus, the findings may not be generalisable to complaining primary insomnia 
patients.  Despite this, the strengths of the database method were considered important 
to investigate, with potential for application to the insomnia field.  This could be 
something that the newly formed European Insomnia Network of labs may wish to 
consider in their quest to elucidate mechanisms involved in insomnia.                    
 
7.3. Clinical implications and future directions 
From this body of work, several ‘practice points’ emerge in relation to the clinical 
management of insomnia.  First, it is clear that the daytime consequences of insomnia 
are pervasive and distressing for patients; and their amelioration should be considered a 
major indicator of intervention success.  Both the GSII and DFSAS, though early in 
development, may be useful clinical tools to capture daytime functioning and quality of 
life impairment relevant to insomnia.  Second, prior to treatment initiation, clinicians 
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should be aware that some patients may feel particularly isolated by their insomnia, and 
may have experienced negative clinician-patient interactions during previous treatment-
seeking attempts.  This is important because patients (chapter three) often reported 
being mislabelled as ‘depressed’, something which frustrated and isolated them.  The 
prospect of initiating a ‘psychological’ therapy, then, may be viewed as a threatening 
concession to ‘the problem lies with me and my mind’, particularly for those trying to 
justify sleep disturbance as the main, real, underlying malady.  This, of course, could 
subsequently impact treatment uptake of, and adherence to, cognitive behavioural 
‘talking’ therapies.  For these individuals, group therapy may be a preferred option, if 
available, providing a supportive forum to share experiences.           
 
Possible dangers, potency of side-effects (and their likely time-course), and potential 
implementation difficulties, should be thoroughly discussed with patients prior to the 
initiation of sleep restriction therapy.  This is likely to lead to enhanced safety 
awareness and adherence to behavioural guidelines.  Providing individuals with ‘expert 
patient’ narratives may help in preparation for behaviour change, and also function as 
supportive material during challenging periods of sleep restriction implementation.  
 
The findings from this thesis have wider implications for the insomnia-HRQoL research 
agenda.  There has been a tendency for some authors to conclude (prematurely) that 
improving subjective sleep in insomnia patients may not be accompanied by 
improvements in functioning and HRQoL (e.g. Horne, 2010; Omvik et al., 2008).  The 
likelihood, however, is that the field is only now paying due attention to the daytime 
complaints and experiences of patients; this is borne out in the historical poor 
characterisation and measurement of functioning.  Similar issues have also plagued the 
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objective functioning literature, until recently, with subjective impairments rarely being 
corroborated by objective computerised testing.  In the last 2-3 years there have been 
several important studies, with improved methodological rigour and assessment 
procedures, which have furthered our understanding of possible insomnia-related 
consequences (Shekleton et al., 2010; Riemann et al., 2007; Altena et al., 2008a, 2008b, 
2010; Fernandez-Mendoza et al., in press; Edinger et al., 2008a).  Hence, the argument 
advanced is that, similar to continued progress in elucidating abnormal sleep processes 
in insomnia patients (i.e. increased CAP rate, altered ERP parameters, and elevated 
cerebral metabolism), greater research emphasis is required to refine our knowledge and 
measurement of daytime experiences in those with chronically disturbed sleep.   
 
Naturally, the characterisation of ‘the problem’ is an essential starting point and, as this 
thesis demonstrates, can be achieved effectively within a qualitative framework.  It will 
be important to monitor how these aspects of the insomnia illness experience change 
during, and long after, effective treatment.  This is where qualitative research, 
particularly methodologies we have piloted and used in the present body of work, can 
be informative.  For example, do patients report a change in ‘sleeper identity’ after 
insomnia treatment?  That is, do they now endorse being a ‘normal’ or ‘good’ sleeper?  
Intervention studies might show a reduction in quantitative sleep diary values, but are 
these important and meaningful to patients?  Preliminary data from semi-structured 
interviews (chapter five) suggest a tentative ‘yes’, but do functioning and sleep change 
in the long-term, or is it more that patients cope better with poor sleep and adapt to 
functional impact? Essentially, does CBT-I work by engendering a ‘cognitive 
homeostatic’ (Ruta et al., 2007) response?  These questions are difficult to probe in any 
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great detail with questionnaire measures, instead requiring systematic analysis of the 
patient perspective.   
 
Qualitative work may also help in the design of testing procedures to objectively 
quantify functional impairments.  A recent up-to-date thorough review of the 
neurobehavioural literature came to this very conclusion (Shekleton et al., 2010): 
subjective impairments in insomnia are not revealed by tasks sensitive to sleep loss, 
clearly there should be greater phenomenological focus on self-reports.  In this regard, 
an important next step will be to re-visit the qualitative data collected in the present 
thesis, and focus exclusively on how individuals describe impairments in cognition and 
to what extent these are captured by existing measurement protocols.  One salient 
requirement is for an ecologically valid task to capture memory deficits experienced by 
insomnia patients.  For example, patients tend to report impairments in remembering to 
carry out delayed intentions, such as forgetting to complete particular chores.  Whereas 
commonly used tasks tend to focus exclusively on encoding and working memory 
deficits, it seems that patients are more likely to experience prospective memory 
difficulties, a largely executive functioning-mediated phenomenon, which places 
particular demand on attentional shifting (e.g. Groot et al., 2002).  A paradigm to 
capture this type of prospective remembering (e.g. Rendell & Henry, 2008) would be 
worthwhile pursuing.   
 
Related to this, a poster presented at the 2007 international meeting for the Association 
of Professional Sleep Societies (APSS) described the application of ethnographic 
methods, involving direct observation of people in their homes and workplace, to 
achieve a better insight into experienced functional impairment (Fox et al., 2007).  This 
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work revealed that several aspects of patients’ daytime complaints are not covered by 
existing ‘gold standard’ neuropsychological tests.  Innovative application of ‘bottom-
up’ methodologies like those piloted by Fox and colleagues hold considerable promise 
in aiding the future refinement of testing procedures.  One final way to enhance validity 
of both objective and subjective measures would be to systematically ask patients to 
comment on whether assessments capture their experience in a relevant way.  This 
approach has proved fruitful, for example, in the early design stages of new HRQoL 
scales (Paterson, 2004), and has recently been suggested as an important next step in the 
design and refinement of instruments to assess the poorly understood construct of ‘non-
restorative’ sleep (Vernon et al., in press). 
 
Concerning measurement of subjective functioning, there are a number of promising 
directions.  For example, what are the best predictors of change on our newly developed 
quality of life and functional impairment scales?  If primary insomnia is a problem of 
hyperarousal, does treatment, firstly, reduce arousal parameters (Bonnet & Arand, 
2010), and do these changes map onto perceptions of sleep quality and subsequent 
daytime functioning/HRQoL improvements?  It will be important to assess factors 
relevant to the insomnia syndrome as well as the individual patient.  In light of the 
present ERP findings (chapter six), and others’ (e.g. Devoto et al., 2005; Bastien et al., 
2008), it will be important to assess relationships between self-report measures of 
functioning, neuropsychological testing and evoked potentials; testing out the concept 
of an ‘inverted U’ performance curve more thoroughly (Horne, 2010).  Indeed, this is 
where a prospective standardized database may be most useful.  Despite the 
heterogeneity of insomnia phenotypes, sub-types, and, unsurprisingly, research findings, 
authors still tend to make grand conclusions about ‘what insomnia is’.  The ability to 
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record extensive data, spanning self-report sleep, PSG-recordings, cognitive process 
measures, DNA polymorphisms, subjective and objective functioning variables, and 
structural/functional imaging, for a single individual, may help to identify clusters of 
patients with similar characteristics; paving the way for a better understanding of the 
mechanisms involved in the genesis of ‘the insomnias’, and ultimately in the tailoring of 
treatments.  Although a lofty task, the Brainnet database discussed in chapter six 
suggests an integrative approach is feasible and worthwhile.            
           
Methods developed and applied within this thesis have research implications beyond 
daytime functioning and HRQoL measurement.  These are worth touching on, briefly.  
For example, what are the thoughts, behaviours, and experiences of those with acute 
(adjustment) insomnia, experienced in the context of a life stressor?  It is argued that the 
transition from acute to chronic insomnia may be mediated by maladaptive sleep-
disruptive cognitive processes and behavioural practices; there are, however, little data 
on this.  Collecting real time audio-diary entries, longitudinally, or post-acute insomnia 
episode reflections (semi-structured interviews), might help further understanding of 
relevant factors (and their time course) that contribute to a return to normal sleep or 
alternatively the development of chronic sleep difficulties.  Such topics are important 
yet poorly understood and under-investigated, and would benefit from a mixed method 
approach. 
 
Another interesting angle could be to investigate subjective descriptions of the sleep 
period itself in insomnia patients.  Proximal reflections immediately on awakening 
could prove informative in understanding, for example, dream phenomenology.  Feige 
et al. (2008) recently reported the intriguing finding that REM sleep time was positively 
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related to greater objective-subjective sleep discrepancies; perhaps indicating that dream 
activity reflects waking concerns of patients, leading to the subjective perception of 
being awake.  There is preliminary evidence for REM sleep hyperarousal in PI patients, 
as indexed by absolute and relative cerebral metabolic rate of glucose (Germain et al., 
2007).  Very few studies have systematically looked at dream content in insomnia, but 
subjectively recorded accounts from patients, after forced or natural awakenings (at 
home and/or in the lab), over several nights, may help clarify if there is a robust link 
between what patients experience/think about during the day (audio-diary entries) and 
subsequent sleep mentation.  Qualitative research would be a methodological asset here. 
 
7.4. Concluding remarks 
The body of work presented in this thesis addresses the important concepts of daytime 
functioning and quality of life as applied to insomnia.  The development and application 
of mixed methodologies paved the way for insights that arguably would have been 
unobtainable using conventional quantitative and psychometric procedures.  The 
emergent findings described within have significant implications for insomnia clinical 
practice and research.  Developed methodological approaches may have further utility 
within the field of sleep medicine and research.    
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Appendices 
 
Appendix A: University of Glasgow Sleep Centre interview schedule 
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Appendix B: Focus group core questions 
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Appendix C: Participant instructions for operating dictaphone (audio-diary) 
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Appendix D: Audio-diary entry guidelines 
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Appendix E: Glasgow Sleep Centre brief screen protocol 
 
Source 
 
How did you find out about the University of 
Glasgow Sleep Centre? 
 
 
 
 
Why have you contacted us?  
 
Method of initial contact (mobile, email, 
office phone)? 
 
 
 
Personal  
 
Full Name: 
 
Date of Birth: Age: 
Telephone: 
 
Alternative Telephone: 
 
When is a good time to call? 
 
 
Address: 
 
What GP practice do you attend, and who is 
the GP you normally see? 
 
 
 
Sleep  
 
Do you have difficulty sleeping at the moment? (Y/N) 
 
 
Have you always been a poor sleeper? (Y/N) 
 
 
How long have you had a sleep problem?(yr)  
Do you have difficulty falling asleep? (Y/N) 
 
 
 
How many nights per week do you have difficulty falling asleep? (out of 7) 
 
 
 
How long does it normally take you to fall asleep?(min) 
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Do you have a difficulty with waking up during the night?(Y/N)  
How many nights per week do you have a difficulty with waking up during the 
night?(out of 7) 
 
How long are you normally awake during the night, in total? (min) 
 
 
What time do you normally go to bed? (time) 
 
 
 
What time do you normally get up?(time) 
 
 
How long do you normally sleep?(hr/min)  
Do you have any other difficulties with your sleep (e.g. restless legs, breathing problems, sleep 
walking)? 
Do you work shifts, night shifts? 
 
 
 
Roughly, how many units of alcohol do you drink per week? 
(Remember: One standard (175ml) glass of wine = 2 unit 
                                   One pint of standard lager = 2.3  units   
                                   Spirit & Mixer   = 1 unit) 
 
 
 
Does your sleep disturbance affect how you feel and function during the day (e.g. 
fatigue, sleepiness, concentration, memory, mood, motivation, irritable, 
work/social functioning etc.).  If yes, specify most salient.  
 
 
 
 
Health 
 
Do you keep in good physical health? (Y/N) 
 
 
What physical health problems do you have (if applicable)? 
 
 
What medicines do you take for your physical health? (if applicable) 
 
 
Do you keep in good mental health? (Y/N) 
 
 
What mental health problems do you have (if applicable)? 
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What medicines do you take for your mental health? (if applicable) 
 
 
 
Notes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Office Use 
 
Enquiry taken by: 
 
At (time): 
 
On (date):  
 
Information sent: 
 
⁭ [study name]  ⁭ [study name]  ⁭ [study name]  ⁭ [study name] 
⁭ [study name]  ⁭ [study name]  ⁭ [study name]  ⁭ [study name] 
⁭ [study name]  ⁭ [study name]  ⁭ [study name]  ⁭ [study name] 
 
 
On (date): 
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Appendix F: Treatment PowerPoint slides 
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Appendix G: Seven-day sleep diary 
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Appendix H: Occupational Impact of Sleep Questionnaire (OISQ) 
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Appendix I: Side-effects checklist 
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Appendix J: Sleep Restriction Adherence Scale (SRAS) 
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Appendix K: Sleep restriction therapy audio-diary guidelines 
 
 
 
 
 
 298 
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Appendix L: Post-sleep restriction interview (core) schedule 
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Appendix M: Sleep history from BRID protocol 
 
Only complete this form if you answered YES to the following question in the CORE section. 
 
“In the last month, have you experienced, or have you been told about any of the following 
sleep symptoms - difficulty in falling asleep at night; frequent night awakenings; breathing 
difficulties, snorting, gasping or loud snoring?”   
During the last month how often have you had, or been told about, the following symptoms? 
 
1. Snorting or gasping   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
2. Loud snoring   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
3. Breathing stops, choke or struggle for 
breath 
  Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
4. Frequent awakenings   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
5. Tossing, turning or thrashing   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
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6. Difficulty falling asleep   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
7. Legs feel jumpy or jerky   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
8. Morning headaches   Never 
  Rarely, less than once 
per week 
  1-2 times per week 
  3-4 times per week 
  5-7 times per week 
  Don’t know 
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